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CHAPTER I 
 
GENERAL INTRODUCTION 
 
Significance 
The pancreas is an endodermally-derived organ that is composed of two distinct 
tissue types (Figure 1). The exocrine portion constitutes approximately 98 percent of the 
adult pancreas and is comprised of acinar cells that secrete digestive enzymes into the 
ductal network (Figure 1B). The remainder of the pancreas consists of clusters of 
endocrine cells that are organized into islets of Lagerhans and scattered throughout the 
parenchyma (Figure 1C). These clusters contain 5 different hormone-producing cell 
types, including β (insulin), α (glucagon), δ (somatostatin), PP (pancreatic polypeptide), 
and ε (ghrelin) cells. Insulin is the predominant hormone produced by the pancreas, and 
it functions to regulate glucose homeostasis by communicating with peripheral tissues to 
modulate blood glucose levels. Diabetes mellitus results from inadequate levels of 
insulin, either due to an immune-mediated destruction of β cells (Type 1, T1D), or 
relative decreases in insulin production and secretion compounded by reduced insulin 
sensitivity in peripheral tissues (Type 2, T2D). The primary treatment for T1D is 
exogenous insulin therapy to maintain euglycemia; there has been limited success with 
transplants of cadaveric islets in which recipients achieve temporary insulin 
independence, but eventually the transplanted islets fail or succumb to autoimmunity. 
T2D can be treated with a variety of pharmaceuticals as well as exogenous insulin 
therapy. Drug therapies designed to enhance insulin sensitivity in peripheral tissues or 
decrease glucose output from the liver are often prescribed to treat T2D.  Medicines 
targeted to pancreatic β cells that are designed to enhance insulin secretion, such as  
2	   
A B
C
Figure 1. Vertebrate pancreas composition. (A) The vertebrate pancreas is an endodermally-derived 
organ that resides behind the stomach and in connection with the duodenum. (B) The exocrine 
portion of the pancreas is composed of digestive enzyme-secreting acinar cells and duct cells, which 
carry the digestive enzymes to the intestine. (C) The endocrine component of the pancreas consists 
of clusters of cells known as islets of Lagerhans. Islets contain five different hormone-producing cell 
types, including `(insulin),_(glucagon),m(somatostatin),¡(ghrelin, not pictured )and PP (pancreat-
ic polypeptide) and a characteristic morphology with a dense core of ` cells. Figure modified and 
reprinted with permission from Edlund, 2002. 
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sulfonylureas or secretagogues, are often initially successful, but lose efficacy over time 
as β cells become exhausted (Hanefeld 2007). Thus, an ideal treatment for T2D would 
improve insulin secretion without subsequent fatigue and failure of the β cell.  
In addition to the development of new pharmaceuticals that augment β cell 
function, much work within the diabetes community has focused on the derivation of 
insulin-secreting β cells from embryonic stem (ES) cells or induced pluripotent stem 
(iPS) cells. To this end, the developmental events that take place during 
pancreatogenesis, including the specification of endocrine and β cells, as well as the 
complexities of the in vivo microenvironment that contribute to the successful generation 
of endocrine cell types have been explored extensively. Of particular interest are 
signaling molecules and transcription factors that regulate endocrine cell fates or 
facilitate the differentiation or function of β cells. 
 
Pancreas development 
 
Specification of pre-pancreatic endoderm 
In vertebrates, the pancreas originates from the posterior foregut endoderm after 
receiving both instructive and permissive signals from the notochord, developing blood 
vessels, and mesenchyme. Following gastrulation and formation of the gut tube (Figure 
2), the prepancreatic dorsal portion of the endoderm contacts the notochord, and 
subsequently the fused dorsal aortae, while the developing ventral pancreas is in contact 
with the splanchnic lateral plate mesoderm (LPM, Figure 3A) (Kim, Hebrok, and Melton 
1997a, b, Kumar et al. 2003).  Secreted growth factor signals from these tissues provide 
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Figure 3. Signals from the notochord and dorsal aorta activate key pancreas-related transcription 
factors in the dorsal foregut endoderm. (A) Prior to e8.0 in the mouse, signals from the notochord 
(orange), including Activin b-B and FGF2, inhibit Shh expression (hot pink) in the dorsal endoderm 
(yellow) and permit pancreatogenesis to initiate.  (B) After e8.0, fusion of the dorsal aortae (red) 
displace the notochord from the dorsal endoderm. Direct contact between the dorsal aorta and endo-
derm initiates Pdx1 and Ptf1a expression in the pre-pancreatic region (green). The dorsal aorta also 
secretes factors including VEGF-A, FGF10, and Sphingosine-1, which participate in proliferation of 
panreatic progenitors, pancraetic branching and establishment of endocrine mass. Signals from the 
LPM (light orange), such as FGF, BMP, and RA contribute to patterning of the gut tube, particularly 
induction of Pdx1 and Ptf1a in the developing ventral pancreas (VP). Figure modified and reprinted 
with permission from Henley and Gannon, 2013. 
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instructive cues allowing this region of the foregut endoderm to acquire the pancreatic 
fate, and stimulate the outgrowth and branching of the epithelium. 
Contact between the notochord and dorsal pre-pancreatic endoderm is critical for 
branching of the pancreatic epithelium as well as expression of key hormones involved 
in endocrine differentiation and adult endocrine function (Slack 1995, Kim, Hebrok, and 
Melton 1997a, Hebrok, Kim, and Melton 1998). These events are mediated by the 
notochord-driven repression of sonic hedgehog (Shh) in the region of the endoderm from 
which the pancreas will derive (Figure 3A, yellow). Shh is a secreted morphogen 
involved in growth, differentiation, and function of many developing and adult organs; it 
promotes intestinal fates in the developing endoderm. Its expression is maintained 
rostrally and caudally to the prepancreatic endoderm, suggesting a direct link between 
the proximity of the notochord and repression of Shh (Hebrok, Kim, and Melton 1998, 
Apelqvist, Ahlgren, and Edlund 1997). Activin-βB and fibroblast growth factor (FGF) 2, 
both of which are secreted from the notochord, inhibit Shh expression in the dorsal pre-
pancreatic region (Figure 3A) (Hebrok, Kim, and Melton 1998), thus allowing for 
pancreas development to initiate.  
Following the fusion of the two dorsal aortae at the midline in the mouse at e8.0 
(Figure 3B. red), the dorsal region of the developing pancreas is no longer in contact 
with the notochord. Signals derived from the dorsal aorta and other blood vessels are 
important to specification of the dorsal bud and expression of endocrine hormones, 
specifically insulin. In vitro culture experiments indicate that close proximity of the dorsal 
aorta to endoderm activates expression of pancreatic and duodenal homeobox 1 (Pdx1, 
or Insulin promoting factor 1, IPF1) (Figure 3B) a transcription factor required for 
pancreas development and mature β cell function (Offield et al. 1996, Lammert, Cleaver, 
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and Melton 2001, Jonsson et al. 1994). Endothelial cells are also responsible for 
inducing expression of pancreatic transcription factor 1a (Ptf1a) in the dorsal bud of the 
developing pancreas (Figure 3B) (Yoshitomi and Zaret 2004). Like Pdx1, Ptf1a is crucial 
to pancreas development and differentiation of all pancreatic cell types, but unlike Pdx1, 
Ptf1a is required for acinar rather than endocrine function in the adult (Krapp et al. 
1998);(Kawaguchi et al. 2002). Both Pdx1 and Ptf1a are required for proper pancreatic 
bud outgrowth in mouse and human (Jonsson et al. 1994, Offield et al. 1996, Stoffers et 
al. 1997, Kawaguchi et al. 2002, Sellick et al. 2004). Signals secreted from the blood 
vessels, including vascular endothelial growth factor (VEGF)-A, sphingosine-1-P (S1P), 
and fibroblast growth factor (FGF) 10, play a role in proliferation of progenitors, 
pancreatic branching, and establishment of endocrine mass in mice (Figure 3B) 
(Lammert, Cleaver, and Melton 2001, Cai et al. 2012, Sand et al. 2011, Bhushan et al. 
2001). The data regarding the effect of over-expression of VEGF-A on the development 
and function of the adult pancreas have been conflicting (Lammert, Cleaver, and Melton 
2001, Cai et al. 2012), but nonetheless reflect the importance of blood vessel-derived 
molecules in pancreas specification and differentiation. 
 
Regionalization of the foregut endoderm 
After its specification, the foregut endoderm is designated into discrete regions 
that give rise to specific organs. Much like the patterning of the pre-pancreatic 
endoderm, neighboring structures and tissues secrete signals that enable regionalization 
of the endodermal gut tube along the anterior/posterior axis. Factors including FGFs, 
bone morphogenetic proteins (BMPs), activin, and retinoic acid (see below) are secreted 
from the adjacent LPM to regionalize the gut tube (Kumar and Melton 2003, Dessimoz et 
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al. 2005). The most anterior region of the foregut is demarcated by Sox2 expression and 
gives rise to the lungs, esophagus, trachea, and forestomach (Figure 4). Posterior to the 
Sox2-positive foregut is a region of the gut tube which is marked by expression of Pdx1, 
Ptf1a, motor neuron and pancreas homeobox 1 (Mnx1) and caudal type homeobox 2 
(Cdx2). This segment, called the posterior foregut, gives rise to the antral stomach, 
pancreas, and liver.  BMP4, BMP7, and Activin-A, all of which belong to the transforming 
growth factor β (TGFβ) superfamily of signaling molecules (see BMP Signaling, below), 
are capable of activating Pdx1 expression in the presumptive pancreatic region of 
endoderm (Kumar and Melton 2003). Pdx1 expression is initially observed in the mouse 
at e8.5 in this region (Figure 3B), and later expands to the antral stomach, rostral 
duodenum, and common bile duct by e11.5 (Offield et al. 1996, Guz et al. 1995, Jonsson 
et al. 1994, Wessels 1967). At e9.5 in mice, a subset of cells within the Pdx1 positive 
domain also express Ptf1a; cells double positive for both transcription factors give rise to 
the pancreas, whereas cells positive for only Pdx1 contribute to the stomach and 
duodenum (Figure 4).  
Posterior to the pancreatic domain is the midgut, which is marked by expression 
of Pdx1 (in the most anterior portion) and Cdx2 (Figure 4). This region consists of 
endoderm that will give rise to the duodenum (Pdx1 and Cdx2), and small intestine 
(Cdx2). In the absence of Ptf1a, cells that are destined to become Ptf1a-positive 
pancreatic cells are instead incorporated into the spleen and duodenum, indicating the 
important role of Ptf1a in appropriately regionalizing and populating the developing 
pancreas (Krapp et al. 1998, Kawaguchi et al. 2002). The most posterior region of the 
digestive tract is the hindgut, which is marked by expression of Cdx1 and 2 and gives 
rise to the colon (Figure 4).  
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Figure 4. Regionalization of the gut tube during murine embryogenesis. The gut tube is organized in an anterior-to-posterior 
manner and is compartmentalized into discrete regions that give rise to specific organs. The most anterior portion of the gut 
tube is the foregut, which gives rise to the esophagus, trachea, lungs, and forestomach, and is marked by expression of 
Sox2. The posterior foregut is demarcated by expression of Pdx1 and gives rise to the antral stomach and liver. Portions of 
the posterior foregut that also express Ptf1a/Mnx1 and Cdx2 develop into the dorsal and ventral pancreatic buds and duode-
num,  respectively.  Cdx2 is expressed throughout the midgut, from which the intestine develops, and throughout the hind-
gut, where it is co-expressed with Cdx1 and gives rise to the colon. Figure reprinted with permission from Guney and 
Gannon, 2009.
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Formation of the pancreatic buds 
Development of the pancreas proper initiates around e9.5 in mice and 
gestational day 25 in humans (Pictet et al. 1972) (Figure 2, 5). Pancreatic bud formation 
is marked by the condensation of mesenchyme around the prospective pancreatic 
anlagen. Growth of the buds and subsequent branching morphogenesis are dependent 
on permissive signals secreted from the mesenchyme (Golosow and Grobstein 1962). 
The transcription factor Bapx1 (Nkx3.2) is present in the mesenchyme at the time of 
budding and is responsible for the separation of spleen and pancreas in the developing 
mouse (Asayesh et al. 2006). FGFs are also highly expressed in the mesenchyme at 
this time, and signaling through FGF receptors in the developing pancreatic epithelium 
promotes proliferation and branching morphogenesis. The absence of Fgf10 in mice 
results in blunted pancreatic branching, and loss of expression of the FGF receptor 2B 
(Fgfr2b) also reduces branching morphogenesis (Bhushan et al. 2001, Pulkkinen et al. 
2003). Cells that co-express Pdx1 and Ptf1a in the posterior foregut endoderm evaginate 
from the dorsal and ventral epithelium into the surrounding mesenchyme to form the 
dorsal and ventral pancreatic buds, respectively. In the mouse, the ventral bud emerges 
12 hours after the dorsal bud, and 6 days after the dorsal bud in humans. The dorsal bud 
originates from the midline endoderm between the third and ninth somite pair, and the 
human ventral pancreas emerges from two lateral buds that originate from the same 
level and eventually fuse and then join the dorsal bud later in gestation (Nielsen et al. 
2009, Kumar et al. 2003). The mouse also develops two ventral domains during early 
pancreatogenesis, but only one domain survives to fuse with the dorsal bud.  
Despite their eventual fusion, the dorsal and ventral pancreatic buds in both 
mouse and human are two distinct entities that have differential signaling and 
transcription factor requirements and responses. For example, the ventral bud develops  
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e9.5-e10. e10.5-e11.5 e12.5 e14.5-e15.5 postnatal 
Early MPC: Pdx1, Ptf1a, Hnf6, Sox9 
Duct/Endocrine progenitor ‘Trunk’ cell: Sox9, Hnf1b, Muc-1
MPC ‘Tip’ cell: Ptf1a, Cpa, c-Myc
Endocrine progenitor: Ngn3
Differentiated acinar cell
Differentiated duct cell
Differentiated endocrine cell
Centroacinar cell
Figure 5. Developmental events during murine pancreatogenesis. See text for details. Figure modified and reprint-
ed with permission from Henley and Gannon, 2013. 
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without associating with or receiving direct signals from the notochord, while the dorsal 
bud relies on notochord signaling for proper induction (Figure 3A). As mentioned above, 
Mnx1 is a transcription factor that marks both dorsal and ventral pancreatic buds in the 
developing posterior foregut endoderm (Figure 4). Loss of Mnx1 results in failure of the 
dorsal bud to develop, while surrounding endoderm and mesenchyme are mostly 
unaffected, although there are slight perturbations in β cell differentiation and islet 
organization in the adult organ (Harrison et al. 1999, Li et al. 1999). The dorsal bud is 
also differentially sensitive to expression of islet-1 (Isl1), a transcription factor expressed 
in the developing pancreatic epithelium, mesenchyme, as well as adult endocrine cells. 
Mice lacking Isl1 fail to develop dorsal mesenchyme and thus specifically lack dorsal bud 
outgrowth and also exhibit a paucity of endocrine cells in the ventral bud (Ahlgren et al. 
1997). Indeed, mutations in ISL1 have also been associated with Type 2 Diabetes in the 
Japanese population (Deering, Chinn, et al. 2009). Retinoic acid (RA) signaling also 
plays a differential role in dorsal and ventral bud formation. Retinaldehyde 
dehydrogenase (Raldh) 2 is required for RA synthesis and, when deleted in the mouse, 
results in dorsal pancreatic agenesis (Martin et al. 2005, Molotkov, Molotkova, and 
Duester 2005). The ventral bud is affected when a dominant negative RA receptor is 
expressed in the pancreatic epithelium, indicating that the ventral bud is sensitive to RA 
signaling in general, but not expression of a particular RA synthesizing enzymes 
(Ostrom et al. 2008). 
The period of time following bud evagination from the endoderm is termed the 
‘primary transition’ and takes place in the mouse from e8.5 to e10.5 and from 
approximately the 23rd to 33rd days of gestation in the human (Pictet et al. 1972) (Figure 
2, 5). Little cellular ultrastructural differentiation is seen at this time, but low levels of 
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exocrine-specific enzymes can be detected and the first glucagon- and insulin- positive 
cells are observed. These hormone-positive cells do not express markers of mature 
endocrine cells and are not thought to contribute to the mature endocrine cell population 
of the pancreas (Herrera et al. 1994, Pang, Mukonoweshuro, and Wong 1994, Lee et al. 
1999, Herrera 2000, Wilson, Kalamaras, and German 2002). Essentially, the role and 
fate of these hormone positive cells that arise during the primary transition is unclear.  
 
Fusion of pancreatic buds 
The evagination of the dorsal and ventral pancreatic buds into the surrounding 
mesenchyme is followed by growth and elongation of the buds and, at e12-13 in mice 
and gestational day 37 to 42 in humans, fusion to form a single organ (Figure 2). Fusion 
occurs as a result of organ elongation and rotation of the gut tube (Jorgensen et al. 
2007).  The process of bud fusion is poorly understood, but it has been determined that 
molecules belonging to the Shh family are involved. Absence of Indian hedgehog (Ihh), a 
secreted molecule within the Sonic hedgehog family of proteins, results in ectopic 
branching of the ventral pancreas and formation of an annulus encircling the duodenum 
in mice, which closely resembles annular pancreas seen in humans (Hebrok et al. 2000). 
Fusion of the buds also results in the connecting of the ventral bud duct with the distal 
portion of the dorsal bud duct, establishing the main pancreatic duct (duct of Wirsung) 
that runs the entire length of the organ and connects with the common bile duct. 
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Initiation of branching morphogenesis 
The budding pancreas is initially a pair of small, rounded, and grossly 
morphologically identical fin-shaped buds on the dorsal and ventral sides of the midline 
foregut endoderm. After fusion of the buds, the pancreas undergoes organizational and 
morphological changes within the epithelium and ductal plexus, begnning around e12.5 
in the mouse, to establish a branched organ with an intricate network of ducts (Figure 2, 
5) (Villasenor et al. 2010). It was initially proposed that pancreatic branches arise from 
random buckling of endodermal epithelium (Slack 1995). It has since been determined 
that individual branches emerge from the proliferation of multipotent progenitor cell 
(MPC)-containing tip domains (Figure 5) (Zhou et al. 2008) from the epithelium and 
longitudinal growth, rather than perpendicular elongation of the tip domains from the 
epithelium (Villasenor 2010). 
By e12.5 in the mouse, the buds have fused and form a tear-drop shaped 
structure with little to no external evidence of branching. At this time, however, a multi-
lumenal ductal plexus has been established, and remodels to form a singular lumen as 
branching morphogenesis progresses (Villasenor et al. 2010). The pancreas is divided 
into two lobes; with time, the splenic lobe of the pancreas extends across the stomach 
from the duodenum to the spleen, and the gastric lobe lengthens along the posterior 
stomach. The majority of the dorsal pancreas is composed of the splenic lobe and is 
characterized by its anvil-shaped tail, named as such due to its likeness to the distal 
region of the human pancreas. Development of the tail begins at e12.5 in the mouse 
(and continues throughout development), followed at e13.5 by development of left lateral 
branches and smaller right lateral branches from the proximal portion of the splenic lobe.  
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At approximately e12-e12.5 in the mouse, the pancreas undergoes 
morphological and gene expression pattern changes that establish the ‘tip’ and ‘trunk’ 
domains of the branching organ (Figure 2, 5). Prior to this change, the pancreas is 
populated by MPCs that have the ability to differentiate into acinar, duct, or endocrine 
cells, and express a signature of transcription factors (Pdx1, Ptf1a, Sox9 Nkx6.1, 
hepatocyte nuclear factor 6 (Hnf6) and Hnf1β (Gu, Dubauskaite, and Melton 2002, Solar 
et al. 2009)). The MPC pool maintains itself through Sox9-mediated proliferation; loss of 
Sox9 in mice results in near complete pancreatic agenesis due to failed MPC pool 
expansion (Seymour et al. 2007). Around approximately e12.5 in mice, the pancreas 
segregates into a ‘tip’ and ‘trunk’ domain that, in part, facilitates branching 
morphogenesis (Figure 5). Cells in the ‘tip’ regions are MPCs distinct from those found in 
the emerging bud; the tip pool of MPCs expresses Ptf1a, c-Myc, and carboxypeptidase 
A (Cpa1), and in absence of other acinar markers, has the potential to give rise to all 
three pancreatic cell types. This pool of progenitors also expresses Hnf6 and Pdx1, but 
to a lesser extent than the MPCs found in the developing bud. The ‘trunk’ domain 
extends down from the MPC-containing tips to the main duct, and is populated by cells 
that can give rise to duct or endocrine cells. Marked by expression of Hnf1β, Sox9, 
Mucin 1 (Muc1), Nkx6.1, Hnf6 and Pdx1, the differentiation of bipotent trunk cells into 
endocrine progenitors is mediated by expression of the basic helix-loop-helix 
transcription factor neurogenin 3 (Ngn3). Mice lacking Ngn3 fail to develop intestinal and 
pancreatic endocrine cells, and humans with NGN3 mutations suffer from malabsorptive 
diarrhea and neonatal diabetes (Wang et al. 2006, Pinney et al. 2011). The process of 
establishing the tip and trunk domains overlaps with the ‘secondary transition’ of 
pancreas development, which is described in detail below. 
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Regulation of branching morphogenesis 
Branching morphogenesis is regulated by a diverse group of transcription factors 
and signaling molecules, several of which have been well characterized and are 
described here. The one cut domain-containing transcription factor Hnf6 is expressed 
broadly in the developing endoderm and plays a crucial role in liver and pancreas 
development (Jacquemin et al. 2000, Jacquemin, Lemaigre, and Rousseau 2003, Zhang 
et al. 2009).  Deletion of Hnf6 within the Pdx1-expressing domain results in, among other 
profound changes, decreased pancreatic branching at e14.5 in the mouse and a 
subsequent hypoplastic pancreas (Zhang et al. 2009). Expression of the pro-endocrine 
factor Ngn3 is also important to branching morphology, as mice null for Ngn3 show 
significant reductions in branching as well as dilated ductal structures and stunted 
growth (Magenheim et al. 2011, Beucher, Martin, et al. 2012). As mentioned above, 
branching morphogenesis is also dependent on the expression of FGF ligands and 
receptors. Furthermore, animals globally lacking the ephrin receptors B2 and B3 (EphB2 
and EphB3, respectively), which are normally expressed in the pancreatic epithelium, 
show reduced pancreas size and decreased number and size of lateral pancreatic 
branches, suggesting that ephrin signaling is important to overall pancreatic growth as 
well as establishment of appropriate numbers of branches (van Eyll et al. 2006, 
Villasenor et al. 2010). Overall, branching morphogenesis is important not only to the 
growth of the pancreas as an organ, but also to generating the proper number of 
endocrine, duct, and acinar progenitors that will eventually populate the pancreas as 
mature cells. For example, mice lacking Hnf6 in a global or tissue-specific fashion show 
reduced branching in addition to decreased number of Ngn3+ cells and reduced α and β 
cells at late gestation (Jacquemin et al. 2000, Zhang et al. 2009).   
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Establishment of ductal network 
As an endocrine organ, the pancreas maintains glucose homeostasis in the body 
by releasing hormones directly into the blood stream, while the exocrine portion 
produces digestive enzymes in the acinar tissue and secretes them into the ductal 
network. Digestive enzymes are delivered to the gut by the main pancreatic duct, which 
is connected to smaller, intercalated ducts that are closely associated with enzyme-
secreting acinar cells by inter- and intra-lobular ducts. The primordial ductal system is 
pre-formed prior to the initiation of branching morphogensis, and is reorganized 
throughout development to yield a mature ductal system. Initially, the ductal network is a 
multi-lumenal structure, as shown by whole mount immunolabeling using the ductal 
marker Mucin 1 (Muc1) at e11.5 to 12.5 in mice (Figure 6) (Kesavan et al. 2009). 
Remodeling of the ductal plexi results in the formation of ducts with a single lumen by 
e15.0 in the mouse (Figure 6), and the remodeling of ducts is concurrent with the 
development of MPC tips into protruding branches (Villasenor et al. 2010).  
Remodeling and branching of ducts is partially regulated by Pdx1. In-vivo culture 
experiments using murine-derived pancreatic ductal cells revealed a surge of Pdx1 
expression in cells undergoing branching (Wescott et al. 2009). Additionally, in the 
developing mouse pancreas as early as e12.5, cells negative for insulin but positive for 
Pdx1 and the duct-marker cytokeratin 19 (K19) exhibit branching morphogenesis, 
indicating that although Pdx1 expression is not maintained in adult ducts, it is important 
for duct development.  Branching events in the pancreas also rely on the Rho-GTPase 
Cdc42, which is ubiquitiously expressed in the developing pancreatic epithelium 
(Kesavan et al. 2009). Absence of Cdc42 does not affect the establishment of polarity 
within an individual cell, but does prevent the formation of microlumens at e11.5, and 
subsequent fusion of lumens at e12.5 in mice (Kesavan et al. 2009). 
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Figure 6. Duct modeling during pancreatogenesis. (A) Wild type (WT) multilayered pancreatic epitheli-
um (E-cadherin, red) at e10.5 exhibiting a central lumen (Muc 1, green). (B) At e11.5, microlumens are 
formed (arrowheads) within the multilayered pancreatic epithelium.  The number of microlumens 
increases and individual microlumens fuse to form larger lumens at e12.5 (C) and e13.5 (D). (E) By 
e15.5, Muc1-positive cells (green) have formed a ductal network with a single lumen within the develop-
ing pancreas. Figures modified and used with permission from Kesavan et al., 2009.
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Secondary Transition 
The secondary transition is the developmental time period characterized by a 
monumental increase in differentiation of both exocrine and endocrine cell types from 
the MPC population. This period was initially characterized by Pictet and Rutter with the 
observation of the great increase in exocrine enzymes at e14.5 in rats (Pictet et al. 1972, 
Rutter et al. 1968). The secondary transition marks the progression from a state of 
‘protodifferentiation’ to that of enzyme and hormone production and establishment of 
discrete components of the pancreas via the tip and trunk model of branching 
morphogenesis (see above), and is also marked by vascularization of the developing 
endocrine clusters (Brissova et al. 2006) (Figure 2, 5). These events initiate at 
approximately e13.5 in the mouse and gestational day 39 in the human, and proceed 
through murine e16.5 and human gestational day 45 (Figure 2).  
 
Exocrine development during the secondary transition 
Prior to the secondary transition, there are low levels of enzymes and select 
hormones can be detected in the developing pancreas, and although the ultimate fate of 
the cells generating these products is not known, they are not presumed to contribute to 
adult tissues. The rapid increase in differentiating cells at the secondary transition 
translates into a large induction of enzyme gene expression from the emergent exocrine 
portion of the pancreas. Not surprisingly, this time period is also marked by development 
of the rough endoplasmic reticulum (ER) and zymogen granules in the forming acinar 
cells (Pictet et al. 1972). Indeed, the ‘tip’ region of cells within the tip/trunk model of 
branching morphogenesis is designated, in part, by expression of the acinar-associated 
enzyme Cpa1 and transcription factor Ptf1a. Cpa1 expression is initially detected at 
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e10.5 within MPCs, but is compartmentalized to and increased in the developing tip 
acinar clusters at e12.5 (Figure 5) (Chiang and Melton 2003, Gittes and Rutter 1992, 
Jorgensen et al. 2007). Elastase (Ela) expression also increases during the secondary 
transition, followed later in development by expression of amylase (Amy). Acinar 
differentiation is preceded by apical polarization, demonstrated by localization of Muc1 at 
the apical surface of epithelial cells in the murine bud at e11.5 (Kesavan et al. 2009)  
 
Plasticity of ductal cells during the secondary transition 
In the tip/trunk model of branching morphogenesis, cells residing within the trunk 
domain that are destined to become endocrine or ductal cells express Sox9, Hnf1β, 
Muc1, Hnf6, and Pdx1 (Seymour et al. 2007, Solar et al. 2009, Kopinke and Murtaugh 
2010). A subset of these trunk cells lose their bipotentiality after induction of the pro-
endocrine gene Ngn3 (Figure 5); indeed, lineage labeling in the mouse suggests that 
these bipotent trunk cells have the ability to give rise to endocrine cells throughout 
development, but contention lies with the specific time at which they lose this ability to 
give rise to endocrine cells. Experiments that studied lineage labeled murine Hnf1β+ 
cells from the trunk domain throughout development revealed that this cell population 
cells loses the potentiality to give rise to both duct and endocrine cells at e15.5 (Solar et 
al. 2009). A different study showed that cells expressing Sox9 have the ability to give 
rise to acinar, ductal, and endocrine cell types until postnatal day (P) 1 in mice, but after 
P7, the Sox9+ population only gives rise to acinar and ductal cells (Furuyama et al. 
2011). A second study investigating the fates of Sox9 lineage-labeled cells (which were 
marked in a pulse-chase fashion) determined that Sox9+ cells give rise to all three 
pancreatic cell types from e8.5 until e18.5, but only give rise to duct cells and non-β 
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endocrine cells after P5 in mice (Kopp, Dubois, Schaffer, et al. 2011). There is 
controversy surrounding these studies in terms of the efficiency of the lineage-tracing 
models used to label and track individual cells. What remains clear is that cells residing 
within the trunk domain experience a period of plasticity during which they can adopt an 
endocrine or ductal fate; the specific mechanisms behind the timing of these cell fate 
decisions has yet to be elucidated. 
  
Centroacinar cells/terminal duct cells as a source of progenitors in the ductal 
epithelium 
Centroacinar and terminal duct cells are two distinct, poorly characterized cell 
types that reside at the interface between acini and small ducts (Figure 5). The precise 
function of these cells is still being examined, and it remains unclear whether they are 
equivalent in their capacities. The specific role for centroacinar/terminal duct cells in 
pancreas development has not been assessed, and although some data suggest they 
do not contribute to the regenerating adult endocrine pancreas, these cells contribute to 
the adult acinar population and incorporate into developing endocrine tissue in vitro. 
Sox9+ centroacinar cells are a source of progenitor cells within the ductal/acinar 
boundary and contribute to maintenance of the adult acinar cell population, but they are 
not a source of newly formed endocrine cells after pancreatic injury in the adult mouse 
(Kopp, Dubois, Schaffer, et al. 2011). However, in vitro and ex vivo experiments 
revealed that centroacinar/terminal duct cells isolated from the adult mouse pancreas 
express progenitor cell markers, including c-Met, Sox9, and Nestin, and cluster into 
hormone-secreting, glucose-responsive ‘pancreatospheres’ in culture. This adult cell 
population is also capable of contributing to developing endocrine and exocrine tissue 
when injected into e12.5 mouse dorsal bud cultures (Rovira et al. 2010).  
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Both human and murine adult acinar cells exhibit plasticity in culture and in vivo. 
Human acinar cells readily differentiate into ductal cells in culture, exhibiting CK19, 
Hnf1β, and Sox9 protein expression, in a mitogen-activated protein kinase (MAPK)-
dependent manner (Houbracken et al. 2011). Additionally, mouse acinar cells can 
undergo acinar-to-ductal metaplasia in response to elevated EGFR signaling, as TGFα 
and hepatocyte growth factor (HGF) signaling through EGFR results in 
transdifferentiation into ductal cells through a nestin-positive intermediate (Means et al. 
2005). Furthermore, combined over-expression of Ngn3, Pdx1, and musculoaponeurotic 
fibrosarcoma oncogene homolog A (MafA) in adult murine acinar cells results in 
transdifferentiation of acinar cells into glucose-responsive, insulin-secreting β cells that 
partially restore serum insulin and blood glucose levels in adult mice lacking 
endogenous β cells (Zhou et al. 2008). This suggests that adult human and murine 
acinar tissue are relatively plastic in culture and in vivo and provides promise for the 
generation of other pancreas cell types from human acinar tissue.  
 
Delamination of endocrine progenitors from the trunk domain 
Delamination is a process in the epithelial-to-mesenchymal transition (EMT) 
during which the endocrine progenitors emerge from the epithelial trunk region and 
migrate into the parenchyma (Figure 5). Ngn3+ trunk cells lose contact with the trunk 
lumen and, after activation of Snail2, down-regulate expression of E-cadherin to facilitate 
delamination (Gouzi et al. 2011). The ability to delaminate is lost in Ngn3 mutant 
animals, as cells fated to be endocrine progenitors remain closely associated with ducts 
(Magenheim et al. 2011, Beucher, Martin, et al. 2012). E-cadherin down-regulation is, in 
part, mediated by expression of the co-repressor groucho-related gene (Grg) 3; ex vivo 
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cultures of developing pancreas from mice lacking Grg3 have endocrine progenitors that 
do not delaminate from the ductal epithelium and show decreased numbers of 
differentiated endocrine cells (Metzger et al. 2012). Delamination of differentiating cells 
is also associated with down-regulation of atypical protein kinase C (aPKC), an apical 
surface marker (Georgiou et al. 2008). Conversely, increased expression of Eph3B 
designates delaminating and differentiating endocrine progenitors during the secondary 
transition and is required for delamination (Villasenor et al. 2012, Villasenor et al. 2010). 
 
 
Commitment to endocrine fate: Expression and action of Ngn3 
Within the trunk domain of the developing pancreas, cells destined to become 
endocrine progenitors transiently express Ngn3 (Figure 5). Ngn3+ cells can give rise to 
all five endocrine types (Gu, Dubauskaite, and Melton 2002). High expression of Ngn3 is 
required for commitment to the endocrine lineage, as studies in mice have indicated that 
low levels of Ngn3 expression due to Ngn3 heterozygosity or hypomorphism result in the 
diversion of cells to the acinar or ductal fate; furthermore, complete loss of Ngn3 results 
in the adoption of acinar or ductal fates by failed endocrine progenitors (Wang et al. 
2010, Beucher, Martin, et al. 2012, Zhang et al. 2009). Upon expression of Ngn3, 
endocrine progenitors are temporarily post-mitotic, but following delamination and 
differentiation into specific endocrine cell types, the ability to proliferate is regained.  
Clonal analysis of Ngn3+ cells in the developing mouse pancreas indicates that 
endocrine progenitors expressing Ngn3 are unipotent, each giving rise to a single 
endocrine cell (Desgraz and Herrera 2009). After commitment to the endocrine lineage, 
expression of paired homeobox (Pax) 4 or aristaless related homeobox (Arx) contribute 
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to adoption of β/δ or α cell fate, respectively (Sosa-Pineda et al. 1997, Collombat et al. 
2005, Seymour and Sander 2011).  
The ability of endocrine progenitors to differentiate into specific endocrine cell 
types is an property that changes over the course of pancreas development. Ngn3+ 
endocrine progenitors exhibit windows of competence to differentiate into specific cell 
types (Johansson et al. 2007). For example, cells that differentiate early (prior to e10.5 in 
the mouse) become only α cells. Between e 10.5 and e12.5, differentiating endocrine 
cells become α or β cells, and after e12.5, progenitors differentiate into PP, β, and δ 
cells (Johansson et al. 2007) In accordance with this temporal differentiation pattern, 
over-expression of Ngn3 early within the Pdx1-positive domain in mice results in the 
precocious differentiation of nearly all endocrine progenitors into α cells (Grapin-Botton, 
Majithia, and Melton 2001). While the permissive, instructive, or inhibitory signals that 
govern these windows of competence have not yet been thoroughly characterized, some 
key activators of specific endocrine programs have been identified and are described 
below. 
 
Hnf6: Establishing endocrine mass and function 
Hnf6 belongs to the cut-domain family of transcription factors and was initially 
characterized as a liver-enriched factor required for Hnf3β expression in rat hepatocytes 
(Samadani and Costa 1996). It is expressed in the developing and adult murine central 
nervous system (CNS), liver, and pancreas (Landry et al. 1997). In the CNS, Hnf6 is 
required for maintenance of neuronal and projection identity and participates in the 
formation of hindlimb neuromuscular junctions (Chakrabarty et al. 2012, Espana and 
Clotman 2012a, b, Hodge et al. 2007, Roy et al. 2012, Stam et al. 2012, Audouard et al. 
2012). Deletion of Hnf6 in a global fashion results in early postnatal lethality of seventy 
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five percent of animals as a result of cholestasis-related liver necrosis (Jacquemin et al. 
2000, Clotman et al. 2002). The surviving animals are initially hypoglycemic due to 
impaired liver function, and exhibit glucose intolerance at 10 weeks of age that results 
from impaired endocrine function (Jacquemin et al. 2000). Hnf6 null animals exhibit 
reduced β, α, δ, and PP cells at e15.5, all of which are scattered within and close to the 
pancreatic ducts; islet morphology is not established until 2-3 weeks of age in these 
mutants, at which point the endocrine clusters still lack an α cell mantle and remain 
closely apposed to the ducts (Figure 7) (Jacquemin et al. 2000). Defects in endocrine 
differentiation observed in mice lacking Hnf6 in a global or pancreas-specific fashion can 
be linked to decreased specification of endocrine progenitors, as expression of Ngn3 
and number of Ngn3-positive cells is reduced in both of these models (Figure 7, 8) 
(Jacquemin et al. 2000, Zhang et al. 2009). Consistent with this idea, over-expression of 
Hnf6 in endocrine cells results in an increased number of Ngn3-positive cells during 
development (Figure 8) (Wilding Crawford et al. 2008). Indeed, Hnf6 can stimulate Ngn3 
reporter activity in vitro, suggesting potential direct regulation of the endocrine program 
by Hnf6 itself (in addition to other factors) (Oliver-Krasinski et al. 2009).  
In the developing murine liver, Hnf6 is required for biliary epithelial cell and 
gallbladder cell differentiation and works in concert with the Notch pathway to regulate 
development of the intrahepatic biliary system (Clotman et al. 2002, Vanderpool et al. 
2012). In the adult liver, Hnf6 regulates expression of Gck and glucose-6-phosphatase 
(G6pase), two genes required for regulation of glucose homeostasis (Lannoy et al. 2002, 
Streeper et al. 2001, Clotman et al. 2002). Hnf6 also functions upstream of Foxa2 in the 
liver, and elevated Foxa2 activity in mice is associated with defective glycogen storage 
(Rausa et al. 2000). Additionally, Hnf6 antagonizes the blood glucose-elevating effects  
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Control Hnf6 -/-
C
Figure 7. Hnf6 is required for endocrine cell number and islet 
morphology. (A) Hnf6 null animals, right, display fewer insulin-posi-
tive cells (brown) at e15.5 than control animals, left. (B) Hnf6 null 
animals, right, display fewer glucagon-positive  cells (brown), which 
remain closely apposed to ducts, compared to control animals, left. 
(C) Adult control animals, left, display appropriate islet morphology, 
including a ` cell (red) core and an _ cell (green) mantle, while Hnf6 
null animals exhibit smaller, disorganized islets that lack an _ cell 
mantle and contain glucagon-positive cells (green) scattered 
throughout the acinar tissue. Figures modified and reprinted with 
permission from Jacquemin et al., 2000.
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Control Pdx1PB-Hnf6
Control Pdx1-Cre; Hnf6 F/F
FIgure 8. Hnf6 expression regulates endocrine progenitor 
number. (A) Control embryos possess Ngn3-positive endo-
crine progenitors (green) within the trunk epithelium at e13.5. 
(B) Embryos lacking Hnf6 in the pancreatic epithelium 
(Pdx1-Cre; Hnf6 F/F) show a reduced number of Ngn3-posi-
tive endocrine progenitors (green), while glucagon-positive 
cells (red) are increased at e13.5. (C) Control embryonic 
pancreas showing Ngn3-positive cells (green) and gluca-
gon-positive cells (red). (D) Over-expression of Hnf6 under 
control of the islet-specific enhancer fragment of the Pdx1 
promoter increases the number of Ngn3-positive cells 
(green) at e13.5. Figures modified and reprinted with permis-
sion from Zhang et al., 2009 and Wilding-Crawford et al., 
2008.
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of glucocorticoids in the liver (Pierreux et al. 1999). 
As described above, Hnf6 is expressed in the primary MPCs of the pancreasand 
to a lesser extent in the secondary MPCs and the bipotent trunk domain of the 
pancreatic epithelium (Figure 2, 5). Based on the ability of Hnf6 to activate Ngn3 
expression, it is thought that Hnf6 expression in the trunk region is partially responsible 
for activating the endocrine program. Hnf6 protein is reduced in differentiated, hormone-
positive endocrine cells (Zhang et al. 2009), but its expression persists in the Pdx1-
positive population at low levels for a few days after birth in the mouse (Dr. Diana 
Stanescu and Dr. Doris Stoffers, unpublished data). Islets with sustained Hnf6 
expression exhibit increased α, δ, and PP cells at the expense of β cells, and endocrine 
clusters fail to migrate away from the ducts (Gannon et al. 2000). Furthermore, over-
expression of Hnf6 in islets prevents maturation of β cells, as marked by dramatically 
reduced expression of Glut2 and MafA. As a consequence, maintained expression of 
Hnf6 in the postnatal islet causes diabetes (Gannon et al. 2000, Tweedie et al. 2006). 
These data are consistent with recently published work that suggests that Hnf6 
negatively regulates MafA expression in a β cell line by preventing the binding of Foxa2 
to the Mafa promoter (Yamamoto et al. 2013). 
 
Pdx1: β cell lineage commitment and maintenance 
Pdx1 expression is initiated in the pre-pancreatic endoderm and persists in the 
MPC population of the developing pancreatic buds (Figure 3, 5). As described above, it 
has multiple, distinct roles during pancreas induction, regionalization, organization, 
differentiation, and morphogenesis. Pdx1 is thought to play a role in the activation of the 
endocrine program, as in vitro studies indicated that Pdx1 and Hnf6 activate the Ngn3 
locus in a cooperative fashion (Oliver-Krasinski et al. 2009). Indeed, it is also necessary 
for establishing appropriate numbers of cells committed to the β cell lineage and 
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maintenance of the mature β cell phenotype (Jonsson et al. 1994, Offield et al. 1996, 
Ahlgren et al. 1998, Dutta et al. 1998, Brissova et al. 2002, Gannon et al. 2008). 
Expression of Pdx1 is significantly reduced in Ngn3+ endocrine progenitors, and is 
restored in β cells at late gestation through adulthood; it is also expressed at lower levels 
in δ cells and in the acinar tissue. Global deletion of Pdx1 results in pancreatic agenesis, 
although mutant animals develop a rudimentary dorsal bud and possess first-wave 
glucagon-positive cells (Jonsson et al. 1994, Offield et al. 1996). Reduced expression of 
Pdx1 in animals homozygous for a hypomorphic Pdx1 allele have fewer β cells, 
increased α and PP cells, disrupted islet architecture, and impaired glucose tolerance 
(Fujitani et al. 2006). Loss of Pdx1 in β cells during late gestation (RIP-Cre;Pdx1F/F) 
results in diabetes with age (Ahlgren et al. 1998).  Pdx1 heterozygosity causes reduced 
insulin secretion and glucose intolerance in adult mice due to decreased expression of 
genes regulated by Pdx1 that are involved in β cell function and survival, including 
insulin, the glucose transporter 2 (Glut2), islet amyloid polypeptide (Amylin, IAPP), 
glucokinase (Gck) MafA, and Pdx1 itself (Dutta et al. 1998, Brissova et al. 2002, 
Leibowitz et al. 2001, Waeber et al. 1996, Ohneda et al. 2000, Watada, Kajimoto, 
Miyagawa, et al. 1996, Watada, Kajimoto, Kaneto, et al. 1996, Raum et al. 2006, 
Marshak et al. 2000, Gerrish, Cissell, and Stein 2001).  
Pdx1 is also involved in establishing the proper number of β cells. The burst of β 
cell proliferation just prior to birth (Figure 2) is mediated by Pdx1 in mice, as deletion of 
Pdx1 in β cells in mid-gestation results in decreased β cell proliferation and a 
concomitant increase in α cell replication (Gannon et al. 2008).  Activation of Pdx1 
expression in Ngn3-positive cells biases some endocrine progenitors to the β cell fate, 
resulting in minor increases in β cells at the expense of α cells during the embryonic 
period. This may occur through through recruitment of the islet-enriched histone 
methyltransferase Set7/9 (Yang et al. 2011, Deering, Ogihara, et al. 2009). Postnatally, 
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this maintenance of Pdx1 over-expression within differentiated endocrine cells promotes 
the conversion of α cells to β cells (Yang et al. 2011). Pdx1 is also thought to directly 
inhibit the α cell fate by repressing the glucagon promoter (Ritz-Laser et al. 2002).  
 
Pax4 and Arx: β/δ vs. α lineage committment 
As described above, Ngn3+ endocrine progenitors can give rise to all endocrine 
cell types and, in the presence of permissive factors, such as Pdx1, make specific 
endocrine cell fate decisions. Pax4 is present in the pancreatic epithelium at e9.5 in the 
mouse, and is later restricted to β and δ cells (Sosa-Pineda et al. 1997). Ablation of 
Pax4 in mice results in an increased number of ghrelin+ cells at the expense of β cells, 
and forced expression of Pax4 in the developing pancreas and in adult α cells promotes 
the β cell fate (Collombat et al. 2009). These experiments indicate that Pax4 is 
necessary and sufficient for commitment to the β cell lineage. Conversely, Arx is initially 
expressed in the mouse pancreatic anlagen at e9.5 and is later co-expressed with 
glucagon at e14.5 and also found in PP cells (Collombat et al. 2003, Collombat et al. 
2007). Arx null mice show reduced numbers of α cells with a concomitant increase in β 
and δ cells, and ectopic expression of Arx throughout development or in adult β cells 
results in enhanced α cell differentiation and reduced β and δ cell number (Collombat et 
al. 2003, Collombat et al. 2007). Pax4 and Arx reciprocally inhibit the other’s promoter 
(Collombat et al. 2005). The effects of Pax4 and Arx modulation on the population of β/δ 
and α cells and their mutual antagonism suggests a governing role for these two 
transcription factors in endocrine cell type specification downstream of Ngn3. 
Interestingly, Pax4 and Arx exert similar control over the fates of enteroendocrine cells in 
the developing intestine (Beucher, Gjernes, et al. 2012).  
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Pax6: endocrine cell differentiation and adult α and β cell function 
Pax6 is another paired homeodomain transcription factor expressed at e9.5 in 
the pancreatic epithelium and later in committed endocrine cells (Turque et al. 1994, St-
Onge et al. 1997). Pax6 is detected in both insulin- and glucagon-positive cells, and 
mice lacking Pax6 show reduced numbers of β, δ, and PP cells, with a marked decrease 
in α cells and similar reduction in glucagon expression (Sander et al. 1997, St-Onge et 
al. 1997) . Similar to loss of Pax4, loss of Pax6 results in an expansion of the ghrelin-
expressing cell population, suggesting that it functions to divert endocrine cells away 
from this lineage (Heller et al. 2005). Pax6 transactivates both insulin and glucagon 
promoters, and regulates expression of genes involved in adult β cell function (including 
Pdx1, musculoaponeurotic fibrosarcoma (Maf) A, and Glut2, among others) (Gosmain et 
al. 2012). In total, Pax6 is a key factor in endocrine cell differentiation as well as adult α 
and β cell function. 
 
Nkx2.2: β cell lineage commitment 
NK homeodomain factors are involved in specification of endocrine progenitors 
upstream of Ngn3 expression and commitment to the endocrine cell lineage. Nkx2.2 is 
expressed in the pancreatic bud and Ngn3+ endocrine progenitors, where it functions as 
a repressor of non-endocrine fates, and is later expressed in all endocrine cell types 
except δ cells (Sussel et al. 1998, Schwitzgebel et al. 2000, Doyle, Loomis, and Sussel 
2007). Loss of Nkx2.2 in mice results in the complete absence of β cells, reduced 
numbers of α and PP cells, and increased ghrelin+ ε cells, suggesting a strong role for 
Nkx2.2 in specification of the β cell lineage and partial control of other endocrine cell 
type lineage specification. Indeed, experiments in mice show that Nkx2.2 and Arx work 
in concert to carefully regulate the population of δ and ε cells in the developing pancreas 
(Mastracci et al. 2011). 
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Exocrine development in late gestation 
After the secondary transition, the acinar component of the exocrine pancreas 
expands through proliferation of pre-existing cells and maintains expression of digestive 
enzymes. Expansion of the acinar cell population throughout the secondary transition 
and late gestation is mediated by Wnt signaling (Murtaugh 2008). The ductal portion of 
the exocrine pancreas undergoes changes in gene expression and organelle formation 
at this time. Ducts reach maturity in the mouse between e17 and e18 (Wescott et al. 
2009). Research performed in murine models suggests that Hnf6 regulates expression 
of prospero homeobox1 (Prox1), which is down-regulated in animals lacking Hnf6 
(Zhang et al. 2009). Prox1 expression is required for pancreas development, where it is 
expressed in pancreas progenitors and maintained in ducts, islets, and centroacinar 
cells in the mouse (Wang et al. 2005). Absence of either Hnf6 or Prox1 in the pancreas 
results in increased ductal proliferation and dilated ducts, indicating the roles for both in 
ductal homeostasis and maintenance of differentiation (Zhang et al. 2009, 
Westmoreland et al. 2009). Late gestation is also characterized by the formation of 
primary cilia in ducts. These cilia are immotile and hypothesized to function as chemo- or 
mechano-sensory organelles in the pancreas (Davenport and Yoder 2005). Formation of 
primary cilia is mediated by expression of transcription factors including Hnf6 and Sox9, 
and dysfunctional or reduced primary cilia result in duct dilation, pancreatitis, and cystic 
fibrosis (Zhang et al. 2009, Shih et al. 2012, Cano, Sekine, and Hebrok 2006). Sox9 
expression is upheld in differentiated ducts and also maintains the differentiated state, 
possibly through expression of polycystin 2 (Pkd2), a component of primary cilia (Shih et 
al. 2012). 
During late gestation, acinar cells also acquire their adult morphology and 
orientation. Zymogen granules form during the secondary transition (Pictet et al. 1972) 
and upon differentiation, acinar cells form a rosette structure at the ends of intercalatated 
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ducts (Figure 5) (Reichert and Rustgi 2011). Rosettes are organized such that the nuclei 
of each individual acinar cell is oriented at the basal membrane of the cell and zymogen 
granules containing digestive enzymes are positioned at the apical surface, where they 
are secreted into the ducts (Kesavan et al. 2009). 
 
Endocrine development in late gestation 
The period of time following the secondary transition and prior to birth in the 
mouse is characterized by increased proliferation of endocrine cells and their migration 
away from the ducts to form clusters within the exocrine tissue (Figure 2, 5). Islet 
morphogenesis is initiated at this time, although not fully established until postnatal 
stages. Additionally, β cells initiate changes in gene expression that are associated with 
maturity and glucose responsiveness (Figure 2). 
Once endocrine progenitors acquire a specific endocrine fate and Ngn3 
expression is down-regulated, the cells regain their capacity to proliferate. The late 
gestational period of pancreas development marks the height of endocrine proliferation 
in the mouse, with the peak of proliferation just prior to birth at e18.5 (Gannon et al. 
2008, Rhodes 2005). During early pancreatogenesis, endocrine cells are formed from 
Ngn3+ progenitors by neogenesis, but later in gestation and in the perinatal stages, 
endocrine mass is increased by proliferation of existing cells (Gu, Brown, and Melton 
2003). The source of proliferative stiumuli at this time in murine gestation has not yet 
been completely characterized, but specific genes required for appropriate proliferation 
have been identified. Loss of Pdx1 in insulin-producing cells of the developing mouse 
pancreas results in reduced proliferation of β cells and a subsequent increase in α cell 
proliferation and δ cell number, indicating the requirement for Pdx1 to establish 
appropriate numbers of specific endocrine cell types (Gannon et al. 2008). Connective 
tissues growth factor (CTGF) also regulates β cell proliferation at late gestation, and loss 
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or over-expression of CTGF in a global or tissue specific manner results in altered ratios 
of endocrine cells in the developing pancreas (Crawford et al. 2009, Guney et al. 2011) . 
Additionally, loss of expression of PERK, an eIF2α kinase, is associated with permanent 
neonatal diabetes that is observed in human Wolcott-Rallison syndrome, and contributes 
to decreased β cell proliferation in fetal mice (Delepine et al. 2000, Zhang et al. 2006, 
Feng et al. 2009). 
Concurrent with endocrine cell proliferation is the active migration of cells away 
from ducts (Figure 5) (Puri and Hebrok 2007). Hnf6 and the Bmp, Wnt, and TGFβ 
modulator CTGF are both important to this process. Hnf6 over-expression or loss of Ctgf 
results in endocrine cells that fail to migrate and remain apposed to the ducts (Gannon 
et al. 2000, Crawford et al. 2009). The extracellular matrix is normally remodeled as 
endocrine cells migrate into the acinar parenchyma, partially through TGF-β-mediated 
expression of matrix metalloproteases (Miralles et al. 1998, Perez et al. 2005). Integrin 
signaling is also involved in the emergence of cells from the ductal epithelium and their 
migration into the surrounding extracellular matrix (Cirulli et al. 2000).  Additionally, the 
Wnt and epidermal growth factor (EGF) pathways contribute to endocrine cell migration, 
as does expression of E-cadherin. Inactivation of the Wnt ligand Wnt5 in zebrafish and 
mouse impairs migration of endocrine cells (Kim et al. 2005). Global deletion of EGFR 
causes decreased β cell proliferation and impaired pancreatic branching in the mouse, 
partially through decreased expression of matrix metalloproteinases (Miettinen et al. 
2000).  Furthermore, over-expression of a dominant-negative Rho GTPase, Rac1, 
disturbs E-cadherin-mediated cell-cell contact and islet cell migration in the mouse 
(Greiner et al. 2009).  
Establishment of islet morphology also occurs as endocrine cells migrate from 
the ductal epithelium (Figures 2, 5). Interaction between β cells is required for islet 
formation and function and is mediated by cell adhesion molecules, including cadherins 
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and neuronal cell adhesion molecule (N-CAM) (Dahl, Sjodin, and Semb 1996, Esni et al. 
1999) . As endocrine cells migrate, they organize into clusters in which β cell contact 
each other directly. The arrangement of β cells in this manner and communication 
between cells via gap junctions and connexins allows for pulsatile insulin secretion in 
response to a glucose stimulus (Bergsten and Hellman 1993, Bosco, Haefliger, and 
Meda 2011, Head et al. 2012). 
 
Maturation of β cells 
The hallmark of a mature β cell is regulated glucose responsiveness. Although β 
cells are still maturing at late gestation, key genes involved in adult function are first 
expressed at this time. The ability to respond to changes in blood glucose is dependent 
on expression of Glut2 and prohormone convertase PC1/3, which cleaves proinsulin to 
active insulin (Guillam et al. 1997, Guillam, Dupraz, and Thorens 2000, Goodge and 
Hutton 2000) . Loss of either of these components affects insulin secretion in the 
postnatal animal. β cell maturation is also characterized by the transition of MafB to 
MafA expression (Nishimura et al. 2006, Artner et al. 2010). MafB is expressed in both 
insulin- and glucagon-positive cells at the primary and secondary transition, but its 
expression is restricted to α cells after birth (Artner et al. 2006). MafA expression is 
observed beginning at e13.5 at the secondary transtion in insulin-positive cells along 
with MafB. Activation of genes involved in β cell differentiation, including Pdx1, Nkx6.1, 
Glut2, and MafA, is promoted by MafB expression, and absence of MafB reduces the 
number of insulin-and glucagon-positive cells (Artner et al. 2007). Although MafA is not 
required for β cell development, it is a β cell-specific activator of insulin transcription and 
is required for glucose tolerance and insulin secretion in the adult animal (Zhang et al. 
2005). The transition of MafB to MafA expression is coincident with the re-expression of 
Pdx1 in β cells, which is consistent with the regulation of MafA expression by Pdx1 
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(Raum et al. 2006). Although MafA expression is seen in the mouse at e13.5, complete 
maturation of β cells does not occur until weaning (3 weeks of age) in rodents (Hang and 
Stein 2011) (Aguayo-Mazzucato et al. 2011). 
β cell maturation is also associated with innervation of the pancreas, which 
initiates in the mouse at e10.5 with the migration of neural-crest derived cells into the 
pancreatic buds (Plank, Mundell, et al. 2011, Burris and Hebrok 2007) . Deletion of the 
transcription factor Foxd3 from the neural crest population results in an expansion of 
endocrine mass. However, the expanded population of β cells fails to mature, as 
evidenced by decreased expression of MafA and Glut2 (Plank, Mundell, et al. 2011). 
Thus, endocrine cell maturation is dependent on innervation of the pancreas, which 
initiates during mid-pancreatogenesis and completes postnatally around 3 weeks of age 
(Burris and Hebrok 2007). 
 
Differences in mammalian islet morphology 
After the burst of proliferation in the late gestational and early postnatal periods, 
pancreatic islets assume their characteristic morphology (Figure 2). The murine islet 
consists of a β cell core with α, δ, PP, and ε cells composing the peripheral mantle of the 
islet (Figure 9). This morphology is also conserved in porcine islets, although islets are  
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Beta (`) cells: produce and secrete insulin to lower blood glucose levels; com-
pose the core of the islet (rodents) or are in closer contact with other 
hormone-producing cells in the core (human)
Alpha (_) cells: produce and secrete glucagon to raise blood glucose levels; 
distributed around the perifery of the islet (rodents) or contacting other cells within 
the core of the islet (human)
Delta (b) cells: produce and secrete somatostatin and work in concert with insulin 
to suppress glucagon production; distributed around the periphery of the islet 
(rodents) or more interspersed throughout the islet with other hormone-producing 
cells  (human)
PP cells: produce and secrete the gut hormone pancreatic polypeptide, which 
regulates food intake and endocrine and exocrine pancreatic secretions; distribut-
ed around the periphery of the islet (rodents) or more interspersed throughout the 
islet with other hormone-producing cells (human)
Rodent postnatal islet Human postnatal islet
Figure 9. Postnatal murine and human islet morphology. Figure modified  and reprinted with permission from 
Henley and Gannon, 2013.
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smaller and grouped into multi-islet clusters (Cabrera et al. 2006a). Interestingly, human 
and non-human primate islets differ in the organization of specific endocrine cell types 
compared to mice (Brissova, Fowler, et al. 2005). Humans and non-human primates 
have more of a ‘mixed islet phenotype’, with α, δ, and β cells found within the core of the 
islet, rather than compartmentalized to the periphery and core (Figure 9). Human islets 
are also heterogeneous and display different proportions of specific endocrine cell types 
compared to mice. In particular, human islets are composed of a greater percentage of α 
and δ cells, with a subsequent reduction in percentage of β cells, compared to murine 
islets (Brissova, Fowler, et al. 2005). It is currently unclear what accounts for the 
discrepancies between murine and primate islet morphology, but the reduced number of 
β cells in human or non-human primate islets may be related to their threshold of 
glucose sensitivity. Indeed, human and non-human primate islets have a lower set point 
for sensing glucose and respond lower levels of glucose than mouse islets (Henquin et 
al. 2006, Ling et al. 1996, Cabrera et al. 2006b, Cai et al. 2012). Perhaps primate islets 
are composed of fewer β cells because they are more sensitive to low levels of glucose, 
and therefore fewer β cells are required to maintain normal glucose levels within the 
organism. Currently, the field is assessing the species differences in islet development, 
composition, and glucose sensitivity in effort to better understand β cell function in the 
human context. 
Murine islets are considered functionally mature upon glucose responsiveness 
and expression of Glut2 and MafA and loss of MafB. Although human islets express 
Glut2, the predominant glucose transporter present in human β cells is the higher-affinity 
glucose transporter Glut1 (De Vos et al. 1995, Ferrer, Benito, and Gomis 1995). 
Expression of this transporter may account for the increased sensitivity of human islets 
to low glucose levels. Also present in human β cells is MafB, which is normally restricted 
39	   
to α cells in mice (Dai et al. 2012, Riedel et al. 2012). Cells that co-express insulin and 
glucagon are commonly observed in immature endocrine cells in the developing mouse 
and human pancreas. Surprisingly, adult human islets contain cells that continue to 
express both insulin and glucagon; while they lack Pdx1, MafA, and Nkx6.1, MafB and 
Arx can be detected in this population of cells (Riedel et al. 2012). These cells are 
thought to be mature α cells that transiently express insulin through an unknown 
mechanism, and this phenomenon is not observed in mouse islets (Riedel et al. 2012). It 
is not clear why adult human islets exhibit differential gene expression compared to 
murine islets, but these distinguishing features may partially explain why human β cells 
respond differently to glucose than murine β cells. 
 
BMP and Wnt Signaling 
 
BMP Signaling 
BMP ligands and their receptors belong to the TGFβ superfamily of paracrine 
signaling molecules. This large group of secreted factors is divided into two subgroups 
based on sequence similarity and pathway activation. TGFβ, Activin, and Nodal 
comprise one subgroup, and BMP, Growth and differentiation factor (GDF), and 
Muellerian inhibiting substance (MIS) form the second subgroup. TGFβ signaling 
pathways are evolutionarily conserved and play a role in growth, differentiation, 
migration, adhesion, and apoptosis. BMP signaling is important for developmental 
processes including embryogenesis, neural development, somite formation, limb bud 
expansion, and bone formation (Gazzerro and Canalis 2006). Postnatally, BMPs are 
required for growth, differentiation, apoptosis, and proliferation, and have been 
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implicated in the pathophysiology of osteoporosis, kidney disease, cerebrovascular 
diseases, and cancer (Shi and Massague 2003).  
TGFβ ligands are characterized by their cysteine knot structure and are secreted 
as functional disulfide-linked dimers. All ligands within the TGFβ superfamily bind to 
Type I and Type II trans-membrane serine threonine kinase receptors to initiate pathway 
activity; BMP ligands have a high affinity for Type I receptors, while TGFβ and Activin 
preferentially bind Type II receptors (Figure 10). BMP ligands (BMP 2, 4-7, 8a, 8b, 9, 
and 10) form hetero- or homodimers and bind to BMP receptor type I (BMPRI) or type II 
(BMPRII) to stimulate receptor heterodimerization and activation. BMP ligands bind 
weakly to Type II receptors alone, and with a much higher affinity when already bound to 
Type I receptors. Type II BMP receptors are constitutively active and phosphorylate 
Type I receptors after heterodimerization. Once activated, Type I receptors 
phosphorylate members of the Sma- and Mad-related (Smad) family of proteins, 
specifically receptor Smads (R-Smads) 1, 5, and 8, which then dimerize with the 
ubiquitously expressed co-Smad4 and translocate to the nucleus to facilitate 
transcription of target genes (Figure 10). 
 
Regulation of BMP signaling 
BMP signaling activity is regulated extracellularly and intracellularly at the ligand 
and co-factor level, respectively. BMP signaling can be antagonized intracellularly by 
inhibitory Smads 6 (BMP-specific) and 7 (a general TGFβ-family inhibitor), which 
compete with Smad4 for interaction with the activated Type I receptor (ten Dijke et al. 
2003). Intracellular regulation is also maintained by the HECT-domain ubiquitin ligases 
Smurf1 and Smurf 2, which complex with Smad7 and target activated receptors for  
41	   
BMP
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pSmad 1/5/8
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P
Figure 10. BMP signaling.  Extracellular BMP ligands (blue circles) bind to Type I (TIR) and 
Type II (TIIR) serine threonine kinase receptors to facilitate hetero-oligomerization. The consti-
tuitively active TIIR phosphorylates and activates TIR after ligand binding. After activation, TIR 
phosphorylates BMP-specific Smads 1/5/8, which then dimerize with the ubiquitously 
expressed co-Smad4. This Smad complex translocates to the nucleus to activate transcription 
of target genes.   
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degradation (Ebisawa et al. 2001, Kavsak et al. 2000). TGFβ family antagonists bind to 
and sequester ligands to prevent their interaction with receptors. Extracellular 
antagonists of the BMP pathway are widely expressed throughout development and in 
adult tissues to modulate BMP signaling. Many BMP antagonists, including those 
belonging to the DAN/Cerberus/CAN family of inhibitors, have a cysteine knot structure 
similar to that of BMP ligands (Avsian-Kretchmer and Hsueh 2004). Cerberus, a member  
of the DAN family, induces ectopic head structures in Xenopus and plays a role in 
anterior neural induction and somite formation in mice; it binds to Nodal, Wnt, and BMP 
ligands, allowing modulation of the TGFβ and Wnt pathways (Pearce, Penny, and 
Rossant 1999, Avsian-Kretchmer and Hsueh 2004). Gremlin, also in the DAN family, 
was first isolated from Xenopus neural crest cells and is required for limb development 
(Khokha et al. 2003). In the kidney, Gremlin expression is induced by high glucose and 
is associated with several models of diabetic nephropathy (Lappin et al. 2002, Murphy et 
al. 2002). Other BMP antagonists, including DAN and SOST, are involved in axon 
outgrowth/guidance and negative regulation of bone mineralization, indicating the 
breadth of BMP antagonist location and function (Dionne, Skarnes, and Harland 2001, 
Kusu et al. 2003). 
 
Differential effects of BMP signaling on pancreas development 
As described above, both Activins and BMPs are important to the induction of 
pre-pancreatic and pancreatic endoderm. Interestingly, members of this superfamily 
have differential effects on pancreas development and function. While BMP4 and 7 
promote Pdx1 expression in the early endoderm in the chick, BMP signaling from the 
septum transversum promotes liver fate over pancreas fate in the mouse (Kim, Hebrok, 
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and Melton 1997a, Rossi et al. 2001). Later during development, over-expression of 
TGFβ1 under control of the rat insulin promoter (RIP-Tgfβ1) results in small,disorganized 
endocrine clusters in the mouse, suggesting that increased TGFβ signaling negatively 
affects endocrine development and organization (Sanvito et al. 1995). Consistent with 
this idea, over-expression of Bmp6 in the pancreatic epithelium (Pdx1-Bmp6) results in 
pancreatic agenesis and reduced stomach and spleen size in the mouse (Dichmann et 
al. 2003). Interestingly, over-expression of Bmp4 within the same domain has no effect 
on pancreas development, indicating specific roles for particular BMP ligands during 
pancreatogenesis (Goulley et al. 2007). In contrast to these studies, zebrafish carrying 
the truncated form of the BMP antagonist Chordin (chordino) exhibit an enlarged 
pancreatic primordia and increased expression of pancreatic markers (Tiso et al. 2002). 
Furthermore, the swirl zebrafish mutant, that possesses a mutation in the Bmp2b gene, 
exhibits decreased expression of the endocrine markers NeuroD1 and Islet1 (Isl1) (Tiso 
et al. 2002). Removal of CTGF, a dual BMP/Wnt antagonist that shares functional 
similarity to Sostdc1 (see below) in a conditional fashion causes reduced β cell 
proliferation and vascular density; when CTGF is over-expressed in an inducible fashion 
during embryogenesis, β cell mass is expanded by increased proliferation (Crawford et 
al. 2009, Guney et al. 2011). Interestingly, loss of the dual BMP and Wnt antagonist 
Sostdc1 does not affect pancreas development (Henley et al. 2012). Clearly, there is a 
differential requirement for BMP signaling throughout pancreas development and across 
different species that requires further study to completely understand. 
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Wnt signaling 
The Wnt pathway is a highly conserved signaling pathway that is involved in 
multiple developmental processes and includes over 20 mammalian ligands. Activation 
of the Wnt signaling pathway induces axis patterning, cell proliferation, differentiation, 
gene transcription, and cell adhesion (Nelson and Nusse 2004). Canonical Wnt signaling 
facilitates the stabilization of β-catenin and its transcriptional activation of target genes 
through disruption of the glycogen synthase kinase (GSK) 3/APC/Axin1 destruction 
complex (Figure 11).  Wnt ligands bind to the 7-pass transmembrane domain Frizzled 
Fzd) receptor and LDL-related protein receptor (LRP) 5/6 to activate the intracellular 
phosphoprotein Dishevelled (Dsh).  Dsh disrupts the formation destruction complex, 
which normally phosphorylates β-catenin to target it for degradation.  The stabilization of 
β-catenin allows for its accumulation in the nucleus, where it functions to displace the 
transcriptional repressor Groucho from the TCF/LEF1 complex of transcription factors.  
In the absence of Wnt ligands, Dsh remains inactive and the destruction complex is able 
to phosphorylate β-catenin and target it for degradation (Figure 11). 
 
Regulation of Wnt signaling 
Activity of the Wnt pathway is regulated by extracellular antagonists that bind 
Wnt ligands or receptors. In particular, the Dickkoph (Dkk) family of extracellular Wnt  
antagonists regulate pathway activity by binding LRP5/6 receptors and preventing 
interaction with Wnt ligand/Fzd receptor complexes (Zorn 2001). Wnt ligands are bound 
and sequestered from receptors by soluble Frizzled Related Proteins (sFRPs) or Wnt 
Inhibiting Factors (WIFs) (Kawano and Kypta 2003). sFRPS can also bind to Fzd 
receptors themselves, and may also stabilized Wnt ligands by binding them.  
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Fzd receptor
LPR5/6
Wnt 
ligand
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GSK3
TCF/LEF
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Figure 11. Canonical Wnt signaling. In the presence of Wnt ligand, Fzd and LRP5/6 receptors 
interact and activate Dsh, which prevents the Axin/GSK3/APC destruction complex from phos-
phorylating the coactivator `catenin and targeting it for degradation. When stabilized, `caten-
in can translocate to the nucleus, displace the co-repressor Groucho, and complex with 
TCF/LEF transcription factors to activate target genes.  
Dsh
Groucho
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Wnt signaling in the pancreas 
Multiple Wnt ligands and receptors are expressed in the developing and adult 
pancreas (Heller et al. 2002, Heller et al. 2003).  Studies in Xenopus have established 
the requirement for inhibition of Wnt signaling for proper formation of foregut endoderm 
and development of pancreas and liver (McLin, Rankin, and Zorn 2007). However, low 
levels of Wnt signaling are actually required to maintain foregut endoderm progenitors 
(Zhang, Rankin, and Zorn 2013).  Later in development, Wnt signaling is absolutely 
required for expansion of the acinar cell population (Murtaugh 2008).  As evidence, 
reduced Wnt signaling or ablation of β-catenin prior to or during the secondary transition 
results in a striking, sometimes complete, loss of exocrine tissue, with varying reductions 
in Pdx1-expressing progenitor cells and reduction in size and number of endocrine cells 
(Gittes 2009). Conversely, stabilization of β-catenin using the late (e11.5) Pdx1-Cre 
conditional system causes a 4.6-fold increase in pancreas size, indicating that Wnt 
signaling may play a role in late embryonic/post-natal growth (Heiser et al. 2006). 
Furthermore, conditional expression of constituitively active β-catenin under control of 
the Pdx1 promoter increased β-cell size, enhanced insulin secretion, and improved 
glucose tolerance in mice (Rulifson et al. 2007). To contrast, islets from mice lacking 
LRP5 exhibited decreased levels of intracellular Ca2+ and ATP after glucose stimulation 
and failed to increase insulin secretion after incubation with Wnt3a, which stimulates 
secretion in WT islets (Fujino et al. 2003). These data are especially interesting in light of 
the recent identification of the Wnt pathway transcription factor Tcf7l2 as a T2D 
susceptibility gene.  Of the Tcf2l7 variants that have been associated with diabetes, the 
most likely candidate is a single nucleotide polymorphism (SNP), rs7903146, which lies 
within an intron (Gloyn, Braun, and Rorsman 2009). Although the exact role that Tcf7l2 
plays in the pathogenesis of diabetes has yet to be elucidated, it appears that 
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disregulated levels of Tcf7l2 affect distribution of voltage gated Ca2+ channels in the 
membrane and ultimately alter insulin secretion (Shu et al. 2008, da Silva Xavier et al. 
2009).  In accordance with these data, carriers of the Tcf7l2 risk allele exhibit decreased 
GSIS (Murtaugh 2008). Recent studies have revealed that deletion of Tcf7l2 in the 
glucagon-expressing cells in the gut and brain, but not the pancreas, resulted in 
impaired glucose tolerance and blunted insulin secretion, suggesting that Wnt activity in 
non-pancreatic tissues can affect glucose homeostasis (Shao et al. 2013). 
 
Sostdc1: BMP/Wnt antagonist regulated by Hnf6 
While multiple studies have explored the effect of altered BMP signaling on 
pancreas development, fewer have examined the implications of irregular BMP pathway 
activity on adult pancreas function. Over-expression of Bmp4 within the pancreatic 
epithelium (Pdx1-Bmp4) has no effect on pancreas development, but improves glucose 
homeostasis in adult animals and increases expression of genes involved glucose 
sensing and metabolism and in insulin production and secretion (Figure 12A, C) (Goulley 
et al. 2007). Furthermore, over-expression of a dominant negative Bmpr1a allele (Pdx1-
dnBmpr1a) impairs glucose homeostasis, insulin secretion, and expression of genes 
involved in insulin release in mice (Figure 12B, D) (Goulley et al. 2007). These data 
indicate that positive or negative mediation of the BMP pathway through a specific ligand 
or receptor, respectively, affects islet function.  
Similar to the Pdx1-dnBmpr1a model of impaired islet function, the Hnf6 
transgenic over-expression mouse model exhibits impaired glucose tolerance and 
reduced expression of Glut2, a gene associated with β cell maturity (Gannon et al. 2000, 
Tweedie et al. 2006). Analysis of changes in gene expression in pancreata from Hnf6  
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Figure 12. Characterization of Pdx1-Bmp4 and Pdx1-dnBmpr1a animals. (A) Overexpression of 
Bmp4 under control of the Pdx1 promoter (Ipf1-Bmp4) improves glucose tolerance in adult mice. 
(B) Over-expression of a dominant negative BMP receptor Bmpr1 under control of the Pdx1 
promoter (Ipf1-dnBmpr1a) impairs glucose tolerance. (C) and (D) Changes in gene expression in 
islets isolated from adult Pdx1-Bmp4 and Pdx1-dnBmpr1a mice. Figures modified and reprinted 
with permission from from Goulley et al., 2007.
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over-expressing mice at P1 revealed an up-regulation of the dual BMP/Wnt antagonist 
Sclerostin domain-containing 1 (Sostdc1; USAG-1, Ectodin, Wise; Figure 13) (Wilding 
Crawford et al. 2008). Sostdc1 belongs to the 8-membered ring cysteine knot family of 
secreted BMP antagonists, including Cerberus, DAN, Gremlin, and Connective Tissue 
Growth Factor (CTGF) (Yanagita 2005). Sostdc1 shows overall 37% identity with mouse 
Sclerostin and 60% identity within the cysteine knot structure, and these two molecules 
form a distinct subgroup of DAN family BMP antagonists because they are secreted as 
monomers (Laurikkala et al. 2003).  Sostdc1 has been isolated from the uterus, testes, 
kidney, developing limb buds, teeth, bones, pancreas and regions within the developing 
and adult brain, and binds BMP2 and 4 with high affinity and BMP6 and 7 to a lesser 
extent (Laurikkala et al. 2003, Yanagita et al. 2004, Tanaka et al. 2008).  Studies in tooth 
explants and hair placodes show that Sostdc1 expression is induced by BMP ligands 
(Laurikkala et al. 2003, Narhi et al. 2008), consistent with the increased expression of 
BMP7 in the Hnf6 transgenic model (Wilding Crawford et al. 2008).  Sostdc1 regulates 
the size and placement of enamel knots through regulation of BMP signaling and inhibits 
BMP4- and 7-induced expression of muscle segment homebox (Msx) 2 in developing 
tooth ectoderm (Kassai et al. 2005, Laurikkala et al. 2003).   Injection of Sostdc1 mRNA 
in Xenopus embryos causes a hyper-dorsalized phenotype that is consistent with 
inhibition of BMP, a known ventralizing factor (Itasaki et al. 2003, Yanagita et al. 2004).  
In the kidney, Sostdc1 is the primary BMP antagonist and is localized with BMP7 during 
development and in adulthood, where the ligand functions to protect against renal 
fibrosis by inhibiting and reversing the epithelial-mesenchymal transition (EMT) 
(Yanagita et al. 2006). Mice lacking Sostdc1 are protected from kidney injury and exhibit 
supernumerary tooth formation and fused molars due to enhanced BMP signaling  
(Yanagita et al. 2004, Yanagita et al. 2006, Ahn et al. 2010) .   
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Figure 13. Gene expression changes in the islet-specific 
Hnf6 over-expression model. RNA was collected from whole 
control and Hnf6 over-expressing (Pdx1PB-Hnf6) pancreata 
at P1 and changes in gene expression were detected by 
qRT-PCR. Genes of interest were normalized to tubulin. P < 
0.05. Figure modified and reprinted with permission from 
Wilding-Crawford et al., 2008.
Control
Pdx1PB-Hnf6
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Overview and Aims of Dissertation 
Previous studies in our lab have examined the function of Hnf6 in endocrine 
differentiation and function using mouse models that exhibit reduced or augmented Hnf6 
expression in the developing and adult pancreas (Gannon et al. 2000, Tweedie et al. 
2006, Wilding Crawford et al. 2008, Zhang et al. 2009). These pursuits have revealed 
that Hnf6 participates in processes important to endocrine specification, differentiation, 
and postnatal function through regulation of genes required for these events. Hnf6 is 
expressed in MPCs, bipotent progenitors, and in undifferentiated endocrine cells. 
Maintenance of Hnf6 expression in endocrine cells causes islet dysmorphogenesis, 
increased α cells at the expense of β cells, hyperglycemia, impaired glucose tolerance, 
and the failure of β cells to mature. Removal of Hnf6 reduces endocrine cell number 
during development and, in surviving animals, causes impaired insulin secretion and 
glucose tolerance (Jacquemin et al. 2000). These studies suggest that there is a 
temporal window during which Hnf6 is required to establish endocrine mass and prime 
cells for appropriate function by activating specific genes.  
A multi-pronged approach has been taken by the field to study, treat, and 
potentially cure both forms of diabetes. Efforts are being made to understand the 
immune insult that initiates T1D-mediated β cell destruction, while ongoing efforts to 
better comprehend β cell function, proliferation, and regeneration in the setting of T2D 
are also underway. Additionally, the specification and differentiation of endocrine cells is 
being assessed to improve methods for derivation of β cells in vitro or stimulation of their 
transidifferentiation from other cell types in vivo.  The goal of the studies presented in 
this thesis are to further characterize roles for Hnf6 and its downstream effectors in 
pancreatic endocrine function in the postnatal healthy and diseased states. We 
hypothesize that Hnf6 regulates downstream effectors in a temporal-specific manner to 
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establish β cell maturity and function. This dissertation describes these efforts in four 
chapters. Chapter II describese methods by which the research presented in this thesis 
was performed. Chapter III presents experimental results testing the hypothesis that loss 
of Sostdc1, a dual BMP/Wnt inhibitor regulated by Hnf6, improves adult β cell function in 
the setting of metabolic demand. Chapter IV presents results regarding the cooperative 
role of Hnf6 and Pdx1 in regulation of genes involved in β cell maturity and function, and 
Chapter V details the proposed experiments involving the over-expression of Hnf6 and 
Pdx1 in a human ductal epithelial cell line to explore the potential of generating β cells 
from the ductal epithelium.  
 
The following publications resulted from the research presented in this thesis: 
‘Inactivation of the dual Bmp/Wnt inhibitor, Sostdc1, enhances pancreatic islet 
function’.  Henley, et al., American Journal of Physiology: Endocrinology and 
Metabolism. 2012 Sep 15;303(6).  
‘Normal pancreatic development’. Henley and Gannon, Pathobiology of Human 
Disease: Dynamic Encyclopedia of Disease Mechanisms. In press.
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     CHAPTER II 
 
MATERIALS AND METHODS 
 
Mice 
Sostdc1 mutant allele  
Sostdc1LacZ/LacZ animals were generated as described previously (Yanagita et al. 2006, 
Tanaka et al. 2008, Valenzuela et al. 2003). To summarize, a cytoplasmic lacZ allele 
replaced the open reading frame of Sostdc1 to generate a knock-in allele (Figure 14). 
Sostdc1LacZ/LacZ animals were maintained on a mixed genetic background and genotyping 
of these animals was performed using primers designed to amplify the endogenous 
allele or the LacZ knock-in allele (Table 1). 
 
BRE-LacZ transgenic mice 
 
BRE-LacZ transgenic animals were generated as described elsewhere (Korchynskyi and 
ten Dijke 2002, Monteiro et al. 2004). Briefly, the coding sequence for β-galactosidase 
was inserted downstream of a fragment of the murine Inhibitor of DNA binding 1 (Id1) 
promoter containing the Bmp response element (BRE) multimerized twice. Genotyping 
for the BRE-LacZ transgene was performed using primers specific for the transgene 
(Table 1). 
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FIgure 14. Sostdc1LacZ allele. The Sostdc1LacZ allele was generated using homolo-
gous recombination. A cytoplasmic LacZ allele replaced the first exon of Sostdc1 
to generate a knock-in allele. The LacZ knock-in allele faithfully recapitulates 
Sostdc1 expression in the developing and adult kidney. Reprinted with permission  
from Tanaka et al., 2008.
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Pdx1 mutant alleles 
The Pdx1XSLacZ (Pdx1LacZ) allele was generated as previously described (Offield et al. 
1996). In summary, a nuclear-targeted LacZ allele was fused in-frame with the 5’ end of  
the second exon of Pdx1, replacing the DNA binding homeodomain (Figure 15). This 
allele generates a truncated protein that produces β galactosidase within the Pdx1 
domain. Pdx1LacZ animals were maintained on a mixed genetic background. Genotyping 
for the Pdx1LacZ allele was performed using primers specific for the LacZ knock in (Table 
1).  Pdx1KO animals were generated by homologous recombination, in which intron and 
coding region sequences of the second exon were replaced with an MC1neor cassette 
(Figure 15) (Offield et al. 1996). Genotyping for animals carrying the Pdx1KO allele were 
performed using primers specific for the MC1neor cassette (Table 1). All Pdx1 mutant 
animals were maintained on a mixed genetic background. 
 
Hnf6 floxed allele 
 
The Hnf6 floxed allele was generated as previously described (Zhang et al. 2009). In 
summary, loxP sites were introduced 5’ and 3’ of the cut domain within the first exon 
(Figure 16). Cre-mediated recombination of this locus generates a null allele.  Primers 
designed to amplify the cut domain and the recombined allele were used for genotyping 
(Table 1). Hnf6 floxed animals were maintained on a mixed genetic background. 
 
Cre transgenes 
The Pdx1-Cre and Protamine-Cre (Prm-Cre) transgenes were generated as described 
previously (Hingorani et al. 2003, O'Gorman et al. 1997). In summary, Cre recombinase 
expression is driven by the 4.3kb region of the murine Pdx1 promoter (between XhoI and 
SacI restriction sites), and activates Cre expression as early as e9.5 in the antral  
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Figure 15. Pdx1XSLacZ and Pdx1XB alleles. (A) To generate the Pdx1XSLacz 
(Pdx1LacZ) allele, homologous recombination was used to replace the 
segment of Pdx1 between XbaI and SmaI sites. A nuclear-targeted `-ga-
lactosidase allele that is fused in-frame with the 5’ end of the second exon 
of Pdx1 was inserted, replacing a portion of the homeodomain  (middle 
locus; homoeodomain is shown in red). Homologous recombination was 
used to replace the segment of Pdx1 between the XbaI and SmaI sites 
(including an intron and coding regions of the second exon)  with an MC1-
neor cassette (lower locus). Animals carrying two copies of the Pdx1XB 
allele display pancreatic agenesis, consistent with other Pdx1 null models 
(data not shown). (B) X-gal staining of embryos carrying the LacZ knock-in 
allele revealed evidence of ` -galactosidase activity appropriately within the 
Pdx1 domain. Numbers in (B) represent embyronic days of development. 
V, ventral bud; d, dorsal bud; a, antral stomach; du, duodenum; c, common 
bile duct; p, pancraes; s, stomach. Schematic in (A) was modified from 
Offield et al, 1996. Figures modified and reprinted with permission from 
Offield et al, 1996.   
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Figure 16. Hnf6 floxed allele. To generate the Hnf6 floxed allele, a loxP-FRT Hnf6 flox-neo  construct with 
loxP sites flanking the cut domain (exon 1, green) was designed (middle schematic). The construct was 
electroporated into ES cells and positive clones were selected for neor and TK (gancyclovir) resistance. 
The neor cassette was removed by FLPe recombinase. The resultant floxed allele (bottom schematic) 
was microinjected into C57BL/6 blastocysts to generate chimeric mice. Figure adapted from Zhang et 
al., 2009.
Ex 2
Ex 2
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Figure 17. Pdx1-Cre  transgene. (A) In this transgene, expression of Cre recombinase is under control of 
the 4.3 kb fragment between XbaI and SacI restriction sites of Pdx1 promoter. This promoter contains 
areas I, II, and III, and is sufficient to drive Cre expression in the antral stomach, rostral duodenum, and 
throughout the entire pancreatic epithelium.(B) Recombination of the R26R reporter allele using this trans-
gene is observed as early as e9.5 in the mouse (left) and throughout the pancreatic epithelium by e16.5 
(right). St, stomach; sp, spleen; d, duodenum; dp, dorsal pancreas; vp, ventral pancreas. E9.5 whole 
mount image courtesy of Dr. Jennifer Plank and e16.5 image reprinted with permission from Wicksteed et 
al., 2010. 
XbaI SacI
I II III
Ex 1 Ex 2
-4.6 kb
Pdx1 promoter
I II III
Pdx1-CreTuveson transgene
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stomach, rostral duodenum, and pancreatic epithelium (Figure 17).  Prm-Cre expression 
is driven by a 652-bp fragment of the murine Protamine1 promoter and is expressed in  
the male germ line. Prm-Cre is active in haploid sperm, and recombines target alleles in  
the 2 to 4 cell stage. Primers designed to amplify the Cre transgene were used for 
genotyping (Table 1). All animals carrying the Cre transgene were maintained on a 
mixed genetic background. 
 
EYFP reporter allele 
The enhanced yellow fluorescent protein (EYFP) reporter allele was generated as 
described previously (Srinivas et al. 2001). Briefly, homologous recombination was used 
to introduce an allele containing a transcriptional stop site flanked by loxP sites upstream 
of EYFP into the ROSA26 (R26R) locus. In the presence of Cre recombinase, the 
sequence between loxP sites is recombined, removing the termination signal and  
allowing transcription of the EYFP allele.   Primers designed to amplify the endogenous 
R26R locus and the EYFP insert were used for genotyping (Table 1). 
 
All animals were maintained on a 12-hour light/dark cycle, provided food and water ad 
libitum, and all experiments involving animals were approved by the Institutional Animal 
Care and Use Committee of Vanderbilt University Medical Center.  
 
 
 
Genotyping 
Genotyping was performed using tail or ear punch DNA and the primer sets listed in 
Table 1. 
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Table 1. List of genotyping primers. 
 
 
 	  
 
Primer name Sequence 
Sostdc1 WT 5’ CCTTCTCTGTGTTTTCACTCCG 
Sostdc1 WT 3’ TGATTCAGGGTGCTGTTGC 
LacZ Mut 3’ CCGTAATGGGATAGGTCACG 
BRE-LacZ 5’ CCTTTCGCTATTACGCCAG 
BRE-LacZ 3 TTAAGTTGGGTAACGCCAGG 
LacZ 5’ (For Pdx1LacZ) GCCGTCTGAATTTGACCTGA 
LacZ 3’ (For Pdx1LacZ) TCTGCTTCAATCAGCGTGCC 
Pdx1XB 5’ CAAGCCAGGGAGTTAAATC  
Pdx1XB 3’ AGGTGAGATGACAGGAGATC 
Hnf6 Flox 5’ GTCGTCGACCTCTCTCTGTCTCCCTC 
AGTATCC 
Hnf6 Flox 3’ ATAAGCGGCCGCCCTCCCTCTCTC TTT 
CCATC 
Hnf6 recombined 3’ ATAAGCGGCCGCGCCTGCAGGGTTT 
GGAATCTGTG 
Cre 5’ TGCCACGACCAAGTGACAGC; 
Cre 3’ CCAGGTTACGGATATAGTTCATG 
R26R 5’ (for eYFP) AAAGTCGCTCTGAGTTGTTAT 
R36R 3’ (for eYFP) GGAGCGGGAGAAATGGATATG 
eYFP Mutant 3’ AAGACCGCGAAGAGTTTGTC 
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Percent C57Bl/6 contribution. 
Genetic background of Sostdc1LacZ/LacZ and wild-type littermates was determined by 
Jackson Laboratories (www.jax.org) using genome scanning for strain-specific single 
nucleotide polymorphisms (SNPs) (Petkov et al. 2004). Percent contribution of C57BL/6 
to overall genetic background was calculated by adding the number of C57Bl/6-specific 
SNPs and one-half of the number of total SNPs heterozygous for C57Bl/6 and dividing 
by the total number of SNPs assessed.  
 
Tissue dissection, preparation, and histology 
For embryonic studies, the morning of the vaginal plug was considered to be 
e0.5. Digestive organs were dissected fixed for 1-4 hours in 4% paraformaldehyde (PFA) 
at 4°C, dehydrated in an ascending ethanol series, cleared in Citrisolv (Fisher) or 
xylenes, and embedded in paraffin. For frozen embedding, tissue was fixed as described 
above and placed in a 30% sucrose solution overnight. Following a 30 minute incubation 
in a 50/50 solution of FSC22 (Frozen Section Compound, Leica) and 30% sucrose, 
frozen tissues were embedded in 100% FSC22 and frozen on dry ice. Paraffin-
embedded and FSC22 embedded tissues were cut at 5 µm and 7µm, respectively.  
Paraffin-embedded tissues were deparaffinzed in Citrisolv or xylenes, rehydrated 
in a descending ethanol series to distilled water; frozen tissues were allowed to thaw for 
30 minutes at room temperature and permeabilized in 0.1% Triton in 1X PBS for two 15 
minute intervals. Indirect protein localization was obtained by incubation of tissue with 
primary antibodies (Table 2). Primary antibodies for Glut2, Hnf6, MafA, Sox9, and 
Synaptophysin required antigen retrieval (Table 2). Detection of primary antibodies was  
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Table 2. List of primary and antibodies used for immunohistochemistry.  
 
Primary antibody Source Dilution Antigen retrieval  
Rab anti-glucagon Millipore 1:1000 none 
Rab anti-Glut2 DAKO 1:300 1X TEG buffer, pH 
9.0, 1 minute fast 
boil, 7.5 minute 
slow boil 
Gp anti-insulin DAKO 1:1000 none 
Goat anti-Hnf6  Santa Cruz 1:250 1X Sodium Citrate, 
pH 6.0, 2 hour 
pressure cooker 
Rab anti-Hnf6 Santa Cruz 1:50 1X Sodium Citrate, 
pH 6.0, 2 hour 
pressure cooker 
Rab anti-MafA Bethyl 1:1000 1X TEG buffer, pH 
9.0, 1 minute fast 
boil, 7.5 minute 
slow boil 
Rab anti-Sox9 Millipore 1:5000 1X 10mM Citrate 
buffer, pH 6.0, 10 
minute boil 
Mouse α 
synaptophysin 
Millipore 1:500 1X Sodium Citrate 
buffer, pH 6.0, 14 
minute boil 	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achieved by labeling with species-specific secondary antibodies conjugated to either 
Cy2 or Cy3 fluophores and diluted 1:300.   
For X-gal staining, tissues were permeabilized for 15–30 min in 2 mM MgCl2, 
0.01% sodium deoxycholate, 0.02% Nonidet, P-40 in 1x PBS (permeabilization solution) 
at 4°C, and reacted with 5-bromo-4-chloro-3-indolyl-b-Dgalactopyranoside (X-Gal) 
substrate solution overnight at room temperature. Tissues were post-fixed in 4% PFA for 
1 hour at 4°C. 
Fluorescent and bright field images were captured using an Olympus BX41 
research microscope or the Aperio ScanScope microscope and slide scanner (Vista, 
CA). Digital images were captured using MagnaFire software (Optronics Engineering, 
Goleta, CA) or the ImageScope software of the Aperio software suite (Vista, CA).  
 
 
Analysis of α:β ratio and α/β cell area 
Whole pancreata were serially sectioned at 5µm and sections were 
immunolabeled for insulin and glucagon. At least 1-2% of the entire pancreas was 
imaged (approximately 1 section every 250 µm throughout the pancreas). Slides were 
imaged as described above and using MetaMorph software (v7.7, Molecular Devices) or 
a macro built in Genie (Aperio System, Vista, CA), insulin- and glucagon- positive cells 
were counted or the area of insulin- and glucagon- positive cells was measured, 
respectively. The ratio of α to β cells was calculated by dividing the number of glucagon-
positive cells by the number of insulin-positive cells. Insulin/glucagon-positive area was 
calculated by adding the insulin-positive and glucagon-positive area of each section and 
dividing it by the total pancreas area of each section.  
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Analysis of β cell mass 
Sections ~250 µm apart (10 sections per animal) were immunolabeled for insulin 
followed by a peroxidase-conjugated secondary antibody, visualized using a DAB 
Peroxidase Substrate Kit (Vector Laboratories), and counterstained with eosin. Total 
pancreatic and insulin-positive areas of each section were measured using MetaMorph 
Software. β-cell mass was calculated by the ratio of insulin-positive area to total 
pancreas area of all sections for each animal multiplied by the tissue wet weight. 
 
Analysis of β cell proliferation 
Pancreatic sections 600–900 µm apart (3 sections per animal) were co-labeled 
for insulin and PH3 followed by species-specific Cy2- or Cy3-conjugated secondary 
antibodies. The PH3 primary antibody required antigen retrieval in 10 mmol/l sodium 
citrate, pH 6.5, followed by 0.2% Triton X-100 in PBS. Nuclei were labeled with 1.5 g/ml 
4=,6=-diamidino-2-phenylindole (DAPI, Molecular Probes) in mounting medium. All 
insulin-positive cells on each section were imaged at 400X magnification on an Olympus 
BX41 microscope with a digital camera using Magnafire (Optronics). A minimum of 
3,000 β-cells per animal were counted. Percent proliferating β-cells equaled the number 
of insulin/PH3 double-positive cells divided by the total number of insulin-positive cells. 
 
Assessment of liver glycogen deposition by Periodic acid-Schiff (PAS) stain 
 5 µm sections of adult liver were randomly selected for assessment of glycogen 
deposition by PAS stain. Tissue sections were deparaffinzed and rehydrated in 
deionized water and stained according to manufacturer’s instructions (Sigma). 
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Islet isolation and RNA acquisition 
Isolation of islets from newborn or neonatal pancreas required dissection of the 
organ, collagenase digestion of whole pancreas at 37°C and hand-picking of islets from 
exocrine tissue. Isolation of islets from 4, 8, 12, and 16 week-old animals was performed 
by collagenase digestion from the main pancreatic duct and hand-picking from the 
exocrine tissue. Picked islets were placed immediately in 500µl Trizol reagent or 
RNALater (Ambion), lysed by vortexing or homogenized using a Tissuemiser (Fisher 
Scientific), and RNA was isolated using the RNAqueous (Ambion) or RNeasy Micro/Mini 
kits (Qiagen) according to manufacturer’s instructions and eluted in 10-30 µl elution 
buffer. RNA concentration and integrity were assessed using a ND-1000 
Spectrophotometer (NanoDrop) and the 2100 Electrophoresis Bioanalyzer (Agilent) at 
Vanderbilt Technologies for Advanced Genomics (VANTAGE) Core. cDNA generated 
from neonatal islets required amplification with the SMARTer Pico PCR cDNA synthesis 
kit according to manufacturer’s instructions (Clontech).  
 
Quantitative Real-Time PCR 
cDNA was prepared from 50-350 ng islet or pancreas RNA using the Superscript 
III First-Strand synthesis system (Invitrogen). Real-time reactions were carried out in 
technical duplicate with iQ SYBR Green supermix (Bio-Rad) according to the 
manufacturers instructions on a CFX Real-Time PCR Detection system (Bio-Rad) in the 
Vanderbilt Molecular and Cellular Biology Resource Core. Primers used to assess gene 
expression are listed in Table 3. 
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Table 3. List of primers used for quantitative real-time PCR (qRTPCR). 
	  
	   Forward Primer	   Reverse Primer	  
HPRT (internal control)	   AGT CAA CGG GGG ACA TTAA AA	   TGC ATT GTT TTA CCA GTG TCA A	  
h18S (internal control)	   CGG ACA TTG ACA GAT TGA TAG	   TGC CAG AGT CTC GTT CGT TAT 
CG	  
Sostdc1	   AAC AGC ACC CTG AAT CAA GC	   CAG CCC ACT TGA ACT CGA C	  
Chordin	   GCA GTG GTT CCC AGA GAA TCA	   AAC AAT CGT CCC GCT CAC AGT	  
Ctgf	   CTG GGG ACA ATG ACA TCT	   GTT CGT GTC CCT TAC TTC CT	  
Id2	   CCG CTG ACC ACC CTG AAC	   ACA TAA GCT CAG AAG GGA ATT 
CAG AT	  
Nkx6.1	   TCA GGT CAA GGT CTG GTT CCA	   CGG TCT CCG AGT CCT GCT T	  
Smad1	   TGT GAA CCA CGG GTT CGA	   ATC CTG CCG GTG GTA TTC G	  
Glut2	   GGG GTT GGT GCC ATC AAC	   CAC AAG CAG CAC AGA GAC AGC	  
Bmp4 TGA TAC CTG AGA CCG GGA AG AGC CGG TAA AGA TCC CTC AT 
Bmp7 GGG CTT ACA GCT CTC TGT GG TGG TCA CTG CTG CTG TTT TC 
Bmpr1a AAC GCT TGC GGC CAA TC GAC ATT AGC TTC AAA ACT GCT 
CGA A 
Wnt3a ATG GCT CCT CTC GGA TAC CT GGG CAT GAT CTC CAC GTA GT 
Cyclin d1 GGC ACC TGG ATT GTT CTG TT CAG CTT GCT AGG GAA CTT GG 
Cyclin d2 GTT TGA GAG CAG GGC TTG AC CTG TCT GCC TTT CGT CCT TC 
Cdk4 TAG CCG AGC GTA AGG TGA GT AT CGC ACT AGG CAC AAA GA 
MMP7 GGT GAG GAC GCA GGA GTG AAC GAA GAG TGA CTC AGA CCC AGA 
GAG T 
c-Myc CTC AGT GGT CTT TCC CTA CCC 
G 
TGT CCA ACT TGG CCC TGT TGG 
C 
PPAR-Delta GGC CAT GGG TGA CGG AGC GAT CTT GCA GAT CCG ACT GC 
Chordin GCA GTG GTT CCC AGA GAA TCA 
 
AAC AAT CGT CCC GCT CAC AGT 
 
Gremlin AGA AAC AGC GCC TGA GCA AGA 
 
AAA AGC GGC TGC CTA GGT CAT 
 
Hnf6 AGG AGC CGG AGT TCC AGC TGA AGA CCA GCC TGG GCT 
Hnf6 OC domain ATC CTC ATG CCC ACC TGA ATG GTT TGA GCT CGG TGG TGA TAC 
Pdx1 CGC GTG GAA AGG CCA GTG CTG CCA GCT CCA CCC GGC GG 
hHnf6 GGA GAC CTT CCG GAG GAT GTG CCT ACC CTT CCT CCT TTG GTC 
hPdx1 CTG CCT TTC CCA TGG ATG AAG TCC GAC CCG GGA TAA TCC AAG 
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Analysis of gene expression by TaqMan Low Density array (TLDA) 
To assess changes in islet gene expression, islet RNA was isolated as described 
above and 150-300ng cDNA was prepared using the SuperScript III First Strand 
Synthesis System Kit according to manufacturers instructions (Invitrogen). Genes were 
analyzed using TaqMan Universal PCR Mastermix (with UNG, Applied Biosystems) on  
TLDAs were run on a 7900HT Fast Real-Time PCR PCR system and data were 
analyzed using SDS RQ Study software (Applied Biosystems, Life Technologies). All 
samples were run in triplicate. 
 
Analysis of gene expression by RNA-Seq 
RNA was extracted from whole pancreata at e15.5 (see above) and RNA 
libraries were prepared according to the University of Pennsylvania protocol 
(http://ngsc.med.upenn.edu, Lab protocol, Library preparation for RNA-Seq from total 
RNA). Libraries were single-end sequenced to 100bp on an Illumina hiSeq2000. Reads 
from ribosomal RNA and genomic repeats were identified by aligning the 5’ 50bp of each 
read to ribosomal sequences and the human repeats in RepBase (version 14.10) using 
Bowtie (Langmead et al., 2010) and allowing for up to three mismatches. The remaining 
reads were processed with RUM (Grant et al. 2011) and aligned to the set of known 
transcripts included in RefSeq, UCSC known genes, and ENSEMBL transcripts, and the 
human genome (hg18, NCBI build 36.1). Transcript-, exon- and intron-level 
quantification was done using only the uniquely aligning reads (Langmead 2010).  
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Western blotting 
Islets were isolated from 8-wk-old animals as described above. Following 
isolation, islets were immediately lysed in RIPA buffer and protein content was quantified 
using the Bio-Rad DC protein assay (Bio-Rad). Twenty micrograms of protein per 
sample were electrophoresed on 4–12% Bis-Tris gels under denaturing conditions and 
blotted onto PVDF membrane using the NuPAGE Western blotting system (Invitrogen). 
Blots were then blocked in 5% nonfat milk in TBS (pH 7.6) for 1 h at room temperature 
and probed with the following primary antibodies diluted in 3% nonfat milk in TBS and 
incubated overnight at 4°C: rabbit anti-phospho-Smad1 (Cell Signaling, 1:1,000) and 
mouse-anti-_-actin (Santa Cruz Biotechnology, 1:5,000). Blots were washed in 0.1% 
Tween 20 in TBS for 30 min at room temperature with three changes of buffer. HRP-
conjugated species-specific secondary antibodies were diluted to 1:5,000 anti-rabbit and 
anti-mouse, Jackson ImmunoResearch) in 1% nonfat milk in 1X TBS and incubated for 1 
h at room temperature. Following washes as previously described, protein detection was 
facilitated by an ECL detection system (Amersham) per the manufacturer’s instructions 
using Kodak X-Omat Blue film. Protein levels were quantified using ImageJ software and 
presented graphically using GraphPad Prism software. 
 
In vivo analysis of glucose homeostasis 
Animals were fasted for 16 hours prior to in vivo intra-peritoneal glucose 
tolerance testing (IPGTT). Fasting blood glucose was measured from the tail vein using 
an Accuchek glucometer and glucose strips. Animals received an intraperitoneal glucose 
injection of filter-sterilized glucose (2mg dextrose/g body weight) and blood glucose was 
measured at the 15, 30, 60, 90, and 120 minute time points following injection. 
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Insulin tolerance testing 
Animals were fasted for 6 h prior to an insulin tolerance test (ITT). Fasting blood 
glucose was measured as described above, and animals received an intraperitoneal 
injection of 0.075 U/ml insulin (recombinant human insulin, Sigma-Aldrich, no. I9278) in 
filter-sterilized 1X PBS at 0.1 ml/10 g body wt. Subsequent changes in blood glucose 
were measured at 15-, 30-, 60-, 90-, and 120-min intervals following injection. 
 
 
Islet perifusion 
 
Islet perifusions were performed as previously described (Brissova et al. 2002) 
Islets were isolated from the pancreata of mice on standard chow and high fat diet (HFD, 
60% kcal from fat, BioServ) by collagenase digestion from the main pancreatic duct and 
hand-picked from exocrine tissue. Islets were perifused in a parallel, four-column 
apparatus controlled by peristalsis pumps and submerged in a circulating 37°C water 
bath. Islet effluent was plumbed into four fraction collectors at 3.0 min/fraction and saved 
for analysis of insulin secretion. Twenty to forty islets from each mouse were loaded per 
column and perifused with low (2.8 mmol/l) glucose perifusion medium (38.1 mmol/l 
sodium bicarbonate, 4.0 mmol/l L-glutamine, 1.0 mmol/l sodium pyruvate, 0.5% phenol 
red, 5.0 mmol/l HEPES, and 0.1% BSA in 1.0 l Dulbecco’s modified Eagle’s medium 
without glucose, pH 7.4) for a 30-min equilibration period (baseline) followed by high 
glucose (16.8 mM), high glucose plus 100µM 3-isobutyl-1-methylxanthine (IBMX), and 
high glucose plus 300 µM Tolbutamide. Insulin was measured by solid-phase 
radioimmunoassay (125I-labeled insulin, Diagnostic Products) for mouse anti-insulin (MP 
Biomedical). 
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Generation of transgenes for over-expression of Pdx1 and Hnf6 
 
TetO-HA-Pdx1  
To generate a tagged, inducible form of Pdx1, murine Pdx1 cDNA was cloned 
from the PZL1 plasmid, provided by Dr. Christopher Wright (Vanderbilt University). 
Primers were designed to add a 5’ EcoRV site and an HA tag  and an EcoRV site at the 
3’ end to Pdx1 cDNA, generating an ~800 bp N-terminal HA-tagged version of Pdx1 
flanked by EcoRV sites. PCR was used to generate HA-tagged Pdx1 containing 5’ and 
3’ EcoRV sites from 100ng Pdx1 cDNA and Platinum Taq (Invitrogen). The resultant 
product was digested with EcoRV and gel purified using a Gel Extraction Kit (Qiagen), 
according to manufacturer’s instructions. Concentration and purity of the fragment was 
determined by ND-1000 Spectrophotometer (NanoDrop, (VANTAGE). EcoRV-HA-Pdx1-
EcoRV was cloned into the pTeto7CMV/BGH.polyA/pBSIISK(AscI) (pTetO) vector, 
provided by Dr. Timothy Blackwell (Vanderbilt University), following EcoRV digestion and 
dephosphorylation of the pTetO vector by Calf Intestinal Phosphatase (NEB) . pTetO 
and EcoRV-HA-Pdx1-EcoRV were incubated overnight at 15°C with T4 DNA Ligase 
according to manufacturer’s instructions (NEB). Ligation products were transformed in 
DH5α by standard technique, allowed to recover for 1 hour in a shaking incubator at 37°, 
and 100µl were plated on Luria broth (LB) plates containing Ampicillin. Plates were 
incubated overnight at 37°C. Resultant colonies were picked and cultured overnight in 
1ml LB containing 50ng/µl Ampicillin. Cultures were purified using a Miniprep Kit 
(Qiagen) according to manufacturer’s instructions and eluted in 30 µl elution buffer. 
Presence of the HA-Pdx1 insert was verified by EcoRV digestion and sequencing 
(Figure 18).  
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Figure 18. Schematic of the pTetO-HA-Pdx1 plasmid. The HA-Pdx1 insert was cloned into  the EcoRV site 
of the p(TetO)7CMV/BGH.polyA/pBS II SK (AscI) plasmid to generate the TetO-HA-Pdx1 construct. The 
TetO-HA-Pdx1 fragment was linearized by digestion with AscI. pTetO7CMV promoter ~ 500 bp; HA-Pdx1 
fragment ~ 800 bp; BGH polyA tail ~ 300 bp. Plasmid not drawn to scale. 
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Figure 19. Schematic of the pTetO-Myc-Hnf6 plasmid. The Myc-Hnf6 insert was cloned into  the EcoRV site 
of the p(TetO)7CMV/BGH.polyA/pBS II SK (AscI) plasmid to generate the TetO-Myc-Hnf6 construct. The 
TetO-Myc-Hnf6 fragment was linearized by digestion with NheI. pTetO7CMV promoter ~ 500 bp; Myc-Hnf6 
fragment ~ 1.6 kb; BGH polyA tail ~ 300 bp. Plasmid not drawn to scale. 
NheI NheI
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TetO-Myc-Hnf6 
To generate a tagged, inducible form of Hnf6, murine Hnf6 cDNA was cloned 
from the pGEM-1 parent plasmid, a gift from Dr. Robert Costa (University of Chicago). 
Primers were designed to add a 5’ EcoRV site and a Myc tag and an EcoRV site at the 
3’ end to Hnf6 cDNA, generating an 1.6 kb N-terminal Myc-tagged version of Hnf6 
flanked by EcoRV sites. PCR was used to generate Myc-tagged Pdx1 containing 5’ and 
3’ EcoRV sites from 100ng Hnf6 cDNA and Platinum Taq (Invitrogen). Cloning into the 
pTetO vector was performed as described above with one alteration; additional Nhe1 
restriction sites were added to the pTetO vector by PCR to facilitate the linearization of 
the TetO-Myc-Hnf6 fragment (Figure 19). Presence of the Myc-Hnf6 insert was verified 
by EcoRV digestion and sequencing.  
 
 
Generation of Pdx1 and Hnf6 lentiviral vectors 
 
pLVX-Pdx1-mCherry 
 
Murine Pdx1 cDNA was cloned from the PZL1 expression plasmid. PCR was 
used to add a 5’ XhoI and 3’ SacII restriction sites to Pdx1 cDNA. Following introduction 
of these restriction sites, the XhoI-Pdx1-SacII fragment was digested with XhoI and SacII 
and gel purified. The pPRIG vector, provided by Dr. Patrick Martin (Université de Nice), 
was linearized by double XhoI/SacII digestion, dephosphorylated with Calf Intestinal 
Phosphatase (NEB) and gel purified. To add an internal ribosomal entry site (IRES) 
downstream of Pdx1, the XhoI-Pdx1-SacII insert and linearized pPRIG vector were 
ligated, transformed, cultured, and purified as described above. PCR was performed on 
pPRIG vectors containing the Pdx1 insert to add a BamHI restriction site 3’ of the Pdx1- 
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Figure 20. Schematic of pLVX-Pdx1-IRES-mCherry lentiviral plasmid. To generate a bicistronic vector for lentiviral over-ex-
pression of murine Pdx1, the 1.4 kb Pdx1-IRES insert was digested with XhoI and BamHI cloned into the 
pLVX-N3-GW-mCherry vector. Schmetaic includes components relevant to lentiviral production (s, packaging signal) and 
transcription (RRE, Rev-response element; PPGK, posphoglycerate kinse promoter; WPRE, woodchuck hepatitis virus post-
transcriptional regulatory element). This plasmid map is modified from the pLVX-N3-mCherry vector map (Clontech, Dr. 
Matthew Tyska laboratory) and is not drawn to scale. 
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IRES fragment. Following gel purification, pPRIG vectors containing the Pdx1 insert 
were double digested with XhoI and BamHI to release the 1.4 kb Pdx1-IRES fragment. 
The pLVX-N3-GW-mCherry lentiviral vector, provided by Dr. Matthew Tyska (Vanderbilt 
University), was double digested with XhoI and BamHI, dephosphorylated as described 
above, and ligated with the XhoI-Pdx1-IRES-BamHI fragment as described above to 
generate a Pdx1-IRES-mCherry fragment (Figure 20). The resultant colonies were 
purified and sequenced to verify the presence of the Pdx1-IRES insert.  
 
pLVX-TRE3G-Myc-Hnf6 
To generate an inducible lentiviral vector that over-expresses murine Hnf6, the 
N-terminal Myc tagged Hnf6 cDNA described above was cloned into the pLVX-TRE3G 
response plasmid (Clontech). The pLVX-TRE3G response plasmid is part of the Lenti-X 
Tet-On 3G Inducible Expression system, which includes a pLVX-Tet3G regulator 
plasmid containing a modified form of the Tet-On Advanced transactivator protein. In the 
presence of Doxycycline, the Tet-On 3G protein made by the pLVX-Tet3G vector binds 
the tet operator sequences located in the pLVX-TRE3G vector and activates gene  
expression. pLVX-TRE3G was digested with SmaI to yield a blunt end, linearized 
plasmid, and ligated with 1.6 kb Myc-Hnf6 as described above (Figure 21). After 
transformation, culturing, and purification, samples were digested and sequenced to 
confirm presence and orientation of the Myc-Hnf6 fragment.  
 
Cell culture 
Human ductal epithelial cells (HPDE6) were provided by Dr. Ming-Sound Tsao 
(Ontario Cancer Institute) (Furukawa et al. 1996). To generate this cell line, pancreatic 
tissues were obtained from human pancreatic specimens by Whipple’s procedure, 
immortalized by transfection with human papillomavirus 16-derived E6 and E7 genes,  
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Figure 21. Schematic of pLVX-TRE3G-Myc-Hnf6 lentiviral plasmid. To generate an inducible model of murine Hnf6 lentivi-
ral over-expression, the 1.6 kb Myc-Hnf6 insert was digested with SmaI and cloned into the pLVX-TRE3G vector. Schmeta-
ic includes components relevant to lentiviral production (s, packaging signal) and transcription (RRE, Rev-response 
element; PPGK, posphoglycerate kinse promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element). 
This plasmid map is modified from the pLVX-TRE3G vector map (Clontech) and is not drawn to scale. 
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and cultured on collagen gels. HPDE6 cells display a near normal phenotype, form a 
monolayer on collagen gels, express CK8/18 and CK19, are polarized with surface 
microvilli, and do not form tumors in mice or colonies in soft agar (Furukawa et al. 1996, 
Ouyang et al. 2000). HPDE6 cells were cultured in Keratinocyte Basal Medium, 
supplemented with bovine pituitary extract (20-30 µg/ml) and recombinant epidermal 
growth factor (rEGF, 0.1-0.2 ng/µl) (Lonza, Clonetics). Cells were grown in 25cm2 cell 
culture flasks (Corning) at 37°C. 
  
Statistics 
 Results are expressed as mean + SEM. Statistical significance was calculated by 
Student’s T Test, One-way, or Two-way ANOVA where applicable. P < 0.05 was 
considered significant.  
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CHAPTER III 
 
GLOBAL LOSS OF THE DUAL BMP/WNT INHIBITOR SOSTDC1 ENHANCES 
PANCREATIC ISLET FUNCTION UNDER METABOLIC STRESS 
 
Introduction 
 
 Our lab became interested studying the dual BMP/Wnt antagonist Sostdc1 in the 
context of pancreatic islet function when we observed a 1.8-fold increase in Sostdc1 
expression in pancreata of Pdx1PB-Hnf6 transgenic animals at P1 (Figure 13) (Wilding 
Crawford et al. 2008). Over-expression of Hnf6 in endocrine population causes islet 
dysmorphogenesis, diabetes, and failure of β cells to mature in the postnatal animal, as 
evidenced by reduced expression of Glut2 and MafA (Gannon et al. 2000, Tweedie et al. 
2006, Wilding Crawford et al. 2008). Increased expression of a BMP/Wnt antagonist in 
the setting of islet dysfunction was of interest to us as it had been documented that 
augmenting BMP signaling in the pancreas improves insulin secretion and glucose 
homeostasis by increasing expression of genes involved in insulin production, secretion, 
glucose sensing, and metabolism (Figure 12A, C) (Goulley et al. 2007). Conversely, 
expression of the dominant negative Bmpr1a receptor in the pancreatic epithelium has 
the opposite effect, impairing glucose homeostasis and reducing expression of key 
genes (Figure 12B, D) (Goulley et al. 2007); concordantly, global heterozygosity for the 
BMP receptor Bmpr1a diminishes insulin secretion and causes variability in expression 
of Glut2, Pdx1, Gck, and Insulin in islets (Scott et al. 2009).  
The Wnt pathway is also implicated in islet function. Stabilization of the Wnt 
pathway effector β catenin in the Pdx1 domain enhances islet size, insulin secretion, and 
glucose tolerance in mice (Rulifson et al. 2007). Glucose homeostasis is impaired and 
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insulin secretion is reduced in animals lacking the Wnt co-receptor LRP5, suggesting a 
direct role for Wnt signaling in β cell function (Fujino et al. 2003). Additionally, reduced 
expression of Tcf7l2, a Wnt-specific transcription factor, is associated with diabetes and 
disrupted insulin secretion in multiple populations and experimental models (Gloyn, 
Braun, and Rorsman 2009). Taken together, these data suggest a role for both BMP and 
Wnt signaling in postnatal islet function. 
To examine the role of Sostdc1 in pancreas development and function, we 
utilized animals globally null for Sostdc1. Sostdc1 mutants survive to adulthood and are 
fertile. Due to enhanced BMP signaling in developing and adult teeth, Sostdc1 null 
animals exhibit supernumerary tooth formation and fused molars (Murashima-Suginami 
et al. 2007, Ahn et al. 2010). Augmented BMP signaling in the kidney also protects 
animals lacking Sostdc1 from kidney injury (Tanaka et al. 2008).  
We determined that Sostdc1 null animals have no developmental phenotype and 
exhibit ad lib blood glucose values that are slightly reduced compared to control 
littermates, but have comparable glucose homeostasis profiles, when metabolically 
unchallenged. When placed on HFD, a subset of Sostdc1 mutants are protected from 
diet-induced glucose intolerance and exhibit enhanced insulin secretion (Henley et al. 
2012). These phenotypic changes are not related to the percent genetic contribution of 
C57BL/6 to the animals’ genetic background. Prolonged exposure to HFD elicits a 
compensatory reduction in expression of CTGF and Gremlin in control islets, 
presumably to enhance BMP pathway activity. Loss of Sostdc1 enhances the reduction 
of these genes in the setting of HFD exposure, thus preserving BMP signaling in the islet 
and improving function. This study was the first to examine the effects of augmented 
BMP/Wnt signaling in the context of pancreas function by capitalizing on the absence of 
a dual antagonist.  The results of this study have been published in Henley, et al., 2012. 
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Results 
Sostdc1 is not required for pancreas development or islet morphogenesis 
 Mice carrying a cytopmasmic LacZ allele knocked into the Sostdc1 locus and 
replacing the coding region were used to study the role of Sostdc1 in pancreas 
development and function (Valenzuela et al. 2003, Yanagita et al. 2004, Tanaka et al. 
2008). Sostdc1 null and heterozygous animals were born at expected ratios and 
possessed pancreata that were grossly morphologically similar to control pancreata 
(data not shown). To characterize the expression pattern of Sostdc1 during 
pancreatogenesis, Sostdc1LacZ/+ embryos were dissected at e14.5 and e18.5 and 
immunolabeled to detect β galactodisase activity. At both time points, X-gal staining was 
observed in the acinar component of the developing pancreas and absent from the 
developing insulin-positive clusters (Figure 22A).  In the adult pancreas, X-gal reactivity 
was maintained in the acinar cells and excluded from the islets (Figure 22B), indicating 
that Sostdc1 is mainly expressed in the acinar tissue, and is not expressed at a level that 
can be detected by X-gal staining in the endocrine component of the pancreas at any 
time assessed.  
 To determine if loss of Sostdc1 affects pancreas islet morphogenesis, sections of 
adult control and Sostdc1 knock out (KO) pancreas were immunolabeled for insulin and 
glucagon. We observed normal islet morphology in Sostdc1 mutants, with a dense β cell 
core and an α cell mantle, which were comparable to control littermates (Figure 22D vs. 
22C) These data imply that islet morphogenesis in the mouse is not affected by loss of 
Sostdc1. 
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Figure 22. Sostdc1 localization in the developing and adult pancreas and influence on islet 
morphogenesis. (A) Sostdc1 (blue) is localized to the acinar clusters at e18.5 and is excluded 
from the insulin-positive (dark brown) endocrine tissue. (B) In the adult pancreas, Sostdc1 
remains localized to the acinar tissue (blue) and is not detected by X-gal staining in the islets 
(brown). (C) Sections of pancreas from control animals exhibit proper islet morphology, with ` 
cells composing the core (green) and _ cells distributed around the periphery (red). (D) Sections 
of pancreas from Sostdc1 null animals show islet morphology comparable to control littermates. 
Figures modified and reprinted with permission from Henley et al., 2012.
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Loss of Sostdc1 improves basal and stimulated islet function 
 To evaluate whether global loss of Sostdc1 influences islet function, ad lib 
plasma insulin and blood glucose levels were measured in adult control and Sostdc1 KO 
animals (data provided by Dr. Aris Economides, Regeneron Pharmaceuticals Figure 
23A). Loss of Sostdc1 causes elevated plasma insulin in a subset of animals and 
significantly reduced ad lib blood glucose in male and female adult mice. When 
challenged with an IPGTT, 8 week old males lacking Sostdc1 are glucose tolerant and 
have glucose clearance profiles that are indistinguishable from control male littermates 
(Figure 23B). These data indicate that loss of Sostdc1 reduces ad lib blood glucose 
levels, but does not alter glucose homeostasis without metabolic stress.  
Control and Sostdc1 KO littermates were placed on HFD for 4, 8, and 12 week 
intervals to determine if the absence of Sostdc1 improves islet function under metabolic 
stress. Islets were isolated from control and mutant animals after exposure to HFD for 8 
weeks and subjected to perifusion with high glucose and the secretagogues IBMX and 
Tolbutamide (Figure 24A). Stimulation with high glucose (16.7 mM) caused a non-
significant increase in glucose secretion from Sostdc1 null islets, but no differences were 
observed after IBMX and Tolbutamide stimulation (Figure 24A). It was noted that basal 
insulin secretion from control islets was consistent, while Sostdc1 null islets segregated 
into clusters of low basal insulin secretion (< 1.00 ng/100 IEQ/min) and and high insulin 
secretion (> 2.00 ng/100 IEQ/min) (Figure 24B). When results from Sostdc1 KO islets 
were separated based on basal insulin secretion and graphed accordingly, we observed 
a significant increase in total insulin secretion from islets with higher basal insulin 
secretion (Figure 24B, C). High glucose elicited an 11.3- and 8.3-fold increase in peak 
insulin secretion from control and Sostdc1 KO islets with low basal insulin secretion, and 
a 4.86-fold increase from KO islets with high basal insulin secretion. Despite the reduced  
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Control Sostdc1 KO Control Sostdc1 KO
Figure 23. Loss of Sostdc1 improves basal blood glucose levels. (A) A subset of adult 
male and female Sostdc1 KO animals exhibit a trend toward increased ad lib serum 
insulin (left), and show significantly reduced ad lib blood glucose levels compared to 
controls. (B) At 8 weeks of age, control and Sostdc1 KO  male mice have indistinguishable 
glucose clearance profiles compared to controls. For (B), Control, n = 3; Sostdc1 KO, n = 
5. Error bars represent SEM. Figure (B) modified and reprinted with permission from 
Henley et al. 2012.  
A
B
Sostdc1 KO
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Figure 24. Loss of Sostdc1 improves insulin secretion from isolated adult islets.  (A) Loss of Sostdc1 
does not significantly increase insulin secretion from islets isolated from 8 week old mice after stimu-
lation with  IBMX or Tolbutamide, but elicits a non-significant increase after stimulation with high 
glucose. Control, n = 6;  Sostdc1 KO, n = 10. (B) Separation of Sostdc1 null islets based on low (< 
1.00 ng/100 IEQs/ min) and high (> 2.00 ng/100 IEQs/min) basal insulin secretion reveals that a 
subset of Sostdc1 null islets exhibit increased insulin secretion in response to high glucose. Control 
islets (basal secretion < 1.00 ng/100 IEQs/min), n = 6; Sostdc1 KO islets (basal secretion < 1.00 
ng/100 IEQs/min), n = 6; Sostdc1 KO islets (basal insulin secretion > 2.00 1.00 ng/100 IEQs/min), n 
= 5. (C). Quantification of data presented in (B). Error bars represent SEM. Figures modified and 
reprinted with permission from Henley et al., 2012. 
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fold change in insulin secretion in response to elevated glucose, the Sostdc1 mutants 
with elevated basal insulin secretion exhibited a three-fold increase in insulin release 
overall in response to high glucose compared with the other two groups (Figure 24C). 
Collectively, these data provide evidence that loss of Sostdc1 improves basal and 
glucose-stimulated insulin secretion after exposure to HFD in an in vitro setting. 
 We next examined in vivo glucose homeostasis by intraperitoneal glucose 
tolerance test (IPGTT) in control and Sostdc1 male mice exposed to HFD for 8 and 12 
weeks. At both time points, we observed that control and null animals segregated into 
two groups based on fasting blood glucose (FBG, Figure 25A). Animals exhibited low 
FBG (>125 mg/dl) or high FBG (< 125 mg/dl). During the glucose challenge, Sostdc1 
mutant animals with low FBG exhibited improved glucose clearance compared to both 
control and null animals with elevated FBG (Figure 25A). When subjected to an insulin 
tolerance test (ITT) after 8 and 12 weeks HFD, control and KO animals displayed 
comparable insulin tolerance (Figure 25B and data not shown). These results support 
the idea that improvements in glucose homeostasis can be attributed to augmented islet 
function, also supported by the perifusion data, and do not reflect changes in insulin 
resistance in peripheral tissues. 
 
Analysis of endocrine mass and proliferation in Sostdc1 null animals 
The literature suggests that both BMP and Wnt signaling regulate proliferative 
processes in developing endocrine tissue and adult β cells; animal models display 
reduced or expanded endocrine compartments when BMP or Wnt pathways are 
inhibited or augmented, respectively (Papadopoulou and Edlund 2005, Dessimoz et al. 
2005, Heiser et al. 2006, Hua et al. 2006, Crawford et al. 2009, Guney et al. 2011).  
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Figure 25. Loss of Sostdc1 improves glucose homeostasis and does not affect insulin 
sensitivity. (A) A subset of Sostdc1 null animals with FBG < 125 mg/dl exhibit improved 
glucose homeostasis compared to control and Sostdc1 null animals with FBG > 125 
mg/dl. Control (FGB > 125), n = 6; Control (FBG < 125), n = 11; KO (FBG > 125), n = 10; 
KO (FBG < 125), n = 8). KO (FBG < 125) vs KO (FBG > 125), * P = 0.1, ** P = 0.05. KO 
(FBG > 125) vs Control (FBG > 125), # P = 0.01, ## P = 0.05.  (B) Control and Sostdc1 
mutant male mice exhibit comparable glucose clearance when challenged with insulin. 
Error bars represent SEM. Figures modified and reprinted with permission from Henley et 
al., 2012.   
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Thus, it is possible that the absence of a dual BMP/Wnt regulator may enhance 
proliferation due to activation of either or both of these pathways. To determine if 
improvements in glucose homeostasis in the absence of Sostdc1 could be attributed to 
increased endocrine mass, we measured β cell mass in control and null animals after 
exposure to chow and HFD for 12 weeks (Figure 26A, B). At the time points evaluated, 
there were no differences in β cell mass between genotypes; these data are consistent 
with the IPGTT data from chow-fed Sostdc1 KO animals, which do not display improved 
glucose clearance compared to controls (Figure 26A). β cell proliferation was also 
assessed by immunolabeling for phosphohistone H3 (PH3) after 8 weeks of chow diet 
and 12 weeks HFD (Figure 26C, D). At the time points examined, there were no 
differences in proliferation between genotypes, indicating that loss of Sostdc1 does not 
affect adult β cell proliferation in the basal or stimulated state.  
 
Assessment of genetic background in Sostdc1 null animals 
Investigation of insulin secretion and glucose homeostasis revealed a divergent 
phenotype in Sostdc1 null animals. In particular, we observed a deviation in basal insulin 
secretion from isolated islets after exposure to HFD for 8 wk (Figure 24B) and in FBG 
after exposure to HFD for 12 wk (Figure 25A). Together, these results indicate that in a 
subset of mutant animals, the absence of Sostdc1 benefits β cell function. The Sostdc1 
null animals used in these experiments were of mixed genetic background, consisting of 
C57Bl/6, DBA, and 129Sv. To determine whether the divergent phenotype could be 
attributed to the varying contribution of these different genetic backgrounds, we utilized 
genome-scanning analysis to identify background-specific genetic markers that might be 
correlated with the improved phenotype (Petkov et al. 2004). To this end, tissue samples 
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A B
C D
Figure 26. Analysis of ` cell mass and proliferation in the absence of Sostdc1. Quantifi-
cation of `cell mass in control and mutant male mice after 12 weeks chow (A) or HFD 
(B). Quantification of `cell proliferation by immunolabeling for phospho-histone H3 
(PH3) in control and Sostdc1 null male mice after 8 weeks chow (C) or 12 weeks HFD 
(D). For all figures: Control, n > 2; Sostdc1 KO, n > 4.  Error bars represent SEM. 
Figures modified and reprinted with permission from Henley et al., 2012. 
12 weeks Chow 12 weeks HFD
8 weeks Chow 12 weeks HFD
Sostdc1 KO Sostdc1 KO
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were collected from control and Sostdc1 KO animals and analyzed for SNP markers 
associated with C57Bl/6, DBA, and 129Sv genetic backgrounds (Appendix A). It has 
been well established that the C57Bl/6 strain is prone to impaired glucose tolerance and 
insulin secretion with age due to a mutation within the nicotinomide nucleotide 
transhydrogenase (Nnt) gene (Toye et al. 2005). Thus, we predicted that loss of Sostdc1  
would improve insulin secretion in animals predisposed to β cell dysfunction and 
anticipated that null animals showing the improved phenotype would also show higher 
C57Bl/6 genetic contribution. Interestingly, genome scanning analysis did not reveal any 
striking variations in composition of genetic background within Sostdc1 null animals. 
Indeed, of the mutant animals assessed, contribution of C57Bl/6 to genetic background 
consistently ranged from 44.3 to 54.49%, indicating that broad differences in genetic 
background do not play a role in the divergent phenotype of Sostdc1 KO animals 
(Appendix A). In addition, we assessed whether an increased number of Nnt mutant 
alleles in a given animal was associated with improved glucose homeostasis in the 
absence of Sostdc1. However, we found that the presence of this mutant allele could not 
account for the observed phenotype (data not shown). 
 
Examination of changes in gene expression in the absence of Sostdc1 
 Following analysis of genetic background using strain-specific SNPs, we were 
unable to correlate percentage of specific genetic background with improved insulin 
secretion and glucose tolerance observed in a subset of Sostdc1 null mice. To 
determine whether loss of Sostdc1 affects changes in gene expression that may 
contribute to the observed phenotype, islets were isolated from 8 and 12 week old mice 
and differential gene expression was interrogated by quantitative RT-PCR (qRT-PCR).   
We chose to asses expression of genes that are regulated by BMP and involved in β cell 
function, including Bmp4, Bmp7, Bmpr1a, Smad1, Nkx6.1, Id2, and Glut2 (Goulley et al. 
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2007). We also examined Wnt-responsive genes that have been linked to β cell function, 
including PPAR-delta, c-Myc, matrix metalloprotienase 7 (MMP7), Wnt5a, Cdk, 
CyclinD1, and CyclinD2 (Liu and Habener 2008, Liu et al. 2008, Krutzfeldt and Stoffel 
2010). After exposure to regular chow diet for 4 weeks (8 weeks of age), there were no 
significant changes in expression of genes assessed in male Sostdc1 KO mice 
compared to controls (Figure 27A). After 4 weeks HFD, male Sostdc1 null animals 
exhibit increased expression of the BMP-regulated glucose transporter Glut2, but all 
other genes assessed remain unchanged (Figure 27B). Interestingly, after extension of 
HFD exposure to 8 weeks, Glut2 expression was normalized, while expression of the 
BMP-regulated transcription factor Nkx6.1 and BMP pathway cofactor Smad1 were 
significantly down-regulated in null islets (Figure 28A). Furthermore, expression of 
functionally similar BMP/Wnt modulators Ctgf and Gremlin were also significantly 
reduced in the absence of Sostdc1 (Figure 28A).  
 We were interested in quantifying expression levels of Ctgf and Gremlin in chow-
fed control animals after having observed the significant reduction in these genes after 
exposure to HFD. Control animals exhibited a trend toward decreased expression of 
Sostdc1 and a significant reduction in expression of Ctgf after 8 weeks HFD, whereas 
Gremlin expression increased without significance (Figure 28B). As described above, we 
observed a significant reduction in Sostdc1, Ctgf, and Gremlin in islets from animals 
lacking Sostdc1 after 8 weeks HFD (Figure 27B). The data presented here reveal a 
selective reduction in dual BMP and Wnt modulators after exposure to HFD that is 
greatly enhanced in the Sostdc1 null background. 
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Figure 27. Gene expression in Sostdc1 null islets. (A) Analysis of selected 
BMP/Wnt-responsive gene expression in control and Sostdc1 null islets after 4 
weeks chow. (B) Analysis of selected BMP/Wnt-responsive gene expression of 
control and Sostdc1 null islets after 4 weeks HFD. For each experiment, n > 3 for 
each genotype. Expression levels were normalized against ubiquitiously 
expressed Hprt. * P = 0.05. Error bars represent SEM. Figures modified and 
reprinted with permission from Henley et al., 2012.
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Figure 28. Gene expression in Sostdc1 null islets. (A) Analysis of selected BMP/Wnt-respon-
sive gene expression in control and Sostdc1 null islets after 8 weeks HFD. (B) Quantification 
of changes in specific BMP/Wnt antagonists in control and Sostdc1 null islets after exposure 
to chow or HFD for 8 weeks. For each experiment, n > 3 for each genotype. Expression levels 
were normalized against ubiquitiously expressed Hprt. * P = 0.05; ** P = 0.01; *** P = 0.001. 
Error bars represent SEM. Figures modified and reprinted with permission from Henley et al., 
2012.  
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Evaluation of BMP pathway activity in the absence of Sostdc1 
Gene expression data revealed that, of the genes assessed, BMP/Wnt 
modulators and BMP-regulated genes are altered in the absence of Sostdc1. This 
suggests that the BMP pathway is preferentially targeted by Sostdc1 in islets.  To 
evaluate whether BMP signaling is augmented in islets of Sostdc1 null animals, we 
crossed Sostdc1LacZ/LacZ mice with those carrying the BRE-LacZ transgene, which 
expresses β galactosidase under control of the BMP response element-containing 
fragment of the Id1 promoter (Korchynskyi and ten Dijke 2002, Monteiro et al. 2004). We 
evaluated activation of the BMP pathway by assessing β-galactosidase activity in islets 
of Sostdc1LacZ/LacZ;BRE-LacZ mice compared to BRE-LacZ mice. We predicted that 
elevated BMP signaling in the absence of Sostdc1 would result in activation of the BRE-
LacZ  transgene (and thus X-gal staining) in islets. However, Sostdc1LacZ/LacZ;BRE-LacZ 
animals did not exhibit X-gal staining in islets (data not shown). These data were not 
surprising, given that un-stimulated Sostdc1 KO animals did not display basal 
improvements in glucose homeostasis (Figure 23B). We predicted after exposure to 
HFD for 4 weeks, a situation in which Sostdc1-/- animals show improved β cell function, 
we would observe enhanced BMP signaling. Sostdc1 null animals carrying the BRE-
LacZ transgene and control animals (BRE-LacZ transgene or Sostdc1 KO alone) did not 
exhibit β galactosidase reactivity in islets (data not shown). We did observe X-gal 
staining in the kidneys of animals carrying the BRE-LacZ transgene, as reported by 
others (Blank et al. 2008), indicating that the transgene is operative in BMP-responsive 
tissues (data not shown). Lack of BRE-LacZ activity in islets could be due to activation 
below the level of detection or may indicate that loss of Sostdc1 does not increase BMP 
activity in islets.  
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As a secondary means of evaluating BMP pathway activity in Sostdc1 null 
animals, levels of phosphorylated (activated) Smad1 were assessed by western blotting 
(Figure 29A). At 8 weeks of age, islets from Sostdc1 mutant animals exposed to chow 
diet did not show significantly altered pSmad levels compared to control animals (Figure 
29B). These data indicate that under basal conditions, BMP pathway activity is not 
substantially increased in islets from Sostdc1 null mice.  
 
Discussion 
 
Our studies have explored the modulation of BMP and Wnt signaling in adult islet 
function, an area of study that still requires additional characterization. By utilizing 
animals globally lacking the dual BMP and Wnt inhibitor Sostdc1, we evaluated the role 
of this protein in insulin secretion and glucose homeostasis. Current literature indicates 
that both BMP and Wnt positively regulate β cell function and that loss of components of 
these pathways, either globally or in a tissue-specific manner, impairs β cell function, 
insulin secretion, and glucose homeostasis (Fujino et al. 2003, Dessimoz et al. 2005, 
Goulley et al. 2007, Liu and Habener 2010). The transgenic model of Hnf6 over-
expression generated by our group exhibits defects in insulin secretion that are 
reminiscent of those observed in Bmpr1a and Lrp5 mutant animals (Fujino et al. 2003, 
Goulley et al. 2007, Scott et al. 2009). Concordantly, in Hnf6 transgenic animals there is 
a 2-fold up-regulation of Sostdc1, a dual BMP and Wnt inhibitor that interacts with both 
BMP4 and the LRP6 receptor (Lintern et al. 2009). Taken together, these data suggest 
that irregular modulation of BMP and/or Wnt signaling may contribute to impaired insulin 
secretion observed in certain mouse models of diabetes. 
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A
B
Figure 29. Quantification of pSmad in Sostdc1 null islets. 
(A) Western blot representing pSmad1 levels in control 
and Sostdc1 null islets isolated from 8 week old male 
mice on chow diet. (B) Quantification of and graphical 
representation of (A) using ImageJ. Error bars represent 
SEM. Figures modified and reprinted with permission 
from Henley et al., 2012.  
Sostdc1 KO
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The detection of Sostdc1-driven β-gal activity in the acinar tissue but not the islets of 
Sostdc1LacZ/+ animals implies that Sostdc1 may be secreted from acinar tissue to affect 
islet function. To date, no studies have indicated a role for BMP or Wnt inhibitors in 
pancreatic acinar tissue. However, we were able to quantify a decrease in expression of 
endogenous Sostdc1 in adult islets exposed to HFD compared to control chow (Figure 
28B), suggesting that Sostdc1 is indeed expressed in islets, but at levels too low to 
detect by X-gal staining.  
We saw no alterations to pancreas development in Sostdc1 null animals in terms 
of endocrine cell number or islet morphology. This observation is consistent with the 
previously published model of BMP4 over-expression in the pancreatic epithelium (Pdx1-
Bmp4, (Goulley et al. 2007), which did not exhibit a developmental phenotype. Although 
the role of Wnt signaling in endocrine pancreas development is somewhat controversial, 
it has been well established that Wnt signaling is required for exocrine pancreas 
development (Dessimoz et al. 2005, Murtaugh et al. 2005). Loss of Sostdc1 does not 
grossly affect exocrine development despite the essential need for tightly-regulated Wnt 
activity during this time period. Although we did not detect changes in expression of Wnt 
target genes in islets isolated postnatally (Figure 27, 28), it remains possible that the 
Wnt pathway is altered during development in the absence of Sostdc1. Overall, it 
appears that deletion of Sostdc1 has a specific regulatory effect on the BMP pathway in 
pancreatic islets. Despite being a dual BMP and Wnt antagonist, the loss of Sostdc1 did 
not result in significant modifications in expression of the Wnt responsive genes assayed 
in this study. This came as a surprise as, in HEK293 cells, Sostdc1 preferentially 
interacts with the LRP6 receptor over binding to BMP4 (Lintern et al. 2009).  
We observed divergent insulin secretion and glucose homeostasis phenotypes in 
animals lacking Sostdc1 and hypothesized that this discrepancy was related to genetic 
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variability. Exploring this idea is relevant not only to the present study, but also to the 
human population, which is composed of individuals of mixed genetic background. 
Indeed, murine phenotypes observed on mixed genetic backgrounds may better mimic 
complex genetic traits in humans. Because C57Bl/6 mice are predisposed to β cell 
dysfunction, and because an independently generated Sostdc1 mutant mouse line 
displays a molar fusion phenotype with variable penetrance that correlates positively 
with a higher percent of C57Bl/6 alleles (Toye et al. 2005, Ahn et al. 2010), we predicted 
that animals with a greater contribution of C57Bl/6 to their genetic background would 
exhibit improved insulin secretion and glucose homeostasis in the absence of Sostdc1. 
However, we were unable to correlate low FBG (< 125 mg/dl) or enhanced insulin 
secretion with a higher percentage of C57Bl/6 contribution. In fact, the overall 
contribution of C57Bl/6 did not vary greatly among the animals used in this study. 
Although we observe significantly altered gene expression from Sostdc1 null animals 
compared to control animals, these changes may only positively affect a specific subset 
of animals due to other as yet undefined modifying genetic factors. It remains possible 
that inheritance of a specific modifier gene(s) or genes that are controlled by Sostdc1, 
rather than overall strain contribution, is responsible for the observed phenotype. We did 
evaluate whether the Nnt mutation, previously shown to contribute to impaired insulin 
secretion and glucose homeostasis in the C57Bl/6 strain of mice, correlated with the 
Sostdc1 mutant phenotype, but found no evidence suggesting a correlation. The 
analysis of gene expression presented here is limited to BMP and Wnt pathway-related 
genes, and thus may not be comprehensive enough to identify modifier genes that are 
responsible for the improved phenotype. In the future, global gene expression analyses 
comparing control and Sostdc1 mutant islets would clarify which genes may play a role 
in the phenotype and which signaling pathways are most affected. 
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The preceding data reveal that loss of Sostdc1 results in decreased expression 
of BMP-responsive genes and BMP and Wnt modulators in islets after HFD feeding for 8 
weeks (Figure 28A). These results were surprising to us and contradicted the originial 
hypothesis, suggesting that Sostdc1 may not antagonize BMP signaling in this particular 
situation. However, these data could also reflect a novel means of antagonist regulation 
in islets. The slight reduction of Sostdc1 and significant decrease in Ctgf expression 
seen in control animals on HFD compared to chow for 8 weeks implies a mechanism in 
which expression of dual BMP/Wnt modulators is down-regulated in the setting of 
increased metabolic demand. Given that BMP and Wnt signals positively regulate islet 
function, decreased expression of antagonists of either of these pathways may improve 
or maintain glucose homeostasis in a situation of metabolic stress. It is unclear why 
expression of the BMP-selective inhibitor Gremlin trends toward increased expression in 
control animals after 8 weeks HFD feeding. Gremlin is involved in the differentiation of 
preadipocytes to mature adipocytes, and therefore may be systemically up-regulated 
during exposure to HFD (Rose et al. 2003). Gremlin has also been implicated in 
pancreatic cancer and the pathology of diabetic nephropathy (Namkoong et al. 2006), 
but has not been studied in normal pancreas function.  Of the three BMP and Wnt 
modulators assessed, Gremlin is the most specific of antagonists, as it targets only the 
BMP pathway. This specificity may affect β cell function in control animals on HFD, but 
this idea needs to be tested directly. Nonetheless, we observed consistent reductions in 
both Ctgf and Gremlin expression in the Sostdc1 mutant background after 8 weeks HFD 
feeding. As described above, we also observed reductions in Smad1 and Nkx6.1 
expression in Sostdc1 mutant islets and a trend toward reduced Glut2 expression. As an 
integral part of the BMP-signaling pathway, Smad1 mediates expression of BMP-
responsive genes and it is therefore possible that decreased expression of Smad1 alone 
may contribute to the decreased levels of other BMP-related genes. Roles for Nkx6.1 in 
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endocrine development and differentiation have been established, but its function in the 
adult pancreas is less clear. In vitro studies showed that adenoviral mediated over-
expression of Nkx6.1 in rat and human islets resulted in augmented insulin secretion and 
β cell proliferation (Schisler et al. 2008). Conversely, in vivo over-expression of Nkx6.1 in 
adult murine β cells did not result in significant alterations in glucose homeostasis, 
insulin secretion, or β cell proliferation (Beucher, Martin, et al. 2012). However, Nkx6.1 
participates in maintaining β cell identity by repressing the α cell-specific transcription 
factor Arx, and loss of Nkx6.1 in mature β cells results in conversion to δ cells (Schaffer 
et al. 2013). Because Nkx6.1 is a BMP-responsive gene in islets, reduced Nkx6.1 
expression in Sostdc1 mutant mice may reflect a reduction in BMP pathway activity with 
prolonged HFD exposure, and not impaired function or loss of β cell identity.  
In an effort to analyze BMP pathway activity, we also examined whether loss of 
Sostdc1 would increase activity of a BRE-LacZ reporter transgene in the setting of HFD 
exposure. We initially hypothesized that the absence of Sostdc1 would enhance BMP 
signaling activity in islets when animals were exposed to HFD, and we expected to 
observe β-galactosidase activity in the islets of Sostdc1 KO animals carrying the BRE-
LacZ transgene. We did not find evidence that this reporter is active in islets of Sostdc1 
null animals. This may be because the animals were not exposed to HFD for a sufficient 
amount of time to activate the transgene; however, we observed a significant increase in 
expression of the BMP-responsive gene Glut2 after 4 weeks of HFD, implying that some 
BMP target genes are responding at this time. It may also be that the BRE-LacZ 
transgene is not expressed in islets, although its expression was verified in the kidneys 
of the same animals. 
Given the available published data, it is challenging to explain how decreased 
expression of BMP-responsive genes is associated with improved glucose homeostasis 
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and insulin secretion. Recent literature suggests, however, that the deletion of Id1, a 
BMP-responsive gene, protects animals from HFD-induced obesity and enhances insulin 
secretion (Akerfeldt and Laybutt 2011). This implies that modulation of specific 
components of the BMP pathway may have differing affects on the β cell.  We propose 
that in the Sostdc1 mutant background, there is a significant reduction in expression of 
BMP and Wnt modulators after exposure to HFD that is not observed in control animals 
(Figure 28B). We hypothesize that reduced expression of BMP antagonists enables 
maintenance of sufficient levels of BMP signaling activity to preserve glucose 
homeostasis in the setting of increased metabolic demand. Control animals fail to reduce 
expression of BMP and Wnt modulators, and perhaps BMP signaling activity is 
augmented in control animals to counteract the presence of these antagonists. 
Interestingly, impairments in insulin secretion and glucose homeostasis still occur. The 
changes in signaling activity are reflected in the expression levels of BMP target genes, 
as expression of genes such as Smad1 and Nkx6.1 are reduced in Sostdc1 null animals 
compared to controls.  
In conclusion, we provide evidence that loss of Sostdc1 enhances insulin 
secretion and glucose homeostasis in animals under metabolic stress, in part by 
reducing expression of other BMP and Wnt modulators. Changes in BMP-responsive 
gene expression are present in animals lacking Sostdc1, which implies that Sostdc1 
preferentially targets the BMP pathway in the pancreatic islet. To our knowledge, this is 
the first study to provide evidence for diet-induced regulation of BMP and Wnt 
modulators as well as coordinated regulation by the modulators themselves. These data 
further support a role for BMP signaling in islet function as shown by others (Goulley et 
al. 2007, Scott et al. 2009), and suggest that factors that limit BMP antagonist activity 
could potentiate the positive effects that BMP signaling has on islet function. Future 
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studies examining the loss of Sostdc1, CTGF and Gremlin (either alone or in 
combination) in adult islet function and regulation of BMP and Wnt signaling should 
elucidate whether these extracellular regulators may be targets for drug therapy to 
enhance islet function. 
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CHAPTER IV 
 
COOPERATION BETWEEN HNF6 AND PDX1 IN THE REGULATION OF GENES 
INVOLVED IN POSTNATAL ISLET FUNCTION 
 
Introduction 
 
 Development and function of the endocrine pancreas rely on precise 
spatiotemporal expression of genes that coordinate endoderm specification, endocrine 
differentiation, proliferation, glucose sensing, hormone production and secretion. A key 
factor involved in all of these processes is Pdx1, which is initially expressed in the 
foregut endoderm and persists, at varying levels, throughout pancreas development 
(Figures 2-5). Hnf6 is expressed prior to Pdx1 in the presumptive endoderm and is also 
maintained throughout pancreas development. These two transcription factors are 
initially co-expressed in primary MPCs, and to a lesser extent in bipotent trunk 
precursors (Figure 2, 5) (Zhang et al. 2009). Pdx1 expression is temporarily down-
regulated in Ngn3-positive endocrine precursors, but is re-expressed at high levels in 
differentiating β cells. Conversely, Hnf6 expression persists in endocrine precursors until 
their differentiation and induction of hormone expression, at which point Hnf6 expression 
is down-regulated. However, Hnf6 expression is maintained at high levels in the 
pancreatic ducts and to a lesser extent in the acinar tissue, where it is required to 
maintain differentiation. 
 As described previously, both Pdx1 and Hnf6 regulate expression of genes that 
are involved in endocrine specification, differentiation, and mature endocrine function 
(Jonsson et al. 1994, Ahlgren et al. 1998, Watada, Kajimoto, Kaneto, et al. 1996, 
Watada, Kajimoto, Miyagawa, et al. 1996, Dutta et al. 1998, Ohneda et al. 2000, 
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Marshak et al. 2000, Leibowitz et al. 2001, Jacquemin et al. 2000, Gerrish, Cissell, and 
Stein 2001, Jacquemin, Lemaigre, and Rousseau 2003, Brissova, Blaha, et al. 2005, 
Raum et al. 2006, Wilding Crawford et al. 2008, Yamamoto et al. 2013). Their initial co-
expression in primary MPCs and co-regulation of the pro-endocrine gene Ngn3 suggest 
that these two transcription factors function, in part, to activate the endocrine program 
(Zhang et al. 2009, Oliver-Krasinski et al. 2009). Certain genes may require a threshold 
of Pdx1 and Hnf6 expression to be sufficiently activated; thus, decreased expression of 
Pdx1 and Hnf6 together may result in reduced or lack of expression of target genes. We 
wanted to explore whether haploinsufficiency for both factors would negatively affect the 
development of the endocrine compartment of the murine pancreas. Indeed, single Pdx1 
heterozygous animals develop impaired insulin secretion and glucose intolerance with 
age, but no developmental phenotype for either heterozygous animal has been 
documented (Dutta et al. 1998, Brissova, Blaha, et al. 2005). Thus, we hypothesized that 
double heterozygosity would result in abnormal endocrine pancreas development and 
function due to decreased expression of key genes.  
The first approach utilized animals globally heterozygous for Pdx1 and 
conditionally heterozygous for Hnf6 in the pancreatic epithelium (Pdx1LacZ/+;Pdx1-
Cre;Hnf6F/+, henceforth denoted as Pdx1LacZ/+; Hnf6Δpanc/+). Using this model, changes in 
blood glucose or pancreas weight were not observed at postnatal day 1 (P1). In 
agreement, endocrine mass and α:β cell ratio were unchanged between single and 
double heterozygous animals at P1. Surprised by these observations, we evaluated the 
efficiency of the Cre recombinase system to confirm the timing of Hnf6 recombination. 
Based on reported data, Pdx1-Cre recombination of the R26R-LacZ reporter allele takes 
place at e9.5, a time deemed appropriate for the experiments at hand because it 
precedes the overlap of Pdx1 and Hnf6 expression in primary MPCs at e10.5.  However, 
examination of Cre-mediated Hnf6 recombination revealed inefficient deletion by e10.5, 
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indicating that this specific model of Hnf6 heterozygosity is not appropriate for the 
purposes of this study. 
In order to ensure early Hnf6 inactivation, we generated conditional global double 
heterozygous animals (Pdx1LacZ/+;Prm-Cre; Hnf6F/+) to circumvent the issue of Cre-
mediated timing. Using this approach, it was determined that body weight, pancreas 
weight, and blood glucose levels in double heterozygous at birth are comparable to 
single heterozygous and control littermates. After one day, however, double 
heterozygous animals exhibited elevated blood glucose and reduced body and pancreas 
size compared to controls. Interestingly, these changes are resolved by weaning, 
suggesting compensatory mechanisms that restore islet function in double 
heterozygotes. Currently, we are assessing gene expression changes at birth and 
weaning to determine which genes are primarily affected.  
 
 
Results 
 
 
 
Conditional double heterozygosity does not affect endocrine development or early 
postnatal function 
  
The initial approach to determine whether double heterozygosity for Pdx1 and 
Hnf6 affects pancreas development and function made use of mice that are globally 
heterozygous for Pdx1 and heterozygous for Hnf6 in the Pdx1 expression domain which 
includes the pancreatic epithelium (Pdx1LacZ/+; Hnf6Δpanc). Pancreas weight was 
measured at P1 in single and double heterozygous animals, and at this time, no 
changes were observed between genotypes (Figure 30A). Similarly, there were no 
appreciable differences in blood glucose between single and double heterozygous  
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Figure 30. Analysis of pancreas weight and blood glucose at P1. (A) Pancreas weight in 
single and double heterozygotes was measured at P1. (B) Blood glucose in single and 
double heterozygotes was measured at P1. Error bars represent SEM.  
Figure 31. Assessment of endocrine mass at P1. Distribution of insulin-producing ` cells 
(brown) within acinar tissue (pink) in Pdx1LacZ/+ (A), Hnf6Upanc/+ (B), and Pdx1LacZ/+;Hnf6Upanc/+ 
(C) at P1. (D) Quantification of endocrine mass by synaptophysin immunolabeling in 
single and double heterozygotes. Error bars represent SEM. For (D), Pdx1LacZ/+  n = 4, 
Hnf6Upanc/+, n = 2, Pdx1LacZ/+;Hnf6Upanc/+ , n = 3. 
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animals at P1 (Figure 30B), indicating that endocrine function is not perturbed using this 
particular model of double heterozygosity.  
 Considering the role that Pdx1 and Hnf6 play in regulation of the pro-endocrine 
gene Ngn3, we were interested in evaluating whether endocrine mass was negatively  
affected in the setting of double heterozygosity. Sections of pancreata from single and 
double heterozygotes were immunolabeled with insulin antibodies to examine the 
distribution of β cells within endocrine islets (Figure 31A-C). In general, there were no 
gross differences between genotypes based on this evaluation. Endocrine mass was 
quantified by synaptophysin immunolabeling, and at P1, double heterozygous animals 
do not exhibit changes in endocrine mass compared to single heterozygotes (Figure 
31D). Co-labeling with insulin and glucagon to visualize islet morphology revealed no 
obvious differences between single and double heterozygotes (Figure 32A-C). The ratio 
of α to β cells was also similar between genotypes (Figure 32D). Taken together, these 
data suggest that the Pdx1LacZ/+;Hnf6Δpanc/+ model of double heterozygosity does not elicit 
considerable changes in the endocrine population.  
 
Evaluation of timing and efficiency of Pdx1-Cre-mediated recombination 
 In the aforementioned experiments, one copy of the Hnf6 floxed allele was 
recombined using Cre recombinase driven by the 4.3kb fragment of the Pdx1 promoter 
to achieve Hnf6 heterozygosity in the pancreatic epithelium (Figure 17) (Zhang et al. 
2009, Hingorani et al. 2003). This particular Cre transgene is operative as early as e9.5 
and facilitates reporter allele recombination efficiently throughout the entire pancreatic 
epithelium (Figure 17) (Wicksteed et al. 2010). Because the Pdx1LacZ/+;Hnf6Δpanc/+ double 
heterozygous model did not exhibit endocrine defects at P1, we became concerned that 
the conditional Hnf6 allele was being not recombined at the expected time during 
pancreatogenesis. Specifically, we wanted to determine the timing of recombination in  
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Figure 32. Islet morphology in single and double Pdx1LacZ/+;Hnf6 
Upanc/+ animals at P1. Distribution of _ (red) and ` (green) cells in 
Pdx1LacZ/+ (A), Hnf6 Upanc/+  (B), and Pdx1LacZ/+;Hnf6 Upanc/+ (C) mice 
at P1 reveals normal islet morphology. (D) Quantification of the 
ratio of _ to ` cells in single and double heterozygous animals at 
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relation to the overlap of Pdx1 and Hnf6 expression in primary MPCs (e9.5-e11.5) and 
the birth of endocrine progenitors from the bipotent ductal epithelium (e12.5 onward) 
(Figure 5). To assess recombination of the floxed Hnf6 allele by Pdx1-Cre, embryos 
carrying one copy of the Hnf6 floxed allele, the Pdx1-Cre transgene, and the R26R- 
EYFP reporter allele were harvested at e10.5 and processed for paraffin sectioning. 
Pancreatic tissue from whole embryo sections were isolated and PCR was performed to 
detect the recombined Hnf6 allele. At e10.5, both the recombined and unrecombined 
Hnf6 allele could be detected from DNA isolated from sections of pancreas (data not 
shown). Indeed, both the intact and recombined R26R-EYFP reporter allele could also 
be detected by PCR at this time (data not shown).  
Pdx1-Cre activity was also assessed at the mRNA level. qRT-PCR was 
performed using RNA isolated from the epithelium-derived gut tube containing nascent 
pancreatic buds at e11.5 to assess a potential reduction in Hnf6 expression. At this time, 
however, a significant reduction in Hnf6 expression could not be detected (Figure 33).  
 The efficiency of Pdx1-Cre was also evaluated in the postnatal pancreas of 
single and double heterozygous animals. Using EYFP immunolabeling as a surrogate for 
Pdx1-Cre activity, recombination was assessed in the pancreata of single and double 
heterozygous animals at P1 (Figure 34). At this time, variable immunolabeling of 
endocrine clusters was observed in all three genotypes (Figure 34A’-A’’’), whereas 
labeling of the acinar portion of the pancreas was relatively consistent, regardless of 
single or double heterozygosity (Figure 34C’-C’’’). Collectively, these data indicate that 
the Pdx1-Cre transgene is active at e10.5, but does not recombine the Hnf6 floxed allele 
to an extent that appreciably reduces gene expression until after e11.5. Furthermore, 
Pdx1-Cre activity as evaluated by EYFP immunolabeling suggests that recombination is 
not as efficient in the endocrine population as it is in the acinar population, regardless of 
genotype. 
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Figure 33. Recombination of the floxed Hnf6 allele by Pdx1-Cre recombinase. (A) Quantifi-
cation of Hnf6 expression by qRT-PCR in control and heterozygous animals using primers 
spanning the first and second exons. (B) Quantification of Hnf6 cut domain expression by 
qRTPCR in control and heterozygous animals using primers specific for the cut domain, 
which is flanked by loxP sites. N > 3 for each genotype. Hnf6 expression was normalized 
against the ubiquitously expressed Hprt.
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Figure 34. Pdx1-Cre-medicated recombination of the EYFP reporter allele at 
P1. (A) Sections of single (A’ and A’’) and double heterozygous (A’’’) pancreata 
immunolabeled for EYFP (blue). Arrows indicate variable EYFP recombina-
tion in the clusters labeled with insulin in all three genotypes (see B). (B) Iden-
tical sections from (A) immunolabeled for insulin (brown). (C) Representative 
images of EYFP immunolabeling in acinar tissue of pancreata from single (C’ 
and C’’) and double heterozygous (C’’’) animals at P1. Note consistency of 
labeling in  acinar tissue in all images in (C) compared to endocrine clusters in 
(A). All images shown are from animals carrying both the Pdx1-Cre transgene 
and the R26R-EYFP reporter allele.  
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Global double heterozygosity impairs early postnatal endocrine function 
To eliminate the possibility that timing or efficiency of Pdx1-Cre facilitated 
recombination is not suitable for studying the early genetic interactions between Pdx1  
and Hnf6 in primary MPCs or bipotent precursors, we generated animals globally 
heterozygous for both Pdx1 and Hnf6. To achieve this, Protamine-Cre (Prm-Cre), which 
is expressed in the male germ line and exhibits recombinase activity at the 2- to 4-cell 
zygotic stage, was used to recombine the floxed Hnf6 allele (O'Gorman et al. 1997). 
 To determine if global double heterozygosity affects development of the 
endocrine pancreas, we sacrificed control, single, and double heterozygous animals at 
birth and measured body weight, pancreas weight, and blood glucose levels. At this time 
point, there were no significant differences in the parameters examined (Figure 35A-C). 
However, one day later significant decreases in body and pancreas size in Pdx1LacZ/=, 
Hnf6+/-, and double heterozygous animals were observed (Figure 35D, E). These results 
were unexpected, as there has been no documented developmental or early postnatal 
phenotype for either single heterozygous animal reported in the literature.  
The reduced pancreas size seen in Pdx1LacZ/+ and Pdx1LacZ/+;Hnf6+/- pups after 
birth was reminiscent of the developmental effects of intrauterine growth restriction 
(IUGR) due to placental insufficiency. Specifically, IUGR causes low birth weight and 
reduced organ size while brain size is maintained (Eleftheriades, Creatsas, and 
Nicolaides 2006). This situation was pertinent to our study as Pdx1 is expressed in the 
placenta and is up-regulated during IUGR (Buffat et al. 2007). Thus, we were concerned 
about IUGR due to placental defects in the setting of Pdx1 heteozygosity. To determine 
if single Pdx1 or double Pdx1/Hnf6 heterozygosity results in IUGR and subsequent 
reduced organ size, animals were sacrificed at birth and pancreas, heart, kidney, and 
brain weights were measured (Figure 36A-D). When assessed as a percentage of body 
weight, there were no differences in organ size between genotypes, signifying that single  
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Figure 35. Assessment of weight and blood glucose changes in postnatal double heterozygous animals. 
At birth, double heterozygous (Pdx1LacZ/+;Hnf6+/-) mice have comparable body weight (A), pancreas 
weight (B) and blood glucose (C) compared to Pdx1LacZ/+, Hnf6+/-, and control animals. At P1, single and 
double heterozygous animals weigh less than control animals (D) and Pdx1LacZ/+ and double heterozy-
gous mice have smaller pancreata than control and Hnf6+/- animals (E). Double heterozygous animals 
exhibit elevated blood glucose compared to control and Hnf6+/- animals at P1 (F) * P = 0.01; ** P = 0.05; 
*** P = 0.001. Error bars represent SEM.  
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Figure 36. Organ weight in newborn double heterozygous mice. Pancreas 
(A), heart (B), kidney (C) and brain (D) weights were measured in control, 
single, and double heterozygous animals at birth and graphed as a percent-
age of body weight.  N > 5 for each genotype and each organ. Error bars 
represent SEM. 
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Figure 37. Analysis of body weight in models of single Pdx1 heterozygosity. 
At P1, all experimental animals, including control animals from Pdx1+/- litters, 
weigh significantly less than control animals from Pdx1LacZ/+;Hnf6+/- litters. * P 
= 0.05; ** P = 0.01; *** P = 0.001. Error bars represent SEM. 
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Pdx1 or double Pdx1/Hnf6 heterozygosity does not result in IUGR-related reductions in 
organ size.  
In pursuit of an explanation for phenotype seen in Pdx1LacZ/+ and 
Pdx1LacZ/+;Hnf6+/- pups after birth, we next chose to evaluate the postnatal weights of a 
second model of Pdx1 heterozygosity to ensure that our phenotype was not a result of 
the LacZ knock-in allele behaving as a dominant negative. We compared P1 body 
weights of Pdx1+/- (PdxXB allele, Figure 15) and control littermates with those from our 
Pdx1LacZ/+;Hnf6+/- litters and determined that while all experimental genotypes, as well as 
the control animals from the Pdx1+/- litters, were of comparable body weight and were 
consistent with P1 body weight reported in the literature, the body weights of control 
animals from Pdx1LacZ/+;Hnf6+/- litters were significantly heavier  (Figure 37, data not 
shown). We determined that the control pups born from females carrying the Prm-Cre 
transgene were significantly heavier than pups born from females without the transgene. 
Because these heavier pups were skewing the data, all litters born from Prm-Cre 
positive females were removed and the data were re-analyzed. In this curated data set, 
only Pdx1LacZ/+;Hnf6+/- pups exhibited reduced body and pancreas weight at P1 
compared to controls (Figure 38A, B). Double heterozygous pups exhibited elevated 
blood glucose compared to controls and Hnf6+/- animals at P1 (Figure 35C, 38C).  
Elevated blood glucose can be caused by reduced endocrine mass or impaired 
endocrine function. To determine if Pdx1LacZ/+;Hnf6+/- pups possess reduced endocrine 
mass compared to control and single heterozygous littermates, α and β cells were 
immunolabeled with antibodies against both glucagon and insulin (Figure 39A-D) and 
the mass of each cell population were quantified (Figure 40A-B). These analyses 
indicated that islet morphology is maintained in the setting of double heterozygosity, and, 
despite having smaller pancreata one day after birth, double heterozygous animals do 
not have evidence of reduced α or β cell mass at this time (Figure 40A, B). The mass of  
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Figure 38. Assessment of weight and blood glucose changes in double heterozygous animals at P1. (A) 
Double heterozygous animals exhibit reduced body weight compared to controls after birth. (B) Double 
heterozygous animals exhibit reduced pancreas weight compared to controls after birth. (C) Double 
heterozygous animals exhibit elevated blood glucose compared to controls and single Hnf6 heterozy-
gotes. * P =0.05. Error bars represent SEM.   
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Figure 39. Islet morphology in single and double heterozygous mice at P1. Representative images of _ 
(red) and ` (green) cell immunolabeling in control (A), Pdx1LacZ/+ (B), Hnf6+/- (C), and Pdx1LacZ/+;Hnf6+/- (D) 
pancreata at P1.
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Figure 40. Analysis of _ and ` cell mass in 
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α or β cells relative to pancreas mass is not statistically different between genotypes 
(Figure 40C-D). Furthermore, the α:β cell ratio is unchanged in Pdx1LacZ/+;Hnf6+/- pups at 
P1 (Figure 40E). These data suggest that endocrine mass is not affected by global  
double heterozygosity at P1.  
 
Glucose homeostasis is restored in double heterozygotes with age 
After observing elevated blood glucose in Pdx1LacZ/+;Hnf6+/- pups one day after 
birth, we wanted to explore whether this phenotype was maintained until and beyond 
weaning (3 weeks of age).  Body weight was measured at weaning in control, single, 
and double heterozygous animals, and revealed that Pdx1LacZ/+;Hnf6+/- animals no longer 
exhibit reduced weight (Figure 41A). Interestingly, with the exception of two mice, 
Pdx1LacZ/+;Hnf6+/- weanlings show restored blood glucose levels at this time; however, 
Pdx1 heterozygotes have elevated ad lib blood glucose, which is consistent with the 
phenotype presented in the literature (Figure 41B). When challenged with an IPGTT at 3 
weeks of age, there are no striking differences in glucose clearance between genotypes 
(Figure 42A). At 6 weeks of age, control, single Pdx1 heterozygotes, and double 
heterozygotes are glucose tolerant while Hnf6 heterozygotes have slightly impaired 
glucose tolerance (Figure 42B). By 8 weeks of age, the impaired glucose clearance in 
Hnf6+/- animals has resolved and is comparable to control and Pdx1LacZ/+;Hnf6+/- mice, 
while the preliminary data suggest Pdx1LacZ/+ animals are glucose intolerant (Figure 
42C).  
Glucose homeostasis is maintained by proper endocrine response to fluctuating 
blood glucose levels and also by storage and release of glucose from the peripheral 
tissues. In particular, the liver is responsible for storing the majority of excess glucose as 
glycogen, which is broken down and released into the bloodstream during fasting or  
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Figure 41. Body weight and ad lib glucose values at 3 weeks of age. (A) Body weights from 
control, single heterozygous, and double heterozygous animals at 3 weeks of age. (B) Ad lib 
blood glucose values for control, single, and double heterozygous animals at 3 weeks of age. 
*** P = 0.001. Error bars represent SEM. 
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Figure 42. Glucose homeostasis in double 
heterozygous animals at 3, 6, and 8 weeks of 
age. Glucose homeostasis assessed by IPGTT 
in control, single, and double heterozygous 
anim ls at 3 weeks (A), 6 weeks (B) and 8 
weeks (C) of age. For (A), Control, n = 17; 
Pdx1LacZ/+, n = 12; Hnf6+/-, n = 10; 
Pdx1LacZ/+;Hnf6+/-, n = 9. For (B), Control, n = 3; 
Pdx1LacZ/+, n = 1; Hnf6+/-, n = 4; Pdx1LacZ/+;Hnf6+/-, 
n = 1. For (C), Control, n = 3; Pdx1LacZ/+ , n = 1; 
Hnf6+/-, n = 3; Pdx1LacZ/+;Hnf6+/-, n = 1. ** P = 0.01 
Control vs. Hnf6+/- . Error bars represent SEM. 
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hypoglycemia. Thus, mobilization of glucose, either to or from its stored form, is 
important for regulation of blood glucose. Because Hnf6 regulates Glut2, Gck, and 
genes involved in gluconeogenesis in the liver, we wanted to assess whether glycogen  
deposition was altered in double heterozygous animals. We assessed glycogen 
deposition in livers from control, single and double heterozygous mice at 8 weeks of age 
(Figure 43). Control animals exhibited characteristic deposition of glycogen, with 
increased localization of glycogen surrounding the ducts and more sparse deposition of 
glycogen elsewhere (Figure 43A). Pdx1 heterozygous animals exhibited somewhat 
reduced glycogen deposition surrounding the ducts compared to controls (Figure 43B), 
while Hnf6 heterozygous animals showed saturation of glycogen deposition throughout 
liver tissue (Figure 43C). Surprisingly, we observed glycogen deposition comparable to 
controls in livers from Pdx1LacZ/+;Hnf6+/- animals (Figure 43D).  
 
Islet morphology and protein localization in weaned double heterozygous animals 
To determine if islet morphology is maintained after weaning in the setting of 
double heterozygosity, pancreatic sections were immunolabeled for insulin and glucagon 
and islet morphology was assessed.  Compared to control animals (Figure 44A), Pdx1 
heterozygotes possessed islets with relatively normal morphology, although insulin 
labeling appeared less intense and some α cells were scattered throughout the β cell 
core (Figure 44B). Islets from Hnf6 heterozygotes appeared mostly normal (Figure 44C), 
and double heterozygote islets exhibited insulin immunoreactivity comparable to control 
animals, but contained excess α cells scattered throughout the β cell core (Figure 44D). 
These data are consistent with the IPGTT results from 3 weeks of age, which showed 
that glucose homeostasis is maintained in Pdx1LacZ/+;Hnf6+/- mice.  
Because Pdx1 and Hnf6 regulate genes important to islet function, we were 
interested in examining localization of these regulated proteins in Pdx1LacZ/+;Hnf6+/- mice.  
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Figure 43. Glycogen deposition at 8 weeks of age. Glycogen deposition (purple) was visualized by Periodic 
acid-Schiff staining in control (A), Pdx1LacZ/+ (B), Hnf6+/- (C), and  Pdx1LacZ/+;Hnf6+/- (D) livers. Dashed-line insets 
are enlarged representations of boxed areas.
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Figure 44. Islet morphology in at 3 weeks of age. Immunolabeling for 
insulin-positive ` cells (green) and glucagon-positive _ cells (red) in 
control (A), Pdx1LacZ/+ (B), Hnf6+/- (C), and Pdx1LacZ/+;Hnf6+/- (D) islets.
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Figure 45 MafA localization at 3 weeks of age. Immunolabeling for 
insulin-positive ` cells (green) and MafA (red) in control (A), Pdx1LacZ/+ 
(B), Hnf6+/- (C), and Pdx1LacZ/+;Hnf6+/- (D) islets.  
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Thus, pancreatic sections from control, single, double heterozygous animals were 
immunolabled for insulin and the Pdx1- and Hnf6-regulated transcription factor MafA. In 
control and Hnf6 heterozygous animals, the majority of insulin-positive β cells were 
positive for MafA in nuclei (Figure 45A,C). Pdx1 heterozygous animals also possessed 
MafA-positive insulin-positive cells, but fewer insulin-positive cells were labeled (Figure 
45B). Of important note, double heterozygotes with elevated ad lib glucose at weaning 
(Figure 41B) exhibited very few MafA-positive β cells at this time (Figure 45D); MafA 
localization in double heterozygous animals with normal ad lib glucose levels has not yet 
been assessed.  Control, single and double heterozygous animals were also 
immunolableled for Glut2, the glucose transporter regulated by Pdx1. Control and Hnf6 
heterozygous animals exhibited bright, membrane-localized Glut2 immunolabeling 
(Figure 46A, C). Pdx1LacZ/+ islets displayed weak, somewhat diffuse Glut2 
immunolabeling, as did Pdx1LacZ/+;Hnf6+/- animals with elevated ad lib blood glucose (> 
175 mg/dl) (Figure 46B, D). Interestingly, islets from double heterozygous animals with 
normal ad lib blood glucose (< 175 mg/dl) exhibited slightly brighter Glut2 localization, 
although not comparable to controls (Figure 46E). These data suggest a possible 
connection between ad lib blood glucose levels and proper Glut2 localization/protein 
expression in Pdx1LacZ/+;Hnf6+/- animals at 3 weeks of age.  
 
Gene expression changes at 4 weeks of age 
After observing changes in protein immunolabeling in double heterozygous mice, 
we wanted to assess whether our results could be attributed to changes in gene 
expression. To this end, we examined changes in gene expression by custom TaqMan 
Low-Density Array (TLDA). Candidate genes for the TLDA were chosen based on 
involvement in β cell maturity, islet function, or because they were regulated by Pdx1. 
Islets were isolated from control, Pdx1LacZ/+, Hnf6+/-, and Pdx1LacZ/+; Hnf6+/- animals at 4  
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Figure 46. Glut2 immunolabeling at 3 weeks of age. Localization of the 
glucose transporter Glut 2 (red) in control (A), Pdx1LacZ/+ (B), Hnf6+/- (C), 
Pdx1LacZ/+;Hnf6+/- with high (> 175 mg/dl) ad lib glucose (D) and 
Pdx1LacZ/+;Hnf6+/- with low (< 175 mg/dl) ad lib glucose (E). 
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weeks of age and RNA was extracted for TLDA analysis.  Preliminary data revealed 
trends in expression of certain genes. As expected, expression of Pdx1 was reduced in 
Pdx1LacZ/+ islets compared to control islets (Figure 47). Pdx1 expression was unchanged 
between control and Pdx1LacZ/+; Hnf6+/- islets, but slightly elevated in islets from Hnf6+/- 
animals. Hnf6 was not detected in single or double heterozygous islets (Figure 47), 
which is consistent its down-regulation upon endocrine cell differentiation. MafA was 
detected at a higher level in Pdx1LacZ/+;Hnf6+/- islets than Pdx1LacZ/+ islets (Figure 47), 
indicating that Hnf6 heterozyosity may somehow rescue reduced MafA expression in the 
Pdx1LacZ/+ background. These data are not surprising considering the recent evidence 
indicating that Hnf6 negatively regulates MafA expression in vitro (Yamamoto et al. 
2013). Expression of Glut2, the glucose transporter regulated by Pdx1, is unchanged in 
Hnf6+/- islets compared to controls, but is reduced comparably in Pdx1 heterozygotes 
and double heterozygotes (Figure 47). Surprisingly, Ctgf expression was elevated in 
double heterozygous islets compared to all other genotypes. This is of particular interest 
considering that Ctgf is not normally maintained in postnatal endocrine cells, and 
consistent with published data that suggest that Hnf6 negatively regulates Ctgf in the 
postnatal murine pancreas (Wilding Crawford et al. 2008).  Additionally, we also 
observed decreased expression of Ins1 and Ins2 in Pdx1LacZ/+;Hnf6+/- islets compared to 
controls (Figure 47).  
 
 
Discussion 
Studying the cooperative roles of transcription factors during pancreas 
development is a straightforward means of better understanding the complex genetic 
interactions that take place during pancreatogenesis. Evaluating the effect of double 
Pdx1/Hnf6 heterozygosity developmentally and postnatally provides insight regarding  
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the role of these transcription factors in establishing endocrine identity and preserving 
endocrine function. It has been well documented that both Pdx1 and Hnf6 regulate  
genes required for the specification and postnatal function of endocrine cells; indeed, 
these two transcription factors cooperatively regulate Ngn3 in vitro.  
We first examined how double heterozygosity affects pancreas development and 
postnatal function using a model of global Pdx1 heterozygosity and conditional Hnf6 
heterozygosity (Pdx1LacZ/+;Hnf6Δpanc/+). Our preliminary results indicated that double 
heterozygosity using this model did not affect endocrine development or function despite 
the established roles that both genes have in regulation of endocrine specification genes 
and genes involved in β cell function (Figure 30, 31). Indeed, neither Pdx1 or Hnf6 single 
heterozygotes have documented developmental phenotypes, but this does not preclude 
the possibility of a genetic interaction-driven phenotype in double heterozygotes. The 
absence of phenotypical change in Pdx1LacZ/+;Hnf6Δpanc/+ pups at P1 motivated us to 
examine our model of Pdx1-Cre-driven Hnf6 heterozygosity. Upon analysis, we 
determined that efficient recombination of the Hnf6 allele does not take place, if at all, 
until after e11.5. (Figure 33). It is possible that, using Pdx1-Cre, deletion of Hnf6 may not 
occur during the overlap with Pdx1 expression in MPCs to affect that specific cell 
population of interest. If deletion occurs after the period of Pdx1/Hnf6 co-expression, it 
may be too late during pancreatogenesis to effectively examine cooperation of these two 
transcription factors in the progenitor population. Although it is still being determined 
exactly when Hnf6 is recombined, we suspect that it occurs after the birth of endocrine 
progenitors, but concurrent with the onset of acinar differentiation. This notion is 
supported by EYFP immunolabeling at P1, a surrogate for Pdx1-Cre activity. At this time, 
we observed efficient and consistent EYFP immunolabeling in the acinar population, but 
less consistent labeling in the endocrine clusters (Figure 34). These results suggest that 
Cre efficiently recombines the EYFP allele as acinar cells are differentiating, which 
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occurs after endocrine differentiation. Although we cannot assume that Pdx1-Cre 
recombines the floxed Hnf6 and EYFP alleles with the same efficiency or at the same 
time, the available data indicate that recombination of the latter allele does not take 
place as early as we had anticipated.  
To avoid the issues of tissue-specific Cre timing and efficiency, we employed the 
Prm-Cre transgene to generate Hnf6 heterozygotes at the 2- to 4-cell zygotic stage 
(essentially, a globally heterozygous model). Using this model, we were confident that 
Hnf6 heterozygosity would occur well before initiation of pancreatogenesis. Indeed, we 
observed a phenotype in Pdx1LacZ/+;Hnf6+/- pups shortly after birth (Figure 35). We were 
surprised, however, to also observe a phenotype in single Pdx1 heterozygote pups at 
this time. These results prompted us to identify the cause of reduced postnatal weight 
and organ size in experimental animals.  It has been well established that decreased 
body weight and organ size in newborn animals may result from placental insufficiency 
and IUGR (Eleftheriades, Creatsas, and Nicolaides 2006). Interestingly, Pdx1 has been 
isolated from the murine placenta and is up-regulated during placental insufficiency 
(Buffat et al. 2007). We hypothesized that reduced body and pancreas weight in single  
Pdx1 and double Hnf6/Pdx1 heterozygous animals may result from decreased 
expression of Pdx1 in the placenta and subsequent insufficiency. When organ weights 
were measured and compared to body weight, they were directly proportional to the 
body size, indicating that reduced pancreas size manifests postnatally and is most likely 
not a result of IUGR (Figure 36). 
We also explored the possibility that the Pdx1LacZ knock-in allele was behaving as 
a dominant negative to explain our unexpected P1 results. In both Pdx1 mutant alleles, a 
portion of the second exon, including the homeodomain, is absent, and partial Pdx1 
protein generated from Pdx1LacZ allele is more stable than the Pdx1+/- allele because it is 
fused to β galactosidase. The first exon of Pdx1 is intact in both mutant alleles (Figure 
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15). This exon contains an FPWMK motif that enables interaction with the cofactor Pbx1, 
which is required for proliferation and morphogenesis of the embryonic pancreas (Kim et 
al. 2002). The Pbx1:Pdx1 interaction is necessary for proliferation of the endocrine 
portion of the developing pancreas (Dutta 2001). Furthermore, adult animals 
heterozygous for both Pbx1 and Pdx1 develop normally, but exhibit overt diabetes by 10 
weeks of age due to impaired endocrine function (Kim et al. 2002). This research 
indicates that N-terminal interactions between Pdx1 and other factors are important for 
development and function, and suggest a possible explanation for the observed 
phenotype in pups from Pdx1LacZ/+;Hnf6+/- litters.  
To determine whether the postnatal changes were related to Pdx1 heterozygosity 
or the stability of the β-galactosidase fusion protein, we examined a second model of 
Pdx1 heterozygosity. The P1 pups generated from Pdx1+/- litters were indistinguishable 
from those generated from Pdx1LacZ/-containing litters in terms of body weight (Figure 37) 
However, this experiment revealed that control animals from Pdx1LacZ/+;Hnf6+/- litters 
weighed significantly more than all other experimental and control animals (Figure 37). 
We determined that the heavier control pups from Pdx1LacZ/+;Hnf6+/- litters were born to 
females carrying the Prm-Cre transgene. This situation has not been reported in the 
literature, but it is possible that the insertion site of the Prm-Cre transgene somehow 
influences pup size. Indeed, females that undergo hyperglycemia or gestational diabetes 
give birth to macrosomic offspring (Oh, Gelardi, and Cha 1988). Thus, if an as yet 
undefined characteristic of the Prm-Cre transgene causes elevated blood glucose during 
pregnancy, the pups may be larger as a result. We removed all pups born to Prm-Cre 
positive females, re-analyzed the curated data, and observed that only double 
heterozygous animals exhibited reduced body/pancreas weight and elevated blood 
glucose at P1 (Figure 38).  
After removal of macrosomic pups from the data set, one characteristic of 
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Pdx1LacZ/+;Hnf6+/- postnatal animals remained consistent: in both data sets, global double 
heterozygous animals exhibited hyperglycemia after birth. Considering that endocrine 
mass and ratios are unchanged in Pdx1LacZ/+;Hnf6+/- animals (Figure 40), it is most likely 
that elevated blood glucose is a reflection of impaired endocrine function. This idea 
becomes more interesting when one considers the expression pattern of Pdx1 and Hnf6, 
as these two factors initially overlap, but are not co-expressed in mature β cells, or any 
other endocrine cell type. It is possible that Pdx1 and Hnf6 overlap in postnatal 
endocrine cells that are still undergoing differentiation and have not yet activated 
hormone expression (Dr. Diana Stanescu, personal communication).  However, it is 
interesting to consider the mechanism by which decreased expression of two 
transcription factors affects a cell population in which the factors are not normally co-
expressed. It is possible that the initial co-expression of Pdx1 and Hnf6 in MPCs and, to 
a lesser extent, endocrine progenitors, primes the cells for postnatal function. This notion 
is not novel, as deletion of Hnf4α in the embryonic liver affects gene expression in 
differentiated hepatocytes long after expression would normally be down-regulated 
(Kyrmizi et al. 2006). Similarly, deletion of the transcription factor Foxd3, which is not 
expressed in islets during pregnancy, causes decreased β cell proliferation and glucose 
intolerance during pregnancy (Plank, Frist, et al. 2011).  In line with this, it is possible 
that co-expression of Pdx1 and Hnf6 in MPCs has a priming affect that later influences 
islet function. To address this, we are currently assessing changes in gene expression in 
double heterozygous animals by RNA sequencing (RNA-Seq) and TLDA at e15.5 and 
P1, respectively. 
Given that Pdx1LacZ/+;Hnf6+/- animals exhibit elevated blood glucose at P1, we 
anticipated that glucose homeostasis would worsen over time and eventually result in 
glucose intolerance. We were surprised to observe that the majority of double 
heterozygous animals restore glycemic control by 3 weeks of age and maintain glucose 
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homeostasis more effectively than Pdx1 heterozygotes (Figure 41, 42). These results 
suggest that double heterozygous animals somehow compensate for their initial defects 
in glucose homeostasis. The majority of double heterozygotes exhibit normalized ad lib 
blood glucose by weaning, with the exception of two animals. Assessment of glycogen 
deposition in the livers of adult double heterozygous mice revealed no obvious changes 
compared to controls, suggesting appropriate storage and mobilization of glucose in 
these animals. These data are consistent with our 8 week GTT results. We were 
surprised to observe reduced glycogen deposition in Pdx1 heterozygous livers, as Pdx1 
is not expressed hepatic tissue and a Pdx1-related liver phenotype has not been 
reported previously. However, it is possible that reduced insulin signaling in the setting of 
Pdx1 heterozygosity may affect glucose uptake in the liver, resulting in decreased 
glycogen storage (and possibly impaired glucose homeostasis). However, this does not 
explain why Pdx1LacZ/+;Hnf6+/- mice have normal glycogen deposition, as double 
heterozygosity results in decreased Ins1 and Ins2 expression at 4 weeks of age (Figure 
47). Hnf6 heterozygosity could cause decreased glycogen breakdown and glucose 
mobilization in the liver, thus ‘cancelling out’ the reduced glycogen deposition that results 
from Pdx1 heterozygosity in double heterozygous animals. The consequence of Pdx1 
heterozygosity, alone or in combination with Hnf6 heterozygosity, on liver function is a 
topic that requires more attention, and cannot be fully explained by the data presented 
here.  
Preliminary assessment of gene expression in double heterozygotes revealed 
trends that will require additional samples to confirm. However, we observed MafA 
expression in Pdx1LacZ/+;Hnf6+/- islets that was reduced compared to controls, but 
elevated compared to Pdx1 heterozygous islets, suggesting that compound 
heterozygosity rescues this reduction in MafA expression. Pdx1 positively regulates 
MafA expression in islets, while Hnf6 indirectly negatively regulates MafA (Raum et al. 
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2006, Vanhoose et al. 2008, Tweedie et al. 2006, Yamamoto et al. 2013). We 
hypothesize that reduced expression of Hnf6 relieves its inhibition or otherwise promotes 
expression of MafA in the double heterozygous background. Our lab has demonstrated 
that maintained expression of Hnf6 in endocrine cells results in absence of MafA protein 
in β cells (Tweedie et al. 2006). Therefore, reduced Hnf6 expression may, in fact, 
promote increased levels MafA in double heterozygous islets. We also observed 
decreased expression of Ins1 and Ins2 in compound heterozygote islets. These results 
are perplexing, as Pdx1LacZ/+;Hnf6+/- mice are glucose tolerant at all times examined 
(Figure 42). Reduced levels of Ins1/Ins2 expression compared to controls may reflect 
compensatory mechanisms that have not yet been completed. For example, we may 
observe restored expression of Ins1 or Ins2 at 6 or 8 weeks of age. Indeed, analysis of 
glycogen deposition at 8 weeks of age in Pdx1LacZ/+;Hnf6+/- livers suggests normal insulin 
signaling and glucose uptake (Figure 43), indicating that Ins expression may be normal 
at that time. The idea of gradually increasing gene expression to compensate for early 
postnatal β cell dysfunction could also explain reduced Glut2 (Slc2a2) expression in 
Pdx1LacZ/+;Hnf6+/- islets at 4 weeks of age (Figure 47). It is also possible that genes 
related to β cell function are reduced in double heterozygotes because islet function has 
been restored and expression no longer required at high levels. The ongoing 
characterization of gene expression changes in compound heterozygotes will provide 
answers to these remaining uncertainties.  
The trend in elevated Ctgf expression observed in Pdx1LacZ/+;Hnf6+/- islets is 
intriguing, and could possibly be explained by reduced Hnf6 expression during 
embryogenesis. Maintenance of Hnf6 in endocrine cells results in a 2.5-fold reduction of 
Ctgf expression in neonatal pancreata, indicating that Hnf6 negatively regulates Ctgf 
(Wilding Crawford et al. 2008). However, neither factor is expressed in mature endocrine 
cells under normal conditions. Perhaps Ctgf expression is up-regulated in double 
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heterozygous islets to promote proliferation of β cells and improve glucose homeostasis.  
Assessment of gene expression at P1 when Pdx1LacZ/+;Hnf6+/- islets are dysfunctional will 
determine whether this is the case.  
Assessment of protein localization in 3 week old animals revealed reduced 
immunolabeling of Glut2, a Pdx1-regulated gene necessary for glucose homeostasis, in 
a Pdx1LacZ/+;Hnf6+/- animal with elevated blood glucose (Figure 41B, 46). Glut2 
immunolabeling was modestly restored in a Pdx1LacZ/+;Hnf6+/- animal with normal blood 
glucose (Figure 46E) This suggests that Glut2 protein expression may be linked to 
glucose homeostasis, but we have yet to determine if Glut2 down-regulation precedes or 
follows elevated ad lib blood glucose. These data also suggest that some double 
heterozygous animals do not activate the compensatory mechanisms that restore blood 
glucose by weaning. These precise mechanisms and the means by which they are 
activated have not yet been elucidated, but we expect that forthcoming data from RNA-
Seq and TLDA analysis will provide meaningful information regarding changes in gene 
expression that influence islet function. Furthermore, we are also exploring whether 
regulated over-expression of Pdx1 and Hnf6, together, in the developing pancreatic 
epithelium can expand the endocrine compartment or enhance postnatal function in vivo. 
This system will use the Pdx1-tTA allele to drive expression HA- and Myc-tagged 
versions of Pdx1 and Hnf6, respectively, throughout embryogenesis (Figure 18, 19).  
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    CHAPTER V 
 
OVER-EXPRESSION OF PDX1 AND HNF6 AS A MEANS TO EXPLORE THE 
PLASTICITY OF HUMAN DUCT CELLS 
 
Introduction 
Efforts to generate insulin-producing β cells from non-endocrine cell sources 
have increased substantially in recent years. Re-establishing functional β cell mass is a 
primary goal for treating both TID and T2D, though different approaches may be 
required depending on the mechanism of initial β cell death or dysfunction. Indeed, 
endocrine cells have been derived from human induced pluripotent stem cells (hiPS) and 
human embryonic stem (hES) cells (Tateishi et al. 2008, Jiang et al. 2007, Shim et al. 
2007, Phillips et al. 2007, D'Amour et al. 2006, Kroon et al. 2008), and the resultant cells 
have possessed β cell-like qualities (Jiang et al. 2007, Shim et al. 2007, Phillips et al. 
2007, D'Amour et al. 2006, Kroon et al. 2008). Caveats of established differentiation 
protocols include low yield of β cells after differentiation, the length of time to establish 
maturity, and poor glucose-responsiveness of differentiated β-like cells. Despite these 
setbacks, the field continues to move forward in the production of β cells from a variety 
of cell types. 
Differentiating β cells from other sources of pancreatic origin, including exocrine 
tissue, has proved somewhat effective. Exploring the potential of exocrine tissue to 
transdifferentiate into endocrine tissue holds promise, as both of these cell populations 
originate from the same primary MPCs during embryogenesis (Figure 5) (Gu, 
Dubauskaite, and Melton 2002, Kopp, Dubois, Schaffer, et al. 2011, Kopp, Dubois, Hao, 
et al. 2011). The viral over-expression of Pdx1, Ngn3, and MafA together in the acinar 
component of the mouse pancreas results in transdifferentiation of acinar cells into β-like 
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cells that are structurally and functionally similar to endogenous β cells and express 
some appropriate β cell markers (Zhou et al. 2008). Furthermore, administration of the 
Pdx1/Ngn3/MafA virus and induction of acinar transdifferentiation improves blood 
glucose in mice treated with the β cell-specific toxin streptozotocin (STZ), indicating that 
the induced β cells can respond appropriately to glucose (Zhou et al. 2008). When a 
similar experiment was repeated in an acinar cell line, comparable results were 
obtained, including the down-regulation of acinar genes, up-regulation of endocrine 
genes, and amelioration of elevated blood glucose in STZ-treated mice (Akinci et al. 
2012). However, these induced cells lack the glucose-sensing mechanism that is 
characteristic of a functional β cell. Additional experiments have showed that after 
combined pancreatic duct ligation (PDL) and STZ treatment, Ptf1a-positive acinar cells 
have the ability transdifferentiate into β cells after transitioning through a 
CK19/Hnf1β/Sox9-positive ductal and Ngn3-positive intermediate (Pan et al. 2013). 
These data suggest that multiple models of injury and gene manipulation can stimulate 
acinar cells to activate the endocrine program. 
Pancreatic duct cells have also been explored as a potential source of β cells 
(Inada et al. 2008, Solar et al. 2009, Kopinke and Murtaugh 2010, Furuyama et al. 2011, 
Kopp, Dubois, Schaffer, et al. 2011, Xiao et al. 2013). Depending on the model of 
lineage tracing, results regarding the contribution of duct-derived cells to regenerating 
endocrine tissue have been inconsistent. Indeed, in vivo studies using Hnf1β-Cre as a 
lineage marker suggest that bipotent trunk progenitors only give rise to endocrine cells 
until e15.5 (Solar et al. 2009). However, this specific Cre line labeled less than ten 
percent of cells in adults, potentially permitting Hnf1β-positive cells with endocrine 
potential to escape Cre labeling. Additional studies in mice revealed that Sox9+ cells 
contribute to all three pancreatic lineages through embryogenesis, but lose the potential 
135	   
to contribute to β cells shortly after birth, even after stimulation with PDL (Furuyama et 
al. 2011, Kopp, Dubois, Schaffer, et al. 2011). Furthermore, although Ngn3 is activated 
in adult murine pancreatic duct cells following PDL or treatment with alloxan, another β 
cell-specific toxin, lineage tracing of these presumed endocrine progenitors does not 
indicate that they become β cells (Xiao et al. 2013). The conflicting results described 
above, as well as others, contribute to the controversial nature of facultative progenitor 
cells in the pancreas and confirm that more research is required for complete 
understanding. 
To explore the potential of duct cells to transdifferentiate into endocrine cells, we 
employed the HPDE-6 human ductal epithelial cell line. These cells were derived from 
healthy human donor tissue and are non-tumorogenic in mice, express CK8/18 and 
CK19, and are polarized with surface microvilli, (Furukawa et al. 1996, Ouyang et al. 
2000). The goal of these studies is to virally over-express Pdx1 and Hnf6 in HPDE-6 
cells to determine if the endocrine program can be activated. In vitro, Pdx1 and Hnf6 
have an additive affect on Ngn3 reporter activity, and bind to a conserved region of the 
Ngn3 promoter (Oliver-Krasinski et al. 2009) Viral vectors to over-express each 
transcription factor were generated (Figure 20, 21). Analysis of gene expression in 
HPDE-6 cells revealed that both Pdx1 and Hnf6 are expressed endogenously. Future 
directions will include the regulated over-expression of Hnf6 and constitutive over-
expression of Pdx1 individually and in combination, followed by analysis of endocrine-
specific gene and hormone expression. 
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Results 
Generation of Pdx1 and Hnf6 over-expression viral vectors 
 The construction of the pLVX-Pdx1-mCherry and pLVX-TRE3G-myc-Hnf6 
vectors was described previously (see ‘Materials and Methods’). These viral vectors 
were designed to over-express Pdx1 and Hnf6 in a constitutive and regulated manner, 
respectively, in HPDE-6 cells. mCherry and myc tags were added to Pdx1 and Hnf6 
cDNA, respectively, to enable differentiation between endogenous and exogenous 
protein expression by immunolabeling. Additionally, the presence of the fluorescent tag 
to the Pdx1 construct will facilitate fluorescence-activated cell (FAC) sorting in future 
experiments.  
HPDE-6 cells express genes required for Ngn3 activation 
 Prior to viral infection of HPDE-6 cells with Pdx1 and Hnf6 (Figure 20, 21), we 
wanted to asses endogenous expression levels of these two factors. To quantify 
endogenous expression of Hnf6 and Pdx1 in HPDE-6 cells, qRTPCR was performed on 
RNA isolated from the cells. Both Pdx1 and Hnf6 were expressed HPDE-6 cells (Figure 
48).  
 
Discussion 
 This project is designed to test the potential of human duct cells to activate the 
endocrine program when Pdx1 and Hnf6, two factors critical to endocrine development, 
are over-expressed. Pancreatic duct cells have been examined for their potential to 
generate endocrine cells in previous studies with varying results (Gasa et al. 2004, Solar 
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et al. 2009, Kopinke and Murtaugh 2010, Furuyama et al. 2011, Kopp, Dubois, Schaffer, 
et al. 2011, Xiao et al. 2013). Previous work explored the ability of HPDE-6 cells to  
differentiate into endocrine cells by adenoviral infection of Ngn3 alone, and found that 
this method activates expression of Neurod1; however, investigation of whether this cell 
line can activate hormone expression was not completed (Gasa et al. 2004). Our 
approach will instead use lentivirus to generate a stable cell line that over-expresses 
Pdx1 and Hnf6, which will potentially activate Ngn3. We opted to address the experiment 
this way, rather than lentiviral over-expression of Ngn3 itself, as forced expression of 
Ngn3 causes precocious differentiation of endocrine progenitors to the α cell fate 
(Johansson et al. 2007). Furthermore, recent studies have revealed that adenoviral 
infection of human duct cells with Ngn3 alone initiates the neuro-endocrine program, but 
does not fully commit cells to the pancreatic endocrine lineage (Swales et al. 2012). 
These data suggest that other factors are needed to establish the commitment to the 
pancreatic endocrine lineage, and that Ngn3 alone is not sufficient to enforce this 
decision. 
 Our approach to Pdx1 and Hnf6 over-expression also differs from previously 
published models using human ductal cells. As mentioned above, we will utilize lentivirus 
to establish stable cell lines. Furthermore, we plan to regulate Hnf6 expression using a 
doxycycline-inducible system of lentiviral gene expression. In vivo, maintained 
expression of Hnf6 in the endocrine component of the pancreas has detrimental effects 
on lineage allocation and postnatal gene expression and β cell function (Gannon et al. 
2000, Tweedie et al. 2006, Wilding Crawford et al. 2008). We have chosen to transiently 
induce Hnf6 over-expression to avoid these potential issues. As Pdx1 is expressed in 
the progenitors that give rise to ductal epithelium and is maintained at low levels in the 
adult, we will maintain constitutive expression of Pdx1 in our model. Additionally, Pdx1 is  
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Figure 48. Endogenous expression of Pdx1 and Hnf6 in 
HPDE-6 cells. qRT-PCR was performed on RNA isolated 
from HPDE-6 cells. Gene expression was normalized to 18S 
expression.
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maintained at high levels in adult β cells, and thus we expect no deleterious 
consequences of continued Pdx1 expression. 
 The goal of this project is to determine whether simple gene activation can 
activate the endocrine program in human ductal cells. Ultimately, the information learned 
from these studies will not only enrich the current transdifferentiation protocols and 
create new avenues for the generation of β cells, but will provide a better understanding 
of endocrine development in vivo. 
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 Hnf6 is a one-cut domain containing transcription factor required for specification, 
differentiation, maintenance of cell and tissue identity, and regulation of genes involved 
in adult functional processes in the murine liver, central nervous system (CNS), and 
pancreas (Landry et al. 1997, Clotman et al. 2002, Hodge et al. 2007, Chakrabarty et al. 
2012, Espana and Clotman 2012a, b, Roy et al. 2012, Stam et al. 2012, Audouard et al. 
2012). In the pancreas, Hnf6 regulates specification and differentiation of endocrine 
tissue, maturation of β cells, and maintenance of exocrine differentiation (Gannon et al. 
2000, Jacquemin et al. 2000, Jacquemin, Lemaigre, and Rousseau 2003, Tweedie et al. 
2006, Zhang et al. 2009). Thus, Hnf6 plays diverse roles in various stages of pancreas 
development and function, and is therefore an ideal factor to investigate in the quest for 
cell-based T1D and T2D therapies. good 
The focus of this dissertation is the function of Hnf6 and its downstream effectors 
and coregulators in postnatal pancreatic endocrine function. We chose to examine a 
gene regulated by Hnf6, Sostdc1, and its role in the endocrine pancreas after observing 
a near 2-fold up-regulation of Sostdc1 expression in a transgenic mouse model of 
diabetes in which Hnf6 is over-expressed in endocrine cells. The results in Chapter III 
demonstrated that loss of Sostdc1, a BMP and Wnt inhibitor, provides protection against 
diet-induced glucose intolerance and impaired insulin secretion. Autocrine BMP 
signaling promotes insulin secretion, and we showed that HFD induces expression of 
BMP inhibitors. In the absence of Sostdc1, expression of other BMP and Wnt 
antagonists are not increased as they are in control animals. Thus, in Sostdc1 mutant 
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animals BMP/Wnt signaling is not inhibited and is able to maintain islet function. These 
findings support the therapeutic potential for blocking BMP or Wnt antagonist activity in 
adult islets to enhance insulin secretion. Although we observed consistent changes in 
gene expression in Sostdc1 mutant islets from a mixed genetic background, the changes 
in insulin secretion and glucose tolerance were detected in only a subset of mutants. 
Because the phenotype could not be attributed to percent contribution of a particular 
genetic background, the data suggest that other, presently undefined factors may 
influence endocrine function in animals with the improved phenotype. It is possible that 
specific modifier genes that are controlled by Sostdc1 influence islet function. In addition, 
negative regulation of genes involved in endocrine function, including MafA or genes 
pertinent to insulin exocytosis that have not yet been assessed, may be ameliorated in 
the absence of Sostc1. Recent studies have indicated that over-expression of Sostdc1 
enhances proliferation and cell cycle progression in a gastric adenocarcinoma cell line 
(Gopal et al. 2013). In β cells, it is thought that insulin secretion capacity is reduced while 
cells undergo replication. Thus, reduced proliferative capacity in combination with 
expression of genes that positively regulate insulin secretion may enhance function in 
Sostc1null islets. Future endeavors will include the analysis of global gene expression 
changes in Sostdc1 mutant islets to identify potential modifiers and comprehensively 
characterize the mechanism of improved islet function observed in these animals.  
The above-mentioned Hnf6 transgenic model was generated to investigate the 
programmed down-regulation of Hnf6 and its effect on islet development. Hnf6 
expression is maintained throughout pancreas development within primary MPCs, 
bipotent precursors, and endocrine progenitors, during which it is co-expressed with 
Pdx1, and is down-regulated in endocrine cells as they differentiate. Chapter IV of this 
dissertation investigates the cooperative function of Hnf6 and Pdx1 during 
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pancreatogenesis and in the postnatal islet using a model of double heterozygosity for 
both genes. These studies have revealed that Pdx1/Hnf6 co-expression during 
embryogenesis is required for early postnatal islet function, as evidenced by elevated 
blood glucose observed in double heterozygous animals shortly after birth. Although 
these changes are not evident until one day of age, we suspect that gene expression 
changes, or priming of specific genes, takes place prior to the manifestation of the 
phenotype. Thus, these studies provide evidence that Hnf6 is required, briefly, during 
late gestation and the early postnatal period to ensure proper endocrine function (Figure 
49).  Perhaps Hnf6 plays a role in activating, recruiting, or identifying targets of the islet-
enriched methyltransferase Set7/9, which maintains the structure of euchromatin at 
genes required for islet function and also synergizes with Pdx1 to activate insulin 
transcription (Deering, Ogihara, et al. 2009, Francis et al. 2005). In this situation, 
reduced Hnf6 expression during pancreatogenesis could negatively influence Set7/9 
activity in the postnatal islet and result in impaired endocrine function. Future studies to 
explore this possibility could include analysis of the Set7/9 promoter for Hnf6 binding 
sites and assessment of Set7/9 occupancy of target genes in the setting of Hnf6 
heterozygosity.  
By weaning, Pdx1/Hnf6 double heterozygotes show restored blood glucose 
levels, suggesting the activation of a compensatory response that improves function. 
Identifying the precise mechanism by which function is re-established is a prospective 
study that will further characterize the double heterozygous phenotype. Additionally, 
determining specific genes that are co-regulated by Pdx1 and Hnf6 using chromatin 
immunoprecipitation (ChIP) and re-ChIP assays will be immensely informative. 
Currently, we are exploring changes in gene expression during embryogenesis using  
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Figure 49. Model of  required Hnf6 expression in the developing and postnatal pancreas. Hnf6 is expressed in the primary 
multipotent pancreatic progenitors (MPC, pink cells with blue nuclei) at e10.5. Expression is maintained in the bipotent endo-
crine/ductal progenitors (grey), endocrine progenitors (purple), ductal cells (gold), and to a lesser extent in the secondary 
MPCs (teal). Hnf6 persists in a subset of postnatal endocrine cells (red and green cells with blue nuclei), at late gestation 
and in the early postnatal pancreas, but is down-regulated in adult endocrine cells (red and green cells with black nuclei). In 
the adult duct cells (gold with blue nuclei) and acinar cells (light blue with blue nuclei), Hnf6 expression is maintained. It has 
not yet been investigated whether Hnf6 is expressed in centroacinar cells (light pink).
e10.5 pancreatic bud
Hnf6 expression
branching/differentiating 
epithelium
late gestation/neonatal 
islet
mature islet
mature exocrine tissue
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RNA sequencing (RNA-Seq), and we anticipate expression of Pdx1, MafA, and other 
genes related to β cell maturation to be decreased in the double heterozygous state. 
These experiments will provide a more clear understanding of the temporal and 
functional relationship between Hnf6 and Pdx1, which will guide future endeavors 
involving the generation of fully functional β cells in vitro  from stem or progenitor cells or 
in vivo  from facultative progenitors or closely related lineages.  
The role that Hnf6 plays in specification to the endocrine lineage during 
development makes it an excellent candidate to study in the differentiation of β cells from 
non-β cell sources in vitro. Chapter V presents preliminary data and planned 
experiments designed to explore the cooperative relationship between Hnf6 and Pdx1 in 
the activation of the endocrine program in human duct cells. Ongoing investigations are 
determining whether viral-mediated simultaneous over-expression of Hnf6 and Pdx1 can 
stimulate Ngn3 expression and its downstream endocrine program in a healthy human 
duct cell line. This simple scientific inquiry will surely prompt additional studies that 
require further investigation, including the timing and regulation of Pdx1/Hnf6 over-
expression, the requirement of additional factors, the efficiency of transdifferentiation, 
and the functionality of newly-differentiated cells. We can also identify Pdx1/Hnf6 target 
genes in human duct cells by ChIP, and assess epigenetic modifications of these genes 
during the transdifferentiation process.  The information gained from this set of 
experiments will prove useful for differentiation of endocrine cells from a variety of 
sources, and move the field closer to a cell-based therapy for T1D.  
These studies have continued the exploration of Hnf6 and its downstream 
effectors in the postnatal endocrine pancreas. Because Hnf6 is down-regulated in 
hormone-positive cells, much focus has been placed on its role during 
pancreatogenesis. Our lab was the first to examine the effect of maintained expression 
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of Hnf6 in the postnatal endocrine lineage (Gannon et al. 2000, Tweedie et al. 2006, 
Wilding Crawford et al. 2008). The research presented in this thesis reveals novel roles 
for Hnf6 in postnatal islet function.  Specifically, these studies show that loss of Sostdc1, 
a gene activated in response to Hnf6, improves endocrine pancreas function and affects 
expression of other, similarly related genes in islets; these data reinforce the importance 
of the temporal expression pattern of Hnf6. Furthermore, data presented here illustrate a 
cooperative relationship between Hnf6 and Pdx1 that extends beyond the window of co-
expression in progenitor cells and indicates that, together, these two factors prepare 
islets for postnatal function (Figure 49). Additionally, preliminary data and proposed 
experiments are presented in this document that will determine whether combined over-
expression of Hnf6 and Pdx1 can initiate the endocrine program in human duct cells. 
Together, these studies have furthered our knowledge of Hnf6 and its influence on islet 
function in the murine and human pancreas. 
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APPENDIX 
Appendix A: Strain-specific SNP genotyping for Sostdc1 null animals 
Chromosome-bp B6 ## DBA2KFD 5 KO KGJ 1 KO KFM3 KO KFW3KO KFL8 KO KEY1 KO KFD9 KO KFL4 KO KEY2 KO KFO2 KO
KGJ2 
KO
KFX6 
WT
KFO3 
WT
KGK2 
WT
KEW 7 
WT
KGJ 4 
WT
KEW
8 WT
KFN2 
WT
01-005230167-M C T T het C het T het het het het C C C T C T C het C C
01-021004950-M G C C het G G C het het het het G G G het G het G G G G
01-035000687-N T C C T T het het het T het het het T T T T het T T het T
01-058997955-M G A A G G A het A het het A A G G G G G het het A het
01-077241287-M C A A A C A het A het het A A het C C A het het het A A
01-089168561-M A G G A A A A A A A A A A A A A A A A A A
01-102716312-G G T T G G G G G G G G G G G G G G G G G G
01-116988763-M A C C A A A A A A A A A A A A A A A A A A
01-134214449-N G C C G G G G G G G G G G G G G G G G G G
01-150091142-M A G G A A A A A A A A A A A A A A A A A A
01-162977516-M G A A G G G G G het G G het G G G G G het G G G
01-184035421-M C T T het C C C het het het C het het C C C het het C het het
01-193173300-M G A A het het het het het het het G A het het A het A het het A G
02-008298278-G G G A
02-020414303-M G C C het C C G C C C C het C het het het G C C het het
02-038092910-M C T T het T T het T T T T het T T het C het T T T T
02-054004198-M G A A G A het het het G G het G A A het G het G A G A
02-076977189-M T C C C C C C C C C C C C C C C C C C C C
02-096383071-G A T T T T T T T T T T T T T T T T T T T T
02-113220302-M T C C C C C C C C C C C C C C C C C C C C
02-136425886-G T C C C C C C C C C C C C C C C C C C C
02-145828186-N G A A A A A A A A A A A A A A A A A A A A
02-161858323-M C A A A het A A A A A het A het A het het het A A A C
02-172943830-M G A A A het A het A het A het het het het het het het het A het A
03-019363137-G C T T C het het het C C C het C het het C het C C C C het
03-033933315-N T C C T T T T T T T T T T het T T T T T T T
03-051281956-M A A C A A het het A A A A A A het A het A A A A het
03-053161686-M T C T T T T T T T T T T T T T T T T T T T
03-071243972-M A T T A het T T het het T A het T T T het T T het T
Chromosome-bp B6 ## DBA2KFD 5 KO KGJ 1 KO KFM3 KO KFW3KO KFL8 KO KEY1 KO KFD9 KO KFL4 KO KEY2 KO KFO2 KO
KGJ2 
KO
KFX6 
WT
KFO3 
WT
KGK2 
WT
KEW 7 
WT
KGJ 4 
WT
KEW
8 WT
KFN2 
WT
03-086182591-M T G G T het G G het het het T het G G G het G G het het G
03-099146375-M A G G A A het het A het A A het het het het A het A A het het
03-114333031-N A G G G G G G G G G G G G G G G G G G G G
03-133183187-M C T T T T T het het het T T T T het T T het het T T T
03-151125653-M A T T A het het A A A A het A A A A A A het het A
04-003163167-M G T T het het het T het het het het het G het T G T het het het het
04-017970077-M A T T A A A A A A A A A A A A A A A A A A
04-032923355-M C T T het C C het het het het C het T C het het het het het C
04-043070534-M A G G het A het G G het het het G G A het het het het G G A
04-058850394-M C T T C het het het T C C het T het C het T het C T het het
04-072075941-M C T T C T het het het het C C C het het het T het het T C
04-088959560-M C A A C C C C C C C C C C C C C C C C C C
04-106314110-M C A A het C C C C het C C het het C C C het C C C C
04-122948823-M A G G het A A A A het A A het het A A A het A A A A
04-141084977-M A G G G A het het G G G G G G A G G G G A G G
04-151168886-M G T T het het het het het het het T het T G het het T het G G het
05-015030133-M G T T G G G G G G G G G G G het G het G G G G
05-021194830-M C T T C C C C C C het C C C C het C het C C C C
05-039017415-M C A A C C C C C C het C C C C het C het C C C C
05-065734378-N A G G A A A A A A A A A A A A A A A A A A
05-082050497-M C A A C C C C C C C C C C C C C C C C C C
05-094897264-N T C C T T T T T T T T T T T T T T T T T T
05-113995253-M C T T T C C T T T het T het C C C het het T C het het
05-142017413-M A G G G G het G het G G het G A G G G het het G G het
06-003167392-M C T T C C C C C C C C C het C C C C C C C het
06-017592278-N G T T G het het G G G G G G het G G G G G het G G
06-032993330-M C G G C G het C C het het het het het G C C C het G C C
06-045126062-M A G G A A het A A het A A het G het A A het het A A het
06-060887613-G A G G G A A A A het het het A het A A A het G het A
06-076285738-M T A A T T T T T T T T T T T T T T T T T T
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Chromosome-bp B6 ## DBA2KFD 5 KO KGJ 1 KO KFM3 KO KFW3KO KFL8 KO KEY1 KO KFD9 KO KFL4 KO KEY2 KO KFO2 KO
KGJ2 
KO
KFX6 
WT
KFO3 
WT
KGK2 
WT
KEW 7 
WT
KGJ 4 
WT
KEW
8 WT
KFN2 
WT
06-091998787-M A G G A A A A A A A A A A A A A A A A A A
06-112199886-M G T T G G G het G G G G G het G het G het G het G G
06-122941044-M T A A T T T het T T T T T het T T T het T het T T
06-135955068-M C A A A het het A A het A A het A het het A A A het A A
06-149052281-M C G G C C C C C C C C C C C C C C C C C C
07-004201219-N A G G het A het A A A A A het A het het het A A A A
07-014982749-M T C C T het T het T T T T T het T het het het T T T T
07-022058953-N G A A G het G het G G G G G het G het het het G G G G
07-036014647-M G A A G G G G G G G G G G G G G G G G G G
07-048028246-M G T T G G G G G G G G G G G G G G G G G G
07-063201365-M A G G het het het het het A het het het A het G het het het het A A
07-078044642-M G C C het het het het het G het G het G G het G G het het G G
07-093235239-M A C C A C het het het A A A het A A het A A C het A A
07-108090524-M G T T G G G G G G G G G G G G G G G G G G
07-122982432-M T G G T T T T T T T T T T T T T T T T T T
07-135345950-N A G G A A A A A A A A A A A A A A A A
08-015199792-M T C C C C C het C C het het C C C het C C C C C C
08-028926710-M G A A G G G G G G G G G G G G G G G G G
08-039133894-M G A A G G G G G G G G G G G G G G G G G G
08-054093936-M C G C C C C C C C C C C C C C C C C C C C
08-055226913-M T T A T T T T T T T T T T T T T T T T T T
08-067470102-N G C C G G G G G G G G G G G G G G G G G G
08-080610993-N T C C T T T T T T T T T T T T T T T T T T
08-098079794-M G A A G G G G G G G G G G G G G G G G G G
08-109943429-M C T T het C C het C C het C het het het het C C C C C
08-119264649-G C T T C C C C C C C C C C C C C C C C C C
09-008979920-M G T G G G G G G G G G G G G G G G G G G G
09-010567705-G T T C T T T T T T T T T T T T T T T T T T
09-021337884-G T C C T T T T T T T T T T T T T T T T T T
09-034961903-M G A A G G G G G G G G G G G G G G G G G
09-052052234-M T C C T het T T het het T T het T T T T T T het het T
09-065820797-M A G G het het G A G het het het het G het A G A A het het G
09-082788952-M C T T het C het het T het C het het T het C T C C C het T
09-098865563-M T C C het T het het C het T het het C het T C T T T het C
09-110057634-M A G G A A het het het het A A het A het het A A A het A A
10-006360048-M G A A G G G G G G G G het G het het G A het het het G
10-015140823-M G C C G G G G G G G G het G G het G het het G het G
10-034328321-G C A A het A A A het A C het A het A A A A A A A het
10-053898997-M G C C G het C C het C G het C het C G C C C C C het
10-067317776-G A G G het het het A A G het A G A A A A G G G A
10-072471838-G A G G A A het A A A A A A A A A A het A A A A
10-093476458-N T C C T het het T T T T T T T T T T het T het T T
10-108166251-G T C C het het het T T het het T het het T T het T het het het C
10-118769726-M C A A C C het C A het C het het het het A het het het A het het
11-004367508-M G A A G G G het G G het G G G G het G G G G G G
11-019956728-M A G G A A A het A A het A A A A het A het A A A A
11-024515722-M G A A G G G het G G het G G G G het G het G G G G
11-044333996-M A G G G het A het het G het het het het het G G G het het het het
11-059502265-N T C C het T T het T het het T T T T het T het het T T T
11-076223449-M T C C T T T T T het T T T T T T T T T T T T
11-091287860-M A G G A A A het A het A A het A A A A het A A A A
11-107678903-M G T T het T het T het G T het T T het het het G T het het
11-118804416-N G A A G het G G A het G het het het het het het het het het A het
12-011234798-M A G G het het het het G het A G het G het het G A G G G het
12-019201035-M G A A het A A A A het G A het A A het A G A A A het
12-039674614-M G A A A A A het A A A A A A A het A het A A A A
12-054303300-M C A A het C C C het A het A A C C het C het het C het het
12-070670478-M A G G het het het het A het het het het G het G het G G het G G
12-084289638-M C A A het het het A C het het A het A het A het A A het A A
12-099072867-M T C C het C het C T T T het T T C het T C het C het T
12-113315003-M C G G C C C C C C C C C C C C C C C C C C
13-015609597-M A G G A A A A A het A het het A A A A het A A het A
13-030913320-M T C C C het C C het C C het het C T het het het C het het
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Chromosome-bp B6 ## DBA2KFD 5 KO KGJ 1 KO KFM3 KO KFW3KO KFL8 KO KEY1 KO KFD9 KO KFL4 KO KEY2 KO KFO2 KO
KGJ2 
KO
KFX6 
WT
KFO3 
WT
KGK2 
WT
KEW 7 
WT
KGJ 4 
WT
KEW
8 WT
KFN2 
WT
13-046957715-M A G G G het A het G het G A A het het A A A het G het het
13-065339791-N C T T het C C C C het C C C C C C C C het C C
13-077818021-M T A A
13-091042598-M G A A G G G G G G G G G G G G G G G G G G
13-107993079-M A G G G het het A het A het het het A A het A A A het A het
13-117094028-M G A A G G G G G G G G G G G G G G G G G G
14-005055006-M T A A T T T het het het T T het T het A T A A A het T
14-017693796-G G A A G G G het het het G G het G het A G A A A het G
14-037395207-M T G G het T T het het het het T het G het G het G het G het T
14-054014360-M C G G het het het het het het het het G het G G G het G het het
14-068974190-M C G G G het G het G het G het het G het G G G G G het het
14-072865727-G C C T het het het het het het het het het T het T T T T T het het
14-074468555-M G A G het G het het het het het G het G G G G G G G het het
14-095233920-G T C C
14-108203728-M C T T het het het T het het het het het T het C T T het het het het
15-003094890-M A G G het het G het G het G G G G G het G G het het G G
15-020953071-M T C C het het C het C C C C C C C T C het C het C C
15-033125499-M A G G het G het G G G G G G G A G het G het G G
15-052940678-M A T T
15-071604153-N G T T het G G het G G het het het G G het T G het het het
15-086076093-M C G G C C het C het C C het C het C C het G C C C het
15-096231715-M T G G T T het T het T het T T het T T het G T T T het
16-005053446-C G T T G G G G G het G G G G het G het G G G G
16-019621494-C A G G A A A A A A A A A A A A A A A A A A
16-037994236-C G A A G G G G G G G G G G G G G G G G G G
16-055156188-G G A A G G G G G G G G G G G G G G G G G G
16-070833511-G C T T C C C C C C C C C C C C C C C C C C
16-084296159-G T G G T T T T T T T T T T T T T T T T T T
16-091028945-C C G G het C C C C het het het het C C G C het het C het C
17-007230139-M C G G G G G G G G G G G G G G G G G G G G
17-023157746-M A T T T T T T T T T T T T T T T T T T T T
17-039842179-N T C C het C T C het het T T het T het C T het het het het T
17-052179489-M A G G het G A G het het A het het A G het A het G het G A
17-068191393-M T C C C C T C C C T C C T C T T het C het C T
17-086110517-N G A A het het G het het het G het het G A A G A A het A het
17-092673068-N T G G het het T T T het T het het T het G T het het het het T
18-014248154-G T C C T het T C het het C het T T het T T het het T T
18-033822734-M A G G A het G G G G G G het het G A G het het G G G
18-047863056-M A T T T het T T het T T T het T T het T T het T T T
18-065947946-M T G G het het T het T T het T T het T T het T T T T het
18-075832307-M A C C het het A het A A het A A C A A C A A A A C
18-086980249-M G G A het G G A G G G het G A G het het A G G G het
18-088017394-M C T C C C C C C C C C C C C C C C C C C C
19-020257763-M C T T C C C het T C C het het T het het het het T C C het
19-031809029-G G A A G G G het het G G het het A G G het G het G G het
19-054115869-M G C C C G G het het het het het het het G G het het het G het het
19-060030696-N A G G G het het het het G G het G het het G G G het het G G
X-016114535-G C A A C C C C C C C C C C C C C C C C C C
X-025132696-G C G G C C C C C C C C C C C C C C C C C C
X-041569348-G C A A C C C C C C C C C C C C C C C C C C
X-055512473-M T C C T T T T T T T T T T T T T T T T T T
X-071927400-G A T T A A A A A A A A A A A A A A A A A A
X-091976871-G C T T C C C C C C C C C C C C C C C C C C
X-109677875-M A G G A A A A A A A A A A A A A A A A A A
X-115589667-M C A A C C C C C C C C C C C C C C C C C C
X-133535206-G T C C T T T T T T T T T T T T T T T T T T
X-143466659-M A C C A A A A A A A A A A A A A A A A A A
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